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Summary of research reported 
Over four years from 2002 to 2006, a series of concomitant studies were undertaken to explore the 
complications and outcomes of skin cancer surgery. Specifically: 
1. Through prospective studies, to identify risk factors for bleeding and infectious complications 
following skin surgery.  
2. To determine through a randomized controlled trial whether mupirocin ointment versus paraffin 
ointment versus no ointment on a wound following skin closure affords the patient benefit.  
3. To determine whether patients are at increased post operative bleeding risk should they 
remain on warfarin and / or aspirin prior to skin surgery.  
4. To develop and then trial a novel approach (reducing opposed multilobed [ROM] flap) for 
below knee wound closures that may reduce the incidence of skin surgery complications on 
the leg and foot.  
5. To investigate whether patients who suffer surgical complications are less likely to be satisfied 
with the service provision.  
Methods 
A prospective database was maintained for every patient attending the referral based Skincanceronly 
centre from July 1st 2002. Details of past history and skin cancer risk factors were obtained. 
Medications such as aspirin and warfarin were recorded. Procedures were documented including 
outcomes and complications of procedures. The type and site of all procedures was noted. Over the 
first 18 months of the data collection, patients were offered enrolment in a randomized controlled trial 
of placing ointment on wounds prior to a dressing being applied. These patients were also surveyed 6 
months following surgery regarding their perceptions of the outcomes of such surgery. A new 
technique for closing defects below the knee was developed. After the technique had been used for 20 
months, we retrospectively reviewed data and outcomes of this technique compared with traditional 
approaches. 
Results 
Skin surgery below the knee was found to be at increased risk of wound infection. Surgery on or near 
the ear was found to be at greater risk of post operative bleeding than other body sites. Warfarin 
therapy was found to be a risk factor for postoperative bleeding but aspirin did not alter bleeding 
incidence. Skin flap surgery and skin graft surgery resulted in both an increase in bleeding and 
infection incidence when compared to wounds closed directly. Placing mupirocin or paraffin ointment 
on a wound following suturing did not alter wound outcomes.  
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The reducing opposed multilobed (ROM) flap is a novel approach to close medium sized defects (11 
to 45 mm diameter) below the knee. My data demonstrated a reduced flap necrosis incidence when 
compared to traditional closures. Overall complication incidence was also significantly reduced with 
this new technique.  
Patients view of their scar outcome was a key indicator to their view of the overall skin cancer service 
provided. Patients rated wounds on the trunk poorly compared with wounds elsewhere on the body, 
including the face. Suffering complications did not alter patient perceptions of their skin cancer service. 
Discussion 
Postoperative bleeding following skin surgery was uncommon and was usually able to be managed 
conservatively. Adapting to patient perceptions of their skin surgery requires more than responding to 
complaints. An explanation and information regarding trunk scars may assist patients understanding 
that wound outcomes can be less aesthetic in these regions. 
 
Antibiotic wound infection prophylaxis could be considered for: all procedures below the knee, wedge 
excisions of lip and ear, all skin grafts, and lesions in the groin. In view of the risk of antibiotic 
resistance, mupirocin ointment is not indicated for clean surgical wounds.  
 
There was no case for discontinuing aspirin before skin surgery, but the INR should be monitored in 
patients taking warfarin. Skin surgery on or near the ear faces increased bleeding risk. 
Clinicians could consider the ROM flap for elective defects below the knee from 11 to 45 mm in 
diameter. Satisfaction with the scar had the greatest influence on a patients perceptions of their skin 
cancer service. 
Limitations 
A single experienced clinician in a southern Australia locale might not reflect complications, outcomes 
and perceptions of other clinicians in different cultures, climates and circumstances.  
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Abstract 
Background: 
Skin cancer surgery remains the commonest elective procedure undertaken by medical practitioners 
in Australia. The most important complication of skin cancer surgery is recurrence and this is 
extensively reported on. 
However, there is little published about other complications including (a) infection, (b) bleeding and (c) 
poor wound outcomes though complications are said to be at greatest risk below the knee. Nor is 
there much information about patients perceptions of their skin surgery complications.  
Aim: 
This program of studies focused on three key areas of complications of skin cancer surgery; (a) 
infection, (b) bleeding and (c) surgery below the knee. Research methods included clinical trials with 
historical controls, observational studies and a randomized controlled trial 
Setting: 
A single doctor private medical practice confined to managing skin cancers on referral from their 
general practitioners. 
Studies undertaken: 
1) Wound infection 
I first explored risk factors for wound infection following skin surgery. Through a three year prospective 
study I examined predictors of wound infection associated with managing 5091 skin lesions on 2424 
patients. The overall incidence of wound infection was 1.5% (75/5091). Skin flap and skin graft surgery 
resulted in higher incidences of infection of 3% (47/1601) and 9% (6/69) respectively. Surgery below 
the knee proved the only body region of increased infection risk, at 7% (31/448). Post operative 
infection on the face was at low risk of 0.8% (18/2209).  
2) Antibiotic ointment trial 
To investigate whether this infection incidence could be reduced by application of ointment to the 
closed wound prior to dressing, I undertook a randomized controlled trial of mupirocin ointment (562 
wounds on 262 patients) versus paraffin (729 on 269) versus no ointment (510 on 247). Neither 
ointment made a significant difference to any parameter tested, including infection incidence.  
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3) ROM Flap description 
A novel skin flap repair (reducing opposed multilobed or ROM flap) was developed to attempt to 
address the increased incidence of wound infection below the knee. The flap was developed from first 
principles to minimise tissue tension and maximise tissue perfusion at the skin wound edge. 
4) ROM Flap trial 
The ROM flap was then subjected to a retrospective trial on 225 defects below the knee between 11 
and 44 mm in diameter. The incidence of infection was not significantly lower in patients who had their 
defect repaired with the ROM flap at 9% (13/140) versus closure by traditional techniques at 13% 
(11/85) p=0.36. However, overall complication incidence at 14% (20/140) and end flap necrosis 
incidence at 1.4% were lower than in patients managed with this novel repair compared with traditional 
closures (32% and 7% respectively). 
5) Warfarin and Aspirin 
In a prospective trial involving 5950 skin lesions on 2394 patients over four years I maintained patients 
on their warfarin and aspirin medication prior to skin surgery unless the international normalized ratio 
was greater than 3.0. The overall bleeding incidence was 0.7% (40/5950). The following were 
independent risk factors for bleeding: age 67 years or older, odds ratio (OR) 4.7 (95% confidence 
interval, 1.8 to 12.2); P=0.002, warfarin therapy (OR 2.9, (1.4 to 6.3); P=0.006), and closure with a 
skin flap or graft (OR 2.7 (1.4  5.3); P=0.004). Aspirin therapy was not an independent risk factor for 
bleeding.  
6) Bleeding locations 
Next I investigated from this same data set of 5950 procedures whether certain body locations were at 
increased risk of postoperative bleeding. Only surgery in and around the ear demonstrated a 
significantly increased bleeding incidence at 2%, (OR 2.6 (1.2 to 5.7); P=0.012). 
7) Perceptions 
The final study addressed the patients perceptions of their skin surgery through a prospective 
observational study. 778 consecutive patients were surveyed and 576 responded. Suffering infection, 
bleeding or other complications made no difference to the patients perception of their skin cancer 
service. Scars on the trunk were more likely at 27% (21/77) to be rated neutral or negatively by the 
patient compared to non trunk scars at 7% (33/476) or on the face at 5% (15/305), p<0.001.  
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Limitations: 
A single experienced clinician in a temperate southern Australia locale might not reflect complications, 
outcomes and perceptions of other clinicians in different cultures, climates and circumstances.  
Conclusions: 
Wound infection is at increased risk below the knee. Neither mupirocin nor paraffin ointment alter this 
risk or any other outcome assessed. The ROM flap reduces the incidence of overall complications for 
surgery below the knee but does not reduce the infection incidence. 
There is no case for discontinuing aspirin before skin surgery but the INR should be monitored in 
patients taking warfarin. Skin surgery on or near the ear is predictive of bleeding. Suffering 
complications does not adversely impact on the patients perception of their skin cancer surgery 
service. 
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Background to this program of research 
a) Overview: 
There is remarkably little known about skin surgery complications and their risk factors. I was driven to 
explore further the causes of skin surgery complications so as my patients and patients in general may 
benefit. By understanding more about complications we may be able to help minimise them in the 
future. 
I am in private clinical practice in Geelong, Australia. Here I manage solely patients with skin cancers 
or suspected skin cancers referred from other health care professionals, - largely general practitioners. 
The setting provides for an opportunity to launch a program of clinical studies to address some 
unanswered questions regarding skin surgery complications. I manage a large numbers of patients 
with a very narrow range of presenting complaints and diagnoses. Variation in surgical experience and 
technique would not act as a confounder within this program as I was the only clinician managing the 
patients. I had the opportunity to closely supervise all staff involved in the research program face to 
face. This minimized scope for straying outside of methodology and protocols. The setting was ready 
made for a substantial program to investigate complications and outcomes following skin cancer 
surgery. 
 
Medicare data indicate excision of skin lesions including skin cancers is the most common surgical 
procedure undertaken in Australia.1 It was apparent that if further knowledge could be gained 
regarding skin surgery complications then there was a potential benefit for many Australians. These 
procedures are undertaken by a wide range of medical practitioners including plastic surgeons, 
dermatologists and general surgeons. General practitioners manage the majority of skin lesions and 
skin cancers in Australia.1 The most common and least serious of these skin cancers are basal cell 
carcinomas (BCCs), followed by squamous cell carcinomas (SCCs) and the more serious malignant 
melanoma.2, 3 Other uncommon skin cancers are also managed from time to time.4-8  
 
Skin cancer can be managed with numerous surgical and non surgical approaches. These include 
wide local excision9-11, frozen section micrographic controlled surgery (Mohs) 12-15, urgent paraffin 
micrographic margin controlled surgery16, 17, topical imiquimod18-23, topical 5 flurouracil24, 25, 
photodynamic therapy26, 27, cryotherapy28-31 and curettage with or without ablation.30, 32-35 My practice 
incorporated all of the above modalities with the exception of Mohs surgery and photodynamic 
therapy. These two are the least used modalities in clinical practice in Australia. As such, assessing 
complications from my surgery could reflect most skin cancer procedures in this country. 
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Surgical wounds are being closed directly 36, by random pattern skin flaps37, axial skin flaps38, 
myocutaneous skin flaps39, full thickness or partial thickness skin grafts.40, 41 This range of closures 
has been effected in my practice. Defects from 2 to > 200 mm in diameter were managed. 
 
Measured outcomes from skin lesion excision include recurrence rates.28, 33, 42-49 Few studies have 
focused on other (non recurrence) complications of skin cancer management. 
 
Frequent yet poorly addressed questions that may affect outcomes included:  
 When should antibiotics be prescribed?  
 Should warfarin or aspirin be ceased for skin surgery?  
 Are young females the people most likely to be unhappy with skin surgery scars?  
 Does antibiotic ointment on a wound reduce the infection risk?  
 Are there parts of the body that suffer more complications than others? 
 Are there reconstruction techniques that result in fewer complications than others? 
 
No definitive answers to these questions were available from the literature. The incidence of 
complications in skin surgery is reportedly in around 6% of procedures.50, 51 Major life threatening 
complications are reportedly very rare.52  
 
Bleeding complications have been described as the commonest complication of skin excision surgery, 
accounting for about half of all complications, (3%).51 Infection incidence has been reported in the 
order of 2% of surgical excisions51 but can be as high as 8.6% in Australia.53 
 
The program of studies comprising this thesis was designed to answer these questions regarding 
complications of skin surgery especially bleeding and infectious complications. The core of this thesis 
is seven published original manuscripts.  
 
I established a long term large prospective database powered to provide a suitable evidence base to 
examine risk factors for infection and bleeding complications following skin cancer surgery. 
I also effected a randomized controlled trial of ointment on wounds to evaluate this common practice 
in dermatologic surgery. 
Through a prospective trial I addressed whether or not remaining on warfarin and / or aspirin prior to 
skin surgery results in an increased post operative bleeding incidence.  
 
16 
 
Prior to establishing these clinical studies, my practice managed around 1,500 skin lesions per year, 
with just over half of these being malignant. I had managed around 5,000 skin cancers prior to 
establishing these clinical trials. 
 
From the outset a long time course for these studies was envisaged. It would take many years to 
recruit sufficient patients to meet the power requirements of some of the planned studies. As such, I 
was aware that design, ethics approval, recruitment, analysis and publication would take up to seven 
years to complete regarding some of the studies.  
 
The thesis also contains many educational pieces published with the aim of improving skin cancer 
knowledge for medical practitioners.  The core published works are presented in this thesis in two 
columns and a different text colour and font to distinguish them from the single column non published 
text of this thesis.  
 
My practice has been trading as Skin Cancer Only. Patients were and are not accepted for treatment 
without a referral from a health care professional, usually the patients general practitioner. It is a small 
private practice in Belmont, a suburb of Geelong, - the largest provincial city in Victoria. Coming from a 
rural background, I have a Fellowship of the Australian College of Rural and Remote Medicine 
(ACRRM). This College was only recognized for full specialist status in early 2007. I successfully 
completed the rural surgical program auspiced jointly by the Royal Australasian College of Surgeons 
and the Australian College of Rural and Remote Medicine in 1995.  
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b) Types of complications: 
Complications associated with skin surgery can be local or distant to the treatment site.  
Distant complications include metastatic disease54-56, anaesthetic anaphylaxis57 and death.58 
Anaphylaxis can follow administration of local57 and general anaesthetic agents.59 A significant 
adrenaline dosage in the local anaesthetic can result in raised pulse and pressure along with patient 
anxiety.60 Large doses of lignocaine in the local anaesthetic can result in cardiac dysrythmias.61 
 
Local complications can be classified as infective, bleeding, pain related62, wound complications, 
allergy63-65, recurrence47-49, 66-69 and others. 
 
 Infections in skin surgery wounds range from purulent suture foci through local cellulitis and infective 
necrosis to regional lymphadenitis and septicemia70, 71. Unusually, infection might effect organs deep 
to skin such as osteomyelitis.72 
 
Bleeding complications include blood collection deep to the closed wound73, (haematoma) and blood 
loss from the surface (haemorrhage). 51 Bleeding complications can be further classified as 
intraoperative, postoperative and delayed.74 Blood loss is able to be estimated allowing for further 
classifications based on volume of loss.75 
 
Pain complications following skin surgery include severe and persistent pain.76 
 
Wound complications occur in both the wound healing phase77 and long term complications.78  
 
Wound healing complications include suture reaction79, 80, flap necrosis81, dehiscence82, granuloma 
formation83, persistent swelling84, and ulceration85, - all of which may be associated with delayed 
healing.86  
 
Long term poor wound outcomes include suture markings87, keloid88, hypertrophy89, wound 
depression90, elevation91, spread79, hypo-pigmentation92, discolouration92, subcutaneous fibrosis93, 
contour distortion and contracture92, - all of which may result in a suboptimal aesthetic outcome. 
 
Allergic complications include allergy to skin preparations94, latex or wound dressings95, 96, pruritis97 
and contact dermatitis98, 99. Common symptoms of contact dermatitis are; itch rather than pain, skin 
vesicles adjacent to wound, weeping. Causes include dressings, skin preparations, topical 
applications applied and latex.99 
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Recurrence (non distant) can be classified as local69, locally invasive into adjacent structures46 and in-
transit.48, 100, 101 
 
Other complications include an array of uncommon outcomes that are often related to the specific 
surgical site. This includes ectropion formation102 following surgery to the lower eyelid or cheek. 
Nerves may be damaged in skin surgery including the facial nerve103, branches of the trigeminal 
nerve104, the accessory nerve105 and digital nerves.106 Psychological consequences can also follow 
skin surgery.107 
 
While all of these complications have been described in the literature, there is, in the main, limited 
data on the incidence of each following skin surgery and less data on the risk factors for such 
complications. 
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c) Methods 
The series of trials had a common and overlapping methodology prior to commencement. 
The studies involved referred patients who attended the Skincanceronly clinic between July 1st 2002 
and February 28th 2006.  
Inclusion criteria were: patient aged 18 years or more, eligibility to give informed consent and ability to 
comply with treatment requirements; and the presence of a skin lesion for which procedural 
intervention was required. 
 No patient was prescribed antibiotics prior to a procedure or following a procedure unless 
evidence of wound infection was apparent. 
 No patient had his / her aspirin or warfarin ceased prior to or following surgery unless the 
International normalized Ratio (INR) was over 3.0 
 Smokers were not asked to cease smoking prior to or following surgery. 
 Details of past medical history were recorded including: diabetes, heart surgery, pacemaker, 
asthma, rheumatic fever, skin cancers, melanoma, and actinic keratoses.  
 Medications being taken by patients were noted with specific questioning regarding warfarin, 
aspirin, immunosuppressants, and corticosteroids.  
 Patients were asked if they smoked and if so how many per day.  
 Patients were questioned regarding their hat wearing behavior and shirt wearing behavior.  
 Patients were asked whether they had ever been sun burnt to the point of blistering.  
 Patients were also asked whether they had worked in outdoor occupations and if so for how 
long.  
 Patients were also asked regarding their sunscreen usage.  
 Allergies to dressings and medications were also noted.  
Data on patients including all the above information was recorded on a Microsoft Access database 
specifically designed from scratch on Microsoft Access by Dr. Anthony Dixon for the purposes of 
collecting and processing data for these series of studies.  
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One clinician (A.J.D) performed all procedures. Surgical techniques included punch biopsy, elliptical 
excision, incisional biopsy, full and partial thickness skin grafts, curettage and random pattern skin 
flaps. There were occasional axial or myocutaneous flaps undertaken as well as small number of 
partial thickness skin grafts. The site of all removed lesions was recorded and all specimens sent for 
histopathological examination. Where multiple tumours required excision, the most concerning lesion 
was excised first.108, 109 
Some consideration was given to the standard method of skin closure that would be implemented 
throughout this series of prospective studies. Despite some skin surgeons routinely closing all skin 
defects in two layers and others routinely closing in one layer, there has never been a randomized 
controlled trial to compare outcomes of these two popular approaches. The best evidence available 
comes from randomized trials of one versus two layer closure in obstetrics110, gynaecology111 and 
vascular surgery82. The studies show very little if any difference. The largest of these studies and the 
study that most closely reflects skin lesion surgery is that by el Gamel82. In this well executed study, 
bilateral saphenous veins were harvested from 100 patients. Because intervention and control wounds 
were on the same patients, gender, age and other confounders were largely eliminated. There was no 
difference in wound complication rate.  
Without a clear evidence base to determine whether wounds be routinely closed in one layer or two, 
an intermediate approach was implemented during these prospective studies. Most wounds were 
closed with a single layer of interrupted polyamide or nylon. Absorbable deep sutures were used in 
closure only if layers deep to the subcutis required direct closure. The absorbable sutures were either 
braided polyglycolic acid suture or monofilament poliglecaprone.  Wounds selected for closure with 
two layers were larger wounds, those under greater tension and many on the trunk.  
All patients were given a detailed postoperative instruction sheet regarding wound management, 
warning signs and details of return appointments. Patients were followed clinically until wound healing 
was completed, at least until removal of sutures and longer following skin flap or graft surgery, or if a 
complication developed. 
The primary outcome measure of the studies was incidence of infection and postoperative bleeding. 
Other complications were also recorded. 
 
Infection was recorded and classified as: purulent suture site, suture abscess, cellulitis, infective 
necrosis, large subcuticular abscess, regional lymphadenitis and septicaemia. When there was 
abscess formation or evidence of involvement beyond the local site, a wound swab was taken for 
culture; otherwise, the infection was assessed clinically. In the absence of suppuration, a wound was 
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considered infected if three out of the following signs were present: discharge, pain, erythema or 
induration. All wound infections were treated with oral dicloxacillin, 500mg orally four times daily, 
unless sensitivity or allergy deemed this to be inappropriate.  
 
Any post operative haemorrhage or haematoma was recorded. A haematoma was regarded as small 
(up to 5 ml), medium (5 to 50 ml) or large (over 50 ml). A haemorrhage was regarded as small (up to 
25 ml), medium (25 to 100 ml), or large (over 100ml).  
Haemorrhage was further classified as delayed (1 to 24 hours after surgery) and late (more than 24 
hours). 
 
Other complications were recorded for each wound managed. Adverse scar outcomes were classified 
as: wound spread, suture markings, suture reaction, hypertrophy, keloid, discoloration, hypo 
pigmentation, wound depression, wound elevation, dog ears, and contracture. 
 
Other local adverse outcomes recorded were post operative bleeding, allergy to dressing, allergy to 
skin preparation, contact dermatitis, local recurrence, subcutaneous fibrosis, granuloma, dehiscence, 
pruritus, persistent pain, nerve damage, ectropion, nodal involvement and distant metastases.  
 
Post operative pain was also recorded as: no pain, minimal discomfort not requiring analgesia, mild 
pain relieved with paracetamol, moderate pain requiring stronger analgesia, severe pain unrelieved by 
analgesia, worst pain ever experienced.  
Questionnaire at 6-month follow-up  
A questionnaire was sent to all patients managed in the first 18 months of the trials. This questionnaire 
was an integral part of the patient perceptions and ointment randomized controlled trial. The 
questionnaire was first designed following a focus group asking patients what outcomes from their skin 
surgery they felt should be addressed in a formal study of outcomes from the consumer perspective. 
The questionnaire was considerably altered by the ethics review process including the addition of the 
added comments section at the end of the form. 
Six months after surgery each patient was posted a one-page survey to complete and return (Figure 
1). Any patient not returning the survey was sent another at 8 - 9 months after operation. The survey 
asked patients to rate the pain experienced and any inconvenience of the dressing, to comment on 
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their experience, to assess the final aesthetic appearance of the first operated area as excellent, very 
good, good, fair, poor or very poor, and to rate the quality of the service.  
A sub analysis of the first lesions excised was performed for patients who had multiple lesions during 
the study period. Patients who had undergone multiple procedures were asked to rate only the first 
procedure. 
The core peer reviewed published research will be presented in this thesis in a different type and 
colour of font and in two columns and on shaded paper to distinguish this material from the remainder 
of this work which will appear in full page width on white paper with black type. 
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Figure 1 Survey of participants 6 to 9 months following lesion excision.  
 
How would you rate the wound discomfort from the time of the surgery? 
No pain 
Minimal discomfort that did not require pain killers 
Mild pain, relieved by Panadol, Panamax or Herron Paracetamol 
Moderate pain that required stronger pain killers to gain relief 
Bad pain that could not be relieved with pain killers 
The worst pain I have ever experienced 
 
How would you rate the inconvenience of the dressing from the time of the surgery? 
No inconvenience 
A nuisance, but did not interfere with things 
Very disruptive or embarrassing to me 
Could not tolerate the dressing 
 
Rate our performance as either:  
Excellent, Very Good, Good, Fair, Poor or Very Poor to the following 12 questions: 
 
How would you rate the time taken from being referred to Skincanceronly Clinic until the time you were 
assessed by our Doctor? 
How well was the procedure explained to you in advance? 
How would you rate the time taken to have your skin surgery? 
How effective was the local anaesthetic? 
How would you rate the actual operation? 
How would you rate the nursing / reception staff? 
How well was the pathology result explained to you? 
How good was the follow up care by Skincanceronly Clinic? 
How good was the final look of the scar? 
How would you rate the cost of your treatment at Skincanceronly Clinic? 
How good was any written material provided? 
Overall, how do you rate our service? 
 
Please feel free to add any comments 
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d) Statistical analysis 
Demographic details were presented as percentage or mean ± standard deviation (SD) as 
appropriate. Chi-square method (Fisher exact) was used to test the significance of differences 
between proportions and categorical variables.  
 
Analysis of the ointment random controlled trial (RCT) was conducted on an intention to treat basis. 
Patient characteristics and differences between groups in each trial were assessed with analysis of 
variance using Tukey post-hoc analysis, Kuskall-Wallis H test and chi-square test as appropriate.  
 
Key outcome incidences were analyzed using the chi-square test.  The antibiotic ointment (RCT) was 
compared with controls individually using 2 x 2 tables.  
 
In addition this method was also used to assess univariate risk of bleeding / infection estimates and 
these were presented as odds ratios with 95% confidence intervals (bleeding).  
 
Multivariate analysis (bleeding) was tested using binary logistic regression (forward and backward) 
and odds ratio beta-coefficients with 95% confidence intervals shown.  
 
Receiver operator characteristic curves to assess an age cut off value that represented the best 
combination of sensitivity and specificity for risk of a bleeding complication.  
 
The SPSS 12.0.01 and later 14.0.2 (Chicago, Illinois,) statistical software was used for all statistical 
analysis. A p-value of less than 0.05 was considered statistically significant in all studies.  
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Chapter 1 Prospective study of wound infections in 
dermatologic surgery in the absence of prophylactic antibiotics. 
 
Introduction: -  
In this chapter we look at the issues surrounding limited data on the risk factors for wound infection 
with dermatologic surgery. The limitations in existing data prompted a large prospective longitudinal 
study of skin cancer surgery infections. 
 
There is debate regarding the role or otherwise of antibiotics prior to skin lesion excision. They have 
been advocated in clean-contaminated and contaminated wounds but not in clean wounds.112, 113 In 
general, expeditious usage of antibiotics is recommended with most circumstances not justifying 
antibiotics.114-117 Others suggest more liberal usage of antibiotics.118 A reduction in infection incidence 
following both topical and systemic antibiotics prior to cutaneous surgery has been reported.119 
Prophylactic antibiotics are recognized as having a role prior to skin surgery in patients at risk of 
endocarditis114, 120 and those who have had recent joint prosthetic surgery.114 Others claim skin 
surgery is an insignificant risk of endocarditis and that heart patients do not need such prophylactic 
treatment.117, 121 Recent joint prosthesis has also been refuted as an indication.117 Physicians vary 
greatly in their usage of prophylactic antibiotics or otherwise and frequently ignore established 
guidelines.113  
 
In order to improve our knowledge of the role or otherwise of antibiotic prophylaxis a better 
understanding of the risk factors for wound infection is needed. Once we have more accurate data on 
circumstances where a high infection incidence can be predicted, then we are better placed to develop 
more refined guidelines on antibiotic prophylactic usage.  
 
Our prospective study of wound infections over three years was designed to evaluate possible risk 
factors. The trial was published in Dermatologic Surgery in June 2006122 as follows: 
  
26 
 
Prospective study of wound infections in dermatologic surgery in the 
absence of prophylactic antibiotics.   
Authors: 
Anthony J. Dixon1, MBBS FACRRM  
Mary P. Dixon2, B Appl Sci (Nursing) 
Deborah A. Askew3, PhD 
David Wilkinson4 MBChB, FRACGP, MRCP, DSc, 
PhD 
 
1
 Dermasurgeon, Senior Lecturer, School Of 
Medicine, University of Queensland  
2 Nurse Manager, Skincanceronly, Geelong, 
Australia  
3
 Post Doctoral Research Fellow, School of 
Medicine, University of Queensland, Australia 
4
 Professor of Primary Care and Deputy Head, 
School of Medicine, University of Queensland, 
Australia 
 
Abstract: 
Method 
We undertook a 3 year prospective study of 5091 
lesions, (predominantly non melanoma skin cancer) 
treated on 2424 patients from July 2002 to June 
2005. No patient was given prophylactic antibiotics, 
and no patient ceased warfarin or aspirin.  
Objective  
The study aimed to identify wound sites / 
procedures where infection incidence was over 5%, 
such that these circumstances may warrant wound 
infection antibiotic prophylaxis. 
Results 
Overall infection incidence was 1.47%. Individual 
procedures had the following infection incidence: 
curettage 0.73% (3/412); skin flap repairs 2.94% 
(47/1601); simple excision and closure 0.54% 
(16/2974); skin grafts 8.70% (6/69); and wedge 
excision 8.57% (3/35). 
Analysis of regions of the body demonstrated that 
surgery below the knee (n=448) had an infection 
incidence of 6.92% (31/448) (p<.0001). Sub-
analysis demonstrated that all regions below the 
knee were at high infection risk. Elsewhere, groin 
excisional surgery had an infection incidence of 
10% (1/10) (p=.027). No other body site 
demonstrated an infection incidence beyond 5% of 
statistical significance. 
Procedures on the face demonstrated infection 
incidence of 0.81% (18/2209). Diabetic patients, 
those on warfarin and / or aspirin, and smokers 
showed no difference in infection incidence. 
Conclusion 
Based on a prediction of infection incidence over 
5%, the following cutaneous oncologic procedures 
warrant consideration of oral antibiotic wound 
infection prophylaxis; all procedures below the 
knee, wedge excisions of lip and ear, all skin grafts, 
and lesions in the groin. 
Other than under these circumstances, surgery to the 
nose, ear, fingers, lips, skin flap surgery, and 
surgery on diabetics, smokers, and those on 
anticoagulants have previously been considered for 
wound infection prophylaxis but do not warrant 
such intervention based on our data. 
 
 
27 
 
Introduction: 
Low infection rates have been reported with the 
surgical excision of skin tumours, including Mohs 
surgery50, 71 with incidence ranging from below 1 to 
over 4% following skin surgery to clean wounds115, 
120, 123
. 
In a comprehensive review of the subject, 
Maragh114and colleagues points out there are two 
indications for antibiotic prophylaxis in skin 
surgery: (i) wound infection prevention 
(therapeutic) and (ii) distant site infection 
prophylaxis, predominantly endocarditis and recent 
joint prosthetic surgery considerations. Maragh and 
colleagues identifies oral dicloxacillin and 
cephalexin as suitable choices for wound infection 
prophylaxis in selected cases of dermatologic 
surgery. Antibiotic wound infection prophylaxis for 
dermatologic surgery can be topical (including 
within the wound itself124) and systemic. However, 
in a prospective randomized controlled trial, we 
have demonstrated a lack of efficacy of topical 
mupirocin in preventing wound infection in skin 
cancer surgery125. 
 
Usage of wound infection prophylaxis in 
dermatologic surgery varies greatly from surgeon to 
surgeon with some studies reporting widespread 
usage of antibiotics.126 In general, antibiotics are not 
indicated for non-inflamed skin involving 
uncontaminated wounds.115, 116, 127 Antibiotic 
prophylaxis has a greater role when the skin is 
inflamed or infected prior to surgery114, the skin is 
contaminated112, or if the patient is 
immunocompromised.114 
 
The location on the body is a factor in considering 
antibiotics. Extremities are believed to be at higher 
risk of wound infection.85 In particular the lower 
limb has been identified as at high risk of surgical 
wound infection.84 Other body locations reported to 
be at higher risk of wound infection following 
dermatologic surgery include the following: nose128, 
ear71, lip114, groin129, and axilla.130  
 
Aspects of the patients health may also affect their 
propensity to wound infection. In particular, people 
with diabetes are considered to be at increased risk 
of wound infection. This has been demonstrated in 
diabetics who have lacerations131, have cesarean 
sections132, cardiothoracic surgery133, 134, 
laryngectomy135, and knee replacement surgery.136 
In contrast, diabetes was not shown to be a risk 
factor for wound infection in studies regarding 
bariatric surgery 137, leg vein harvesting 84, and 
lower extremity revascularization surgery 85. The 
dermatologic surgery wound infection incidence in 
diabetics compared with non diabetics is not well 
understood, yet diabetes is recognized as a possible 
consideration when considering wound infection 
prophylaxis 114. Smokers may also be at increased 
risk of wound infection such as has been identified 
in hip surgery 138, 139. 
 
More data are needed to determine sites of the body 
and techniques of dermatologic surgery that place 
the patient at increased risk of wound infection. 
With this added information the clinician can make 
a more informed choice regarding situations 
whereby wound infection prophylaxis is 
appropriate. 
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Aim: 
We aimed to identify circumstances where skin 
cancer surgery (SCS) wound infection incidence of 
over 5% is predictable, such that in those situations 
surgery might have oral preoperative antibiotic 
administration considered. Specifically, through a 
three year prospective analysis of wound infections 
in a referral based skin cancer surgery centre, we 
aimed to identify body locations, dermatologic 
procedures and patient circumstances that, in the 
absence of antibiotic prophylaxis, place the patient 
at greater than 5% risk of wound infection. 
 
Method: 
This prospective study of wound infections in SCS 
without antibiotic prophylaxis was approved as part 
of a larger trial by the Barwon Health District Ethics 
Committee. 
 
This study involved patients, and their lesions, 
managed in the 3 years from 1 July 2002 to 30 June 
2005 at the Skincanceronly Centre, Geelong, 
Australia. Patients were not administered antibiotics 
either before or following SCS. In the event that 
wound infection developed, antibiotics were 
prescribed as appropriate. If a lesion was clinically 
infected at presentation, antibiotics were 
administered. Surgery was not undertaken until the 
lesion no longer had clinical features of infection 
and antibiotic therapy had ceased.  
 
Inclusion criteria: 
All patients presenting during the study period were 
considered for enrolment. 
Inclusion criteria required that the patient: 
Be referred to the Skincanceronly Centre for 
management of skin lesion(s). 
Have a skin lesion for which incisional or excisional 
surgery or curettage is deemed appropriate in the 
patients management. Surgical procedures 
included: Mohs surgery; small and large excision 
and closure of lesions; curettage (with or without 
electrodessication); skin flaps; full thickness and 
partial- thickness skin grafts; and wedge excision 
surgery. 
 
Exclusion criteria included: 
Lesions managed entirely by cryotherapy. 
Lesions treated with topical imiquimod or other non 
surgical means. 
Lesions beyond 15 on any given patient were 
excluded to avoid over representation of some 
individuals.  
Partial thickness and full thickness skin graft donor 
sites were excluded.  
Patients requiring prophylactic antibiotics due to 
heart valve or recent prosthetic joint surgery. 
  
One dermasurgeon (AD) performed all procedures 
in one of two operating rooms at either 
Skincanceronly Centre or Geelong Private Hospital. 
All surgery was undertaken using sterile surgical 
gloves, drapes and equipment. The dermasurgeon 
wore a surgically clean gown and a face mask. At 
Geelong Private Hospital the surgical gown was 
sterile and disposable hair cover was worn. 
 
The site of all removed lesions was recorded and all 
specimens underwent histopathologic examination. 
All wounds were closed with nylon or polyamide 
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interrupted skin sutures. Absorbable deep sutures 
were used in closure only if layers deep to the 
subcutis required direct closure. The absorbable 
sutures were either braided polyglycolic acid suture 
or monofilament poliglecaprone. Following surgery, 
all wounds had an application of an occlusive 
dressing unless site specific or patients allergy 
considerations made this impractical. 
 
Because some patients had multiple tumors excised, 
the tumor deemed by the surgeon to be most urgent 
was removed first and a sub analysis of these 
lesions was carried out. 
 
Patient details noted included warfarin and aspirin 
therapy, diabetes, and smoking status. In keeping 
with current practice140, patients on medication 
affecting coagulation such as Warfarin or Aspirin 
did not have this medication ceased prior to surgery 
unless INR levels were excessive to therapeutic 
range. 
 
Patients were followed up at least until removal of 
sutures. Patients were telephoned by nursing staff 
the day following surgery. Patients were strongly 
encouraged to return for removal of sutures. In the 
event that a patient attended elsewhere for removal 
of sutures, they were followed up by phone. 
 
Infection recording 
Any wound infection was recorded and classified in 
the following predetermined groupings: low grade 
infection with or without purulent suture site; suture 
abscess; large subcuticular abscess; infective 
necrosis; cellulitis; regional lymphadenitis; and 
septicemia. Wound infection was assessed clinically 
unless there was evidence of involvement beyond 
the local site. Under these circumstances, a wound 
swab for culture was taken. In the absence of 
suppuration, a wound was considered infected if 
three of the following features were present; 
discharge; pain; induration; and erythema. All 
wound infections were treated with oral 
dicloxacillin 500mg orally four times daily unless 
sensitivity, patient size or allergy deemed this to be 
inappropriate. 
 
Infection incidence for each location / procedure 
undertaken was compared with all other locations / 
techniques using the chi square test. A site or 
method of SCS would be considered at high risk of 
wound infection if an existing incidence of 5% or 
more was reported. 
 
Results: 
Participants 
A total of 5091 skin lesions from 2424 patients were 
treated by excision or curettage in the 3 year study 
period.  The average age of patients was 57.5 years 
(median = 50 years) with 52.5% of patients being 
female. The 5091 lesions managed included 1263 
squamous cell carcinoma(SCCs) (24.8%), 1194 
basal cell carcinoma (BCCs) (23.5%), 132 
melanoma (2.6%), 130 dysplastic melanocytic naevi 
(2.6%) and 2203 other benign lesions (43.3%). The 
benign lesions included 789 actinic keratoses, 110 
cysts, 88 solar lentigenes, 63 angiomata, 26 
lipomata, 31 warts and 280 benign non dysplastic 
pigmented naevi. 
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All patients were followed up at least until removal 
of sutures. Ten patients were not seen at or 
following removal of sutures and were followed up 
through telephone contact. All others were seen by 
surgeon and nursing staff in the follow-up period. 
 
Two patients (three lesions) were excluded because 
antibiotic therapy was commenced prior to surgery. 
One patient had a heart valve prosthesis and another 
had been administered intravenous antibiotics by the 
anesthetist with the management of conscious 
sedation. One patient had more than 15 lesions and 
had all lesions after the 15th excluded from the 
study. No patient was excluded due to recent joint 
prosthetic surgery. 
 
Infections 
Out of the 5091 lesions, 75 wound infections were 
recorded (1.47%). There was no difference in the 
infection rate between men and women. Ten 
wounds were swabbed. One did not demonstrate a 
pathogen. The other nine demonstrated heavy 
growth of staphylococcus aureus. In eight of these 
cases, the bacteria were resistant to Penicillin but 
sensitive to dicloxacillin and cephalexin. At no 
stage were antibiotics adjusted based on culture 
results.  Dicloxacillin was the antibiotic of choice 
other than for three Penicillin sensitive patients who 
were prescribed roxithromycin. 
 
Two patients had serious infections. One patient had 
extensive cellulitis that did not respond to oral 
dicloxacillin. The infection later responded to oral 
ciprofloxacin. Cultures did not identify a pathogen. 
Another patient did not respond to oral dicloxacillin 
and was subsequently managed by another doctor. 
She required hospitalization, debridement and 
intravenous antibiotics. A partial thickness skin 
graft was applied. This failed to take and the defect 
on the shin healed by second intent over many 
months. These were the only two patients who did 
not respond to the initial empirical antibiotic 
selection. 
 
Infection in relation to surgical technique and site 
on body: 
Infection incidence from each surgical technique is 
summarized in Table 1, and at different sites on the 
body in Table 2. All sites below the knee 
demonstrated and increased infection incidence. In 
total, there were 31 infections below the knee, or 
6.92% (p<.0001).  The groin was the only other 
body location that demonstrated infection incidence 
over 5%. 
 
We hypothesized that perhaps only the larger 
defects below the knee were experiencing a high 
infection incidence. A subanalysis revealed that 225 
defects below the knee were over 11 mm in 
diameter. The incidence of infection in this 
subgroup was 11.6% with 26 wound infections 
identified. In contrast, 223 defects smaller than 11 
mm in diameter below the knee demonstrated an 
infection incidence of 2.24% with five wound 
infections identified. (p = .0001). 
 
The types of infection are detailed in Table 3. It was 
noteworthy that abscess formation was not a feature 
of all 31 infections below the knee in contrast to 22 
of 44 infections above the knee (p < .0001). Low 
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grade infections below the knee either developed 
flap necrosis or cellulitis rather than proceeded to 
abscess formation. 
 
While the infection incidence on fingers was 4.88%, 
this was not significantly different to elsewhere. 
Only 41 finger lesions were managed in the 3 year 
period. Similarly, tumors treated with Mohs surgery 
demonstrated no significant difference in infection 
incidence. All three infected curettage wounds were 
on the shin from 35 lesions curetted below the knee 
(8.57%). A sub analysis of procedures undertaken in 
the difficult region; nose, ear, lip, hand and below 
knee is detailed in Table 4. Excluding wedge 
resection and graft operations, there were five 
infections in 346 operations on the ear and lip 
(1.48%). 
 
The types of skin flaps (n=1601) undertaken in this 
3 year period were as follows; 445 transposition 
(27.8%), 295 O - S (18.4%), 282 bilobed (17.6%), 
175 reducing opposed multilobed (ROM)141 
(10.9%), 93 twin advancement (5.8%), 92 V  Y 
(5.7%), 85 A  T (5.3%),and 134 others (8.4%). 
 
 At risk patients 
Diabetes was reported by 135 patients (5.6%) who 
accounted for 285 lesions. There were three 
infections among these wounds (1.1%). This was 
not different from the non-diabetic population (p = 
0.54). A total of 369 (15.2%) patients were on either 
warfarin (n = 64) or aspirin (n = 299) or both (n = 
6).  These patients had 799 operations and 
experienced 10 wound infections (1.25%), which 
did not differ from the general population of 
patients (p = .57). Patients taking warfarin had 162 
operations with three wound infections (1.85%), 
those taking aspirin had 647 operations with seven 
wound infections (1.1%) and patients taking both 
aspirin and warfarin had 10 operations and no 
infections. 
 
There was no difference in infection rates between 
smokers and non smokers (p = .24). A total of  
296 (12.2%) patients declared themselves as 
smokers. These patients had 634 lesions managed, 
having six wound infections, (0.95%). 
 
Other potential influencing factors 
We recognized that as some patients had many 
procedures, they may be weighted excessively in the 
overall analysis. However, a sub analysis of the 
infection incidence of the first lesion on each patient 
treated was not different from the overall infection 
incidence demonstrated (not shown). 
 
We also recognized that infection incidence may 
have been different between the two surgical venues 
studied. One hundred seventy-four tumors excised 
at Geelong Private Hospital resulted in five 
subsequent wound infections (2.9%) This was not 
dissimilar to the overall infection incidence 
identified, (p = 0.12). 
 
Discussion: 
This study aimed to identify circumstances where 
SCS wound infection rates of greater than 5% can 
be predicted and therefore, circumstances where 
prophylactic antibiotics may be indicated. 
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We identified all SCS procedures, including 
curettage, at any site below the knee had a high 
infection incidence. This was expected given the 
compromise in circulation that is recognized in 
these locations. Of note was the finding that when 
infection progressed below the knee, it developed 
into cellulitis or infective necrosis but not abscess. 
We postulate that this lack of abscesses is due to the 
tight skin below the knee and hence reduced dead 
space. The higher wound infection incidence below 
the knee is relevant, given the increased risk of 
wound dehiscence, delayed healing, flap necrosis 
and poor cosmesis that can occur in association with 
wound infection. These adverse outcomes can also 
result in a reduced confidence in the clinician and 
even legal action. Consequently, wound infection 
prophylaxis for below knee procedures should be 
considered.  
 
Skin grafts and wedge excisions were the only types 
of procedures performed above the knee that were 
associated with a high infection incidence. This 
contributed to the higher rates of infection incidence 
on the lips and ears, compared with the rest of the 
body (with the exception of below knee 
procedures). Lip and ear closures that did not 
require a graft or wedge excision had the same 
infection incidence as elsewhere. It was noteworthy 
that diabetics did not suffer a higher incidence of 
wound infection than non diabetics, either above or 
below the knee. 
 
Flap surgery has a significantly higher infection 
incidence than elliptical excision and closure. 
Invariably these are larger / more complicated 
procedures with skin tension and perfusion being 
considerations in explaining this finding. While skin 
flaps are designed to reduce skin wound tension 
(among other features), wound tension is still 
frequently higher than noted in small simple 
elliptical closures. The skin flap often controls 
wound tension across a large part of the repair in a 
large defect where tension would have been 
excessive centrally if closed by ellipse alone. An 
example of this controlling of wound tension is seen 
with the ROM flap below the knee previously 
reported by this author.141 
 
This study has significant limitations. It involves a 
single dermasurgeon working in two surgical 
venues in one southern Australian regional city. 
This region has a temperate climate. The wound 
infection incidence reported may not reflect practice 
elsewhere, such as more tropical / humid climates. 
Wound infections were assessed clinically rather 
than by culture of wound swabs. A relatively short 
follow-up period on some cases may have led to an 
underreporting of late wound infections. The trial 
setting was that of a community based dermatologic 
surgery centre where wound swabs would not be 
routinely taken on wounds where infection is a 
concern. This mimics routine community 
dermasurgical practice in Australia. Other than 
warfarin and aspirin, other medications affecting 
coagulation such as non steroidal anti inflammatory 
medications were not recorded in this database. 
 
Whenever the question of antibiotic prophylaxis is 
considered, disadvantages include the risk of 
antimicrobial resistance arising from such liberal 
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administration. Further, antibiotics subject the 
patient to adverse reactions including allergic skin 
manifestations. A significant improvement in 
wound outcomes would be needed in future studies 
to justify the extra intervention of prophylactic 
antibiotics, given these significant reservations. This 
study has identified sites and procedures of high 
risk; it does not determine whether antibiotic wound 
infection prophylaxis will afford the patient benefit 
in these circumstances. While there is existing 
evidence that antibiotic prophylaxis will reduce the 
subsequent wound infection incidence, a 
randomized controlled trial specific to these high 
infection scenarios is needed to determine whether 
the sites / procedures identified improve sufficiently 
with such prophylaxis. 
 
Conclusion: 
Our results suggest that a 5% or higher incidence of 
wound infection in the absence of antibiotic 
prophylaxis is more likely following; 
all SCS procedures at any site below the knee, 
although small defects do not demonstrate the same 
infection rate as larger ones; wedge resections of lip 
or ear, all skin grafts; and lesions in the groin. 
Therefore, oral antibiotics need to be considered 
prior to surgery in these circumstances. 
 
While flap surgery has over five times the infection 
rate of elliptical excisions, the only locations where 
flap surgery suffers an infection rate above 5% are 
those below the knee. As such, wound infection 
prophylaxis for flap surgery above the knee is not 
indicated. Mohs surgery requires special 
consideration. The repeated surgery and intermittent 
wound packing at a single site results in wounds 
being clean-contaminated and are as such, at an 
increased infection risk. Furthermore, wound 
infection prophylaxis may need to be repeated in 
these cases due to the duration from the 
commencement to the conclusion of surgery in 
some cases.114 
 
Patients who are smokers, diabetics and those on 
aspirin or warfarin medication do not have an 
infection incidence different from the general 
population, and as such need not be considered for 
wound infection prophylaxis, other than under the 
circumstances for the population detailed above.  
When deciding about antibiotic wound infection 
prophylaxis, the clinician needs to involve the 
patient in the decision making process. Advice to 
the patient should include the likelihood of infection 
and other factors such as whether or not the wound 
is contaminated, whether the patient is immune-
compromised, whether the patient is considered at 
increased risk of endocarditis, and whether the 
patient has had recent joint prosthesis surgery.  To 
assist clinicians to give the best possible advice to 
patients about the efficacy of antibiotic wound 
infection prophylaxis, more research that is specific 
to the sites and circumstances indicated is needed to 
provide a comprehensive evidence base to support 
decision making in this area. 
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TABLE 1 
Infections by technique 
Technique Total cases  Infection Infection % P value to rest 
Curette 412 3 0.73% NS p = .19 
Skin flaps 1601 47 2.94%  < .0001 
Ellipse 2974 16 0.54%  < .0001 
Skin grafts 69 6 8.70%  < .0001 
Wedge excision 35 3 8.57%  = .0005 
All techniques 5091 75 1.47% 
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TABLE 2 
Infections by location 
Location Total cases Infection Infection 
% 
P value to rest 
Below knee - TOTAL 448 31 6.92%  < .0001 
Calf 290 16 5.39%  < .0001 
Shin 113 11 9.73%  < .0001 
Foot 45 4 8.89%  < .0001 
Thigh 96 2 2.08% =N S 
Groin 10 1 10%  = .025 
Upper limb - TOTAL 762 16 2.10%  = .12 
Fingers 41 2 4.88%  = .07 
Hand 328 8 2.44%  = .13 
Forearm 215 4 1.86%  = .63 
Arm 178 2 1.12% N S 
Head - TOTAL 2502 19 0.76%  < .0001 
Scalp 293 1 0.34%  N S (.1) 
Forehead 349 4 1.15% N S 
Temple 105 2 1.90% N S 
Zygoma 127 1 0.79% N S 
Nose 479 1 0.21%  = .016 
Ear 247 7 2.83%  = .025 
Lips 165 3 1.82% N S 
Cheek, jaw, eyelids, 
elsewhere 
737 0 0%  = .0001 
Trunk / neck / elsewhere 1273 6 0.47%  = .0006 
TOTAL 5091 75 1.47% 
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TABLE 3 
Details of infection at various sites 
 Low grade 
infection 
Abscess Infective flap 
necrosis 
Cellulitis Total 
Below Knee 14 0 1 16 31 
Thigh & groin 0 1 0 2 3 
Upper limb 4 5 1 5 15 
Trunk 3 3 0 0 6 
Head & neck 5 13* 0 2 20 
Total 26 22 2 25 75 
* Only one abscess was large and subcuticular, an abscess at nasolabial border, incised and drained. 
 
TABLE 4 
Subanalysis of infections in difficult areas by procedure type. Number of infections in parentheses. 
 Nose Ear  Lip Hand & 
fingers 
Below knee including 
percentage 
Ellipse 147 (0) 88 (3) 116 (0) 166 (3) 211 (5)   2.4% 
Curette 13 (0) 3 (0) 1 (0) 14 (0) 34 (3)   8.8% 
Skin flap 319 (1) 102 (1) 27 (1) 171 (6) 201 (21) 10.4% 
Skin graft 0  40 (2) 0 18 (1) 2 (2)    100% 
Wedge excision 0 14 (1) 21 (2) 0 0 
Total 479  (1) 247  (7) 165  (3) 369  (10) 448  (31)  6.92% 
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Summary  
My first published paper has identified circumstances in dermatologic surgery where antibiotic 
prophylaxis may be considered due to a predicted infection incidence of over 5%. 
 
It would have been preferable if the analysis was undertaken on people as well as skin lesions.  
Given some patients had several lesions excised, there is not complete independence between the 
excision of one lesion on a given patient and further lesions on that same patient.  
 
It would also have been preferable if the analysis undertaken in this study was multivariate rather 
than univariate. 
 
This study does not in itself identify a significant advantage of antibiotic usage in such 
circumstances. A randomized controlled trial of antibiotics would be required to determine the 
extent to which, if any, infection incidence was reduced by preoperative antibiotics and hence 
whether or not routine usage should be recommended. Clinicians use both topical and systemic 
prophylactic antibiotics to attempt to reduce wound infections. There is limited evidence that one 
route is preferable. 
 
I commenced to address, (and the next chapter details), this topical versus systemic question in 
my second study. Through a randomized controlled trial of antibiotic ointment versus control, we 
may be able to provide skin surgeons with advice regarding application of antibiotic ointment on 
wounds prior to a dressing being applied.  
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Chapter 2 Randomized clinical trial of the effect of applying 
ointment to surgical wounds before occlusive dressing 
In this chapter we pursue findings from the infection prospective study. We have identified 
circumstances where prophylactic antibiotics may be considered. Now we explore the value or 
otherwise of topical antibiotics on a closed wounds as an infection prophylaxis strategy. 
 
To further evaluate the benefit, or otherwise, of the application of antibiotic ointment and 
petrolatum on wounds following suturing, we effected a prospective randomized controlled of the 
placing of mupirocin (antibiotic) ointment versus paraffin versus control (no ointment). This study 
was published in the British Journal of Surgery125 in August 2006. The full text of this published 
manuscript follows: 
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Randomized clinical trial of the effect of applying ointment to surgical 
wounds before occlusive dressing 
Abstract: 
Background: A blinded randomized clinical trial 
was undertaken to evaluate the effect of applying 
ointment to a wound before occlusive dressing in 
comparison with no ointment or sterile paraffin. 
Methods: Some 778 patients with 1801 surgical 
wounds following excision of skin lesions were 
enrolled in the trial. No ointment was placed on 
510 sutured wounds of 247 patients, paraffin 
ointment was put on 729 wounds (269 patients) 
and mupirocin ointment on 562 wounds (262 
patients). Wound infection, scar, haemorrhage, 
dehiscence and other complications were assessed 
at suture removal. At 6-9 months after surgery, 
patients were surveyed to assess the wounds, with 
a response rate of 74%. 
Results: There were no significant differences in 
outcome for all end points evaluated. The 
infection rate was 1.4 % with no ointment, 1.6 per 
cent for paraffin and 2.3 per cent for mupirocin (P 
=0.490) Total complication rates were 3.5, 4.7 
and 4.8 per cent for no ointment, paraffin and 
mupirocin respectively (P =0.590). Some 10.9, 
10.3 and 8.2 per cent of patients respectively had 
a neutral or negative perception of their wounds at 
6-9 months after surgery (P =0.650), There was 
no difference in postoperative pain, degree of 
inconvenience, overall level of satisfaction with 
treatment.  
Conclusion: Putting ointment on a surgical wound 
before occlusive dressing does not benefit the 
patient. In view of the risk of antibiotic resistance, 
mupirocin ointment is not indicated for clean 
surgical wounds. 
 
Introduction: 
Ointment is often placed under an occlusive 
dressing after the excision and closure of a skin 
lesion 118, 142-144 in the belief that it improves the 
aesthetic outcome and that antibiotic ointment 
may reduce the incidence of wound infection. An 
infection rate of 2 - 5 per cent may be expected 
for uncontaminated wounds following skin lesion 
excision 71, 145 with higher rates below the knee 
and in the groin85, 146. A number of topical 
antimicrobial and antiseptic preparations are 
available, 147, 148 but there is little evidence to 
support their use on uncontaminated surgical 
wounds. 
Mupirocin ointment is considered to be an 
effective and safe topical bactericidal antibiotic149 
that results in a reduced postoperative infection 
rate when used on contaminated lesions before 
excision.144 It is as effective as oral antibiotics in 
the prevention and treatment of superficial skin 
infections149, 150 and compares favorably with oral 
antibiotics for the management of post excisional 
and experimental skin infections77, 151. Although 
these favorable effects cannot be extrapolated to 
the prevention of infection in non-contaminated 
wounds, mupirocin is widely advocated for clean 
wounds to reduce infection rates.118, 144 
Mupirocin resistance has been observed in 
methicillin-resistant Staphylococcus aureus 
(MRSA) isolates 152 ,and  a high  incidence of 
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mupirocin MRSA resistance has been reported in 
Malaysia153. Mupirocin has a role in interrupting 
the colonization of MRSA in affected patients, 
including preoperative surgical patients154, but 
continuing  widespread usage may reduce its 
effectiveness in this respect.155 156  
Moist occlusive dressings are used routinely by 
the authors after excising skin lesions as they have 
been reported to improve healing and to result in 
fewer infections and other complications.108, 156-161 
A blinded randomized controlled study was 
undertaken to determine whether the use of 
ointment, ointment containing an antibiotic 
(mupirocin), or no ointment under occlusive 
dressings would reduce the incidence of infection 
and other wound complications in patients with 
non-contaminated surgical wounds. Effects on 
patient comfort and long-term satisfaction with 
the appearance of the healed wound were also 
investigated.  
 
Methods: 
The trial was conducted in accordance with the 
Declaration of Helsinki and approved by Barwon 
Health Research & Ethics Committee. All patients 
gave signed informed consent. 
From the authors previous experience, an 
infection rate of approximately 4 per cent might 
be expected; a reduction to less than 1% would be 
clinically significant. It was determined that  500 
surgical wounds in each of the three groups would 
provide an 80 per cent likelihood of detecting  a 
four-fold difference in the incidence of infection 
between the antibiotic ointment group and the 
control group receiving  no ointment or paraffin 
(alpha of 0.05). Recruitment therefore continued 
until at least 500 surgical wounds were 
represented in each treatment group. Individual 
wound repairs in the same patient were treated as 
independent events, whether performed 
synchronously or at a different time (up to 15 
lesions per patient were permitted, to avoid 
overrepresentation of some individuals). 
Newly referred patients who attended the 
Skincanceronly clinic between July 1st 2002 and 
December 31st 2003 (when sufficient numbers had 
been recruited) were invited to participate. 
Inclusion criteria were: patient aged 18 years or 
more, eligible to give informed consent and able 
to comply with treatment requirements; and 
presence of a skin lesion for which incisional or 
excisional surgery was deemed appropriate and 
that would result in a wound appropriately closed 
with interrupted polyamide sutures. 
Patients were excluded if the skin was 
contaminated or infected before surgery, if the 
surgical site was not amenable to a moist 
occlusive dressing (eg. eyelid, lip), or if the 
patient had a known allergy to the occlusive 
dressing or one of the ointment preparations. 
Partial thickness skin graft donor sites were also 
excluded. 
Patients (not wounds) were randomized 
prospectively to one of three groups before the 
placement of moist occlusive dressings: no 
ointment, sterile paraffin (Lacri-Lube®, Allergon, 
Urvine, CA, USA) and mupirocin ointment 
20mg/gm (Bactroban®, GlaxoSmithKline, 
Middlesex, UK). 
Allocation to a treatment group was undertaken 
by an independent person drawing one of 150 
discs, (50 each of three different colours) from a 
barrel. Upon completing the barrel, the process 
was repeated. Neither surgeon nor patient was 
aware of randomization, although patients could 
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not be completely blinded to the application of an 
ointment by the nursing staff. 
One surgeon (A.J.D) performed all procedures. 
Surgical techniques included punch biopsy, 
elliptical excision, incisional biopsy, full and 
partial thickness skin grafts, and random pattern 
skin flaps. The site of all removed lesions was 
recorded and all specimens sent for 
histopathological examination. Where multiple 
tumours required excision, the most concerning 
lesion was excised first.108, 109 
All patients were given a detailed postoperative 
instruction sheet regarding wound management, 
warning signs and details of return appointments. 
Patients were followed clinically until wound 
healing was completed at least until removal of 
sutures and longer following skin flap or graft 
surgery, or if a complication developed. 
 
The primary outcome measure was the incidence 
of wound infection, which was recorded and 
classified as: purulent suture site, suture abscess, 
cellulitis, infective necrosis, large subcuticular 
abscess, regional lymphadenitis and septicaemia. 
When there was abscess formation or evidence of 
involvement beyond the local site, a wound swab 
was taken for culture; otherwise, the infection was 
assessed clinically. In the absence of suppuration, 
a wound was considered infected if three out of 
the following signs were present: discharge, pain, 
erythema or induration. All wound infections 
were treated with oral dicloxacillin, 500mg orally 
four times daily, unless sensitivity or allergy 
deemed this to be inappropriate. 
Other complications were recorded for each 
wound managed. Adverse scar outcomes were 
classified as: wound spread, suture markings, 
suture reaction, hypertrophy, keloid, discoloration, 
hypo pigmentation, wound depression, wound 
elevation, dog ears, and contracture. 
Other local adverse outcomes recorded were post 
operative bleeding, allergy to dressing, allergy to 
skin preparation, contact dermatitis, local 
recurrence, subcutaneous fibrosis, granuloma, 
dehiscence, pruritus, persistent pain and nerve 
damage, ectropion, nodal involvement and distant 
metastases. 
Post operative pain was also recorded as: no pain, 
minimal discomfort not requiring analgesia, mild 
pain relieved with paracetamol, moderate pain 
requiring stronger analgesia, severe pain 
unrelieved by analgesia, worst pain ever 
experienced. 
Questionnaire at 6-month follow-up: 
Six months after surgery each patient was posted a 
one-page survey to complete and return. Any 
patient not returning the survey was sent another, 
at 8 - 9 months after operation. The survey asked 
patients to rate the pain experienced and any 
inconvenience of the dressing, to comment on 
their experience, to assess the final aesthetic 
appearance of the first operated area as excellent, 
very good, good, fair, poor or very poor, and to 
rate the quality of the service. Each patients 
categorical scores were converted to ordinal 
variables for analysis as follows: excellent, 10, 
very good, 8, good, 6, fair, 4, poor, 2 and very 
poor, 0. 
Patients who had undergone multiple procedures 
were asked to rate only the first procedure. A sub 
analysis of the first lesions excised was performed 
for patients who had multiple lesions during the 
same operation. Further, the survey sent to 
patients pertained only to the first lesion excised.  
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Statistical Analysis: 
Analysis was conducted on an intention to treat 
basis. Patient characteristics and differences 
between groups were assessed by means of 
analysis of variance using Tukey post-hoc 
analysis, Kuskall-Wallis H test and chi-square test 
as appropriate. All key outcome incidences were 
analyzed using the chi-square test and antibiotic 
ointment was compared with controls individually 
using 2 x 2 tables. All analysis was performed 
using SPSS version 12.0.1 (SPSS, Chicago, 
Illinois, USA.) 
 
Results: 
Some 778 patients were recruited from a total of 
926 referred to the clinic over the study interval 
who required therapy that involved surgical repair 
of incisions; 148 patients were excluded (figure1).  
 Patient characteristics and numbers of incisions 
in each group are detailed in Table 1. One patient 
had more than 15 lesions treated and so only the 
first 15 were included within the study. There 
were no significant differences between the 
groups.  
Each enrolled patient had a median of 1 
(interquartile range of 1; range 1  15) surgical 
wounds managed over the 18-month study 
interval. Second and subsequent operations 
included surgery to different skin sites as well as 
some lesions (predominantly malignant 
melanoma) that were managed in two stages with 
two excisions and closure. 
Some 69.4 per cent of wounds were closed with 
elliptical excisions and direct closure; 29.9 per 
cent of closures involved a random pattern skin 
flap, and  0.7%  a skin graft. There was no 
difference between groups. 
Post operative complications: 
Complications per wound closed are detailed in 
Table 2. There was no difference in the number of 
total complications between groups (p= 0.590). 
Overall complication rates were 3.5 per cent in the 
no ointment group, 4.7 per cent for paraffin and 
4.8 per cent for mupirocin. No patient experienced 
an allergic or other adverse reaction attributable to 
the ointment. 
Infection: 
There was a total of 32 wound infections, giving 
an overall rate of 1.8 per cent, with no significant 
differences between the groups (p=0.490) (Table 
2). Infections were predominantly suture 
abscesses and cellulitis. All wound infections 
responded to oral antibiotics, predominantly 
dicloxacillin. No abscess required drainage, and 
no infection necessitated intravenous antibiotics 
or patient hospitalization. No patient had more 
than one infected wound. 
A sub-analysis of the excision region found a 
significant increase in the risk of wound infection 
in lower limb lesions. The 225 leg lesions had an 
infection rate of 4.4 per cent, compared with 1.4 
per cent for other body areas (p<0.001), although 
the group to which the patient was randomized did 
not influence the risk of infection in the leg. 
(Table 2). 
A sub-analysis of the first lesion on each of the 
778 patients revealed no difference in the 
incidence of skin infection, wound problems, 
bleeding or total complications between the three 
groups. The rate of skin infection of first wounds 
was 1.6 per cent for no ointment, 3.3 per cent for 
paraffin and 2.3 per cent for mupirocin (p=0.460). 
The mean incidence of infection for first wounds 
was 2.3 per cent, and there was no statistically 
significant difference from the pooled data (not 
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shown). Further sub-analysis of small excisions 
and skin flap closure also showed no differences 
between groups (data not shown). 
 
Non-infective complications: 
There were fewer scar complications in the no-
ointment group than when ointment was used, a 
difference that appeared to be due largely to an 
increased risk of skin necrosis in the mupirocin 
group (p=0.007) (Table 2). Of the seven cases of 
skin necrosis, five were in flaps and two in 
elliptical excisions, (one scalp and one ear). 
Survey at 6-months: 
A total of 576 patients (74.0 per cent) returned the 
completed survey. Non responders were not 
significantly different to responders with regards 
age, sex, sites of wounds or complication rate 
(data not shown). 
The application of ointment to the wound made no 
difference to the degree of wound pain or dressing 
discomfort experienced after excision (Table 3). 
Analgesics were used by 25.6, 29.7 and 25.3 of 
patients in the no-ointment, paraffin and 
mupirocin groups respectively (p=0.540). Few 
found their dressing disruptive, embarrassing or 
intolerable. (1.1, 2.5 and 2.6 per cent in the three 
groups respectively (p=0.540). 
With regard to the appearance of the surgical scar 
at 6-9 months, there was no difference between 
patients in the three groups for any variable (Table 
3). Patients who described their wound outcome 
as excellent, very good or good were grouped as 
positive wound responders. The incidence of 
neutral or negative scoring was 10.9, 10.3 and 8.2 
per cent in the no-ointment, paraffin and 
mupirocin groups respectively (p=0.650), and 9.8 
per cent overall. 
 
Discussion: 
To the authors knowledge, no substantial 
evidence has been published regarding the value 
of applying ointment to clean surgical wounds 
after suturing. Current understanding of the role of 
antibiotic prophylaxis in skin cancer surgery has 
been reviewed by Maragh et al.114, and there is 
little evidence regarding the use of topical 
antibiotics. 
This study has shown that paraffin and mupirocin 
ointment provide no additional benefit to the 
patient. Existing advice regarding the role of 
ointments on wounds142, 143, (largely antibiotic 
ointment) following skin lesion surgery and 
before dressing should  be reviewed in the light of 
these findings. 
This study has limitations. The primary analysis 
was on wounds not patients, even though it was 
patients who were randomized. One wound per 
patient could have been studied, but this would 
have involved so many patients that the decision 
was taken to treat each wound as a separate event. 
The sub-analysis of the first wound treated in each 
patient did give the same findings, and no patient 
with several incisions had more than one infected 
wound.  
All operations were performed by a single 
surgeon in a rural city in southern Australia, a 
region with a temperate climate. The findings with 
topical antibiotic usage may not be applicable in 
tropical and subtropical climates114. The wounds 
in this study were not examined routinely by 
medical or nursing staff at 6-9 months after 
surgery, and long term outcomes were limited to 
the patients perception at self - assessment. 
Ideally, both patient and professional long term 
wound assessments would have been undertaken. 
Wound infection was assessed clinically rather 
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than by the culture of wound swabs. The trial 
setting was that of a community dermatological 
surgery centre where wound swabs would not 
taken routinely where infection was a concern.  
The incidence of wound infection was lower than 
expected when the study, including its power, was 
designed. With the identification of a placebo 
infection incidence lower than expected, the 
power to find benefit from ointment is reduced. 
However, the low incidence of infection in the no 
ointment group further raises the question as to 
why infection prophylaxis need be attempted in 
skin excision surgery. 
Of concern was the finding that the rate of skin 
edge necrosis was higher in the mupirocin group. 
Although the incidence was only 1.1 per cent in 
this group, it included six of the seven cases of 
postoperative skin necrosis found in the study, 
raising the possibility that mupirocin may impede 
skin edge perfusion.  
Individual patient considerations that influence 
the decision to use prophylactic antibiotics for 
skin surgery include risk of endocarditis, recent 
joint replacement surgery and wound 
contamination. 
In keeping with other investigators,86, 114 the 
present study  found that surgical wounds on the 
leg  had a significantly increased  risk of infection. 
However, even these sites at greater risk of 
infection did not benefit from the application of an 
antibiotic ointment before wound closure. 
 
Conclusion: 
This prospective randomized controlled trial 
showed that a single application of paraffin or 
mupirocin ointment applied at the time of wound 
dressing made no difference to infection rates, 
pain experienced, wound discomfort, or long term 
wound aesthetic outcomes when compared with 
no ointment application. Mupirocin use was 
associated with a higher incidence of skin 
necrosis. These findings argue strongly against the 
use of ointment on a clean surgical wound before 
the application of a moist occlusive dressing. 
Considering issues of antibiotic resistance, topical 
mupirocin should no longer be applied to clean 
surgical wounds.  
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Assessed for eligibility 
(n=926) 
148 patients excluded on assessment 
Wound not amenable to dressing (n = 96) 
Allergy to dressing (n = 25) 
Contaminated would (n = 8) 
Patient declined to be randomized (n = 8) 
Patient declined involvement (n = 5) 
778 patients enrolled for randomization 
(1801 wounds included) 
Allocated to no 
ointment 
247 patients 
(510 wounds) 
Allocated to Paraffin 
ointment 
269 patients 
(729 wounds) 
Allocated to 
Mupirocin ointment 
262 patients 
(562 wounds) 
All wounds followed up until healing complete, being a minimum to the time of 
removal of sutures and longer if healing slow or complications experienced 
180 completed survey 
at 6  9 months 
(72.9%) 
All surveys analyzed 
202 completed survey 
at 6  9 months 
(75.1%) 
All surveys analyzed 
194 completed survey 
at 6  9 months 
(74.0%) 
All surveys analyzed 
67 failed to 
return survey 
68 failed to 
return survey 
67 failed to 
return survey 
Figure 1: Participant flow chart 
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Table 1: Characteristics of and number of wounds per enrolled patients  
 No ointment Paraffin Mupirocin Total p-++ 
No.of patients 247 269 262 778 
 
Mean (s.d.) Age (years) 58.3 ± 17.3 60.5 ± 18.0 59.1 ± 18.3 59.3 ± 18.3  0.420 
No. of men* 140 (56.7) 138 (51.3) 140 (53.4) 418 (53.7)  0.470 
No. of Wounds included in study 510 729 562 1801  0.273 
Median no. of wounds per pt# 1 (2) 1 (3) 1 (2) 1 ( 1)  0.110 
Values in parentheses are * percentages and # interquartile range unless indicated otherwise. 
 
Table 2: The incidence of post-operative complications per wound managed 
 No ointment 
(n=510) 
Paraffin 
(n=729) 
Mupirocin 
(n=562)  
Total (n=1801) P* 
Wound infection 7 (1.4) 12 (1.6) 13 (2.3) 32 (1.8) 0.490 
Suture abscess 1 5 5 11 
 
Cellulitis 5 5 7 17 
 
Infective necrosis 0 2 0 2 
 
Purulent sutured wound 1 0 1 2 
 
Lower limb (n=225)@ 1 of 57 (1.8) 5 of 102(4.9) 4 of 66(6.1) 10 of 225 (4.4) 0.490 # 
Scar complictns (other) 0 (0) 5 (0.7) 7 (1.2) 12 (0.7) 0.044 
Skin necrosis 0 1 6 # 7 
 
Hypertrophic scar 0 2 1 3 
 
Wound elevation 0 1 0 1 
 
Wound depression 0 1 0 1 
 
Post operative bleed 6 (1.2) 4 (0.5) 2 (0.4) 12 (0.7) 0.230 
Wound dehiscence 3 (0.6) 6 (0.8) 4 (0.7) 13 (0.7) 0.890 
Other complications 2 (0.4) 7 (1.0) 1 (0.2) 10 (0.6) 0.510 
Total complications 18 (3.5) 34 (4.7) 27 (4.8) 79 (4.4) 0.590 
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Values in parentheses are percentages. * Pearsons x2 test. # P=0.007 versus no ointment and paraffin. @ Excisions 
on the lower limbs. 
 
Table 3: Patient reporting (for the first wound treated) of post-operative pain, dressing inconvenience and final 
appearance of surgical scar. 
 No ointment 
(n=180) 
Paraffin 
(n=202) 
Mupirocin 
(n=194) 
Total 
(n=576) 
Wound pain  
    
No pain 58 (32.3) 63 (31.2) 66 (34.0) 187 (32.5) 
Minimal  no analgesia required 72 (40.0) 76 (37.68) 73 (37.6) 221 (38.4) 
Mild  paracetamol sufficient 40 (22.2) 53 (26.2) 42 (31.6) 135 (23.4) 
Moderate  stronger analgesia required 4 (2.2) 5 (2.5) 7 (3.6) 16 (2.8) 
Severe  not relieved by analgesia 2 (1.1) 2 (1.0) 0 (0) 4 (0.7) 
Worst pain ever experienced 0 (0) 0 (0) 0 (0) 0 (0) 
Did not answer 4 (2.2) 3 (1.5) 6 (3.1) 13 (2.3) 
Dressing problem * 
    
No inconvenience from dressing 99 (55.0) 96 (47.5) 87 (44.8) 282 (49.0) 
Nuisance  but no interference 74 (41.1) 94 (46.5) 91 (46.9) 259 (45.0) 
Disruptive or embarrassing 2 (1.1) 2 (1.0) 3 (1.5) 7 (1.2) 
Could not tolerate dressing 0 (0) 3 (1.5) 2 (1.0) 5 (0.9) 
Did not answer 5 (2.7) 6 (3.0) 10 (5.2) 21 (3.6) 
 Appearance of surgical scar at 6-9 months 
    
Excellent or very good 130 (72.2) 151 (74.85) 146 (75.3) 427 (74.1) 
Good 25 (13.9) 24 (11.92) 23 (11.9) 72 (12.5) 
Fair 10 (5.6) 16 (7.9) 14 (7.2) 40 (6.9) 
Poor / very poor 9 (5.0) 4 (2.0) 1 (0.5) 14 (2.4) 
Did not answer 6 (3.3) 7 (3.5) 10 (5.2) 23 (4.0) 
     
Values in parentheses are percentages. There were no significant differences between the groups. * One patient from the 
paraffin group and one from the mupirocin group commented on the dressing, but did not select a category. 
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Summary 
In chapters 1 and 2 we have identified circumstances where an increased risk of wound infection 
might be expected. We have also indicated that topical antibiotic ointment on a closed wound does not 
appear to be a useful antibiotic prophylaxis strategy. 
 
There is an issue in this study in that at times patients had several lesions excised. Repeated lesion 
excisions on the same patient results in a lack of absolute independence. This problem has been 
partly addressed in this study by the further analysis of the first lesion on each patient. However, the 
study was not powered to see significant results on a patient level.  
 
The question remains regarding the role or otherwise of prophylactic systemic antibiotics prior to skin 
surgery. Administration of such antibiotics may be parentral or oral. For simple excisions only an oral 
administration is likely to be acceptable to patients. A randomized controlled trial of this administration 
route would be beneficial in the future to address some outstanding questions. 
 
In my prospective study of infections122, we identified that wounds below the knee are at the highest 
risk of infection following excision of lesion. Findings are consistent with the more recent study by Heal 
et al.53 
 
Is there a way to reduce the infection incidence below the knee? Could a variation in technique 
improve outcomes? These are some the questions that arose following the first two published studies. 
 
The following chapter details the design and theory behind my novel theoretical complication 
minimizing below knee closure. 
49 
 
Chapter 3 Reducing Opposed Multilobed flap repair, - a new 
technique for managing medium sized low leg defects following 
skin cancer surgery 
 
The previous studies raise concerns regarding surgery below the knee. An increased infection 
incidence was noted. This chapter explores a novel skin closure approach for defects below the knee. 
We postulate that the technique may reduce surgical complications in this region, including the high 
infection risk identified in chapter 1. 
  
Traditionally medium and larger skin defects below the knee have been closed with split skin grafts. 
However, it is reported that skin flap repairs have advantages over graft closures in these locations.11  
 
It is recognized that a flap with a substantial length relative to its base has an increased risk of end 
flap necrosis.162 A flap design below the knee needed a minimal length:base ratio. This was the 
overwhelming principle used when we were designing a flap for usage below the knee. The flap was 
designed from first principles from years 2000 to 2002. Once a basic lay out was considered, it was 
subjected to further computer modeling and then spring tension analysis.  
 
The design eventually developed was called the reducing opposed multilobed flap repair or ROM 
repair. The flap technique and the principles that resulted in the design were published in 
Dermatologic Surgery in November 2004.141 The manuscript is as follows: 
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Reducing opposed multilobed flap repair, - a new technique for 
managing medium sized low leg defects following skin cancer surgery. 
Abstract: 
Following skin cancer excision, skin defects on the 
low leg between 10 and 35 mm in diameter can be 
problematic. Direct closure of the wound risks 
excessive wound tension and wound dehiscence. 
Skin grafts heal slowly and often remain unsightly. 
Traditional skin flaps have a limited role. 
The Objective was to develop a random pattern skin 
flap that offers significant advantages over 
traditional techniques including grafting. The 
reducing opposed multilobed flap involves a series 
of semicircular lobes extending both cephalic and 
caudal from the defect. The technique involves 
lobes most distant from the primary defect being 
transposed in turn closer to the defect. The 
technique does not result in the unnecessary 
excision of Burrows triangle skin. The reducing 
opposed multilobed (ROM) flap reduces skin 
tension concerns, lowers the risk of flap necrosis 
and allows for quicker and more aesthetic healing. 
After 20 cases, we have yet to experience 
dehiscence, infection or delayed healing. The 
healing wound is resistant to contraction and 
invariably produces an acceptable aesthetic 
outcome. 
The ROM flap repair allows the dermatologic 
surgeon an additional option when faced with a 
medium sized lower leg defect following skin 
cancer excision. 
Introduction: 
Surgical defects on the low leg following excision 
of skin tumors are often problematic. The skin can 
be tight, especially anteriorly. Skin can be thin and 
of poor quality. Medical conditions such as 
peripheral vascular disease and diabetes can further 
compromise prospects of wound healing. 
 
Traditionally small (< 10mm) defects on the low 
calf are closed by direct closure. Larger defects are 
traditionally closed by split skin graft.163 
 
There has been much attention to defects between 
10 and 35 mm in diameter. To avoid the need for a 
split skin graft, a number of techniques have been 
popularized for these medium sized defects. 
 
We describe a new random pattern flap technique 
for closing elective intermediate low leg skin 
defects. The reducing opposed multilobed flap 
(ROM Flap) addresses many of the shortfalls of 
previous skin closures of this size in this region. 
Replacing graft closure with a random-pattern flap 
repair enables the dermatologic surgeon to handle 
some low limb skin tumors in their own surgery that 
might otherwise require hospitalization. 
Background: 
Following excision of a skin tumor from the low 
calf, the elective defect remaining can be difficult to 
address. There is often minimal adjacent skin 
available for closure. Blood supply can be poor. The 
older populations that often suffer non melanoma 
skin cancer in this region are even more likely to 
have skin of poor quality and reduced perfusion.  
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Primary closure is limited on the lower leg to small 
defects. Even 10 mm diameter defects cannot 
always be closed directly. Skin tension can remain 
excessive and wound breakdown is relatively 
common. In addition, closing such defects with an 
ellipse means that skin at each of the tapered ends of 
the ellipse is wasted. That is, skin is removed 
beyond that required for adequate margin clearance 
of the tumor. In a patient with tight skin and 
considerable prospects of additional skin tumors 
elsewhere on the low leg, such skin wastage is not 
in the patients interests. 
 
Random pattern flaps have been tried on the lower 
leg with limited success. Random pattern flaps can 
minimize skin wastage. However, skin tension 
can remain excessive for optimal healing. Excessive 
skin tension in closing a skin flap predisposes the 
flap to partial necrosis, usually to the extremity of 
the flap. 
 
Furthermore, the length to base ratio of most 
random pattern flaps is such that perfusion to the tip 
of the flap becomes even more questionable. For 
example, a rhombic transposition flap has a length 
to base ratio of 1:1. The distal segment of this 
popular flap often lacks perfusion in usage on the 
lower leg, especially if the patient is elderly. A 
random pattern flap to the low leg needs to have a 
very favorable length to base ratio to ensure an 
acceptably low risk of end flap necrosis. 
 
Other techniques for managing medium sized low 
leg defects include allowing the wound to heal by 
second intention. This approach has a role in some 
patients, but is invariably slow and involves 
considerable time with leg elevation. Furthermore, 
substantial nursing care and attention is required 
through the wound healing process. Others manage 
these types of defects with a purse string suture 
encompassing the entire defect. This often reduces 
the size of the defect to heal by second intention. 
Surgical technique: 
The diameter of the elective defect is measured. A 
mark is placed at the most cephalic aspect of the 
defect. From this point, a semicircle is drawn with a 
diameter 60 % of the diameter of the defect. A 
semicircle the same size is then drawn at the caudal 
end of the defect. The caudal semicircle must be 
orientated in the opposite direction to the cephalic 
semicircle. (See Figure 1) 
 
Two more semicircles are drawn at the cephalic and 
caudal aspects of the original semicircles. These 
semicircles are 60 % of the diameter of the first 
semicircle. Additional semicircles are repeated, 
each being 60% the diameter of the preceding 
semicircle until the diameter of such semicircles 
measures 5  8 mm in diameter. (Figure 2) 
 
Incisions are made along the semicircular surgical 
markings. The skin is then undermined in all 
directions. (Figure 3). 
 
Starting at the extremities of the wound, the 
smallest semicircular flap is transposed into the 
adjacent larger semicircular defect. The suture is 
placed in keeping with the cross markers in Figure 
1. The result is demonstrated in Figure 4.  
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The next semicircle flap is then transposed into its 
adjacent larger defect and sutured as indicated by 
the star markers in figure 1. Figure 5 demonstrates 
the closure at the completion of this stage. This 
process continues until the two largest semicircular 
flaps are transposed into the primary defect. (Figure 
6). 
 
This suturing process to this point may require deep 
anchor sutures at the locations identified in Figure 
1. In our experience this is not often necessary. Skin 
hooks are helpful in positioning the lobes for deep 
and superficial suturing.  
The semicircles transposed into the primary defects 
are then sutured in place as shown in Figures 6-8. 
Additional sutures are then placed in the smaller 
transposed flaps to ensure wound edges are suitably 
approximated. (Figure 7 and 8). Figure 9 shows the 
completed repair. In this case the wound is on the 
antero-medial aspect of the right low leg and 
follows resection of an invasive squamous cell 
carcinoma.  
 
Why 60%? We undertook modeling using a spring 
tension gauge on skin hooks. If the lobes were all 
reduced by 55%, the tension borne by the centre of 
the repair was significantly higher than the tension 
borne at the ends (peripheral tension).  
 
With 70% reducing lobes, the peripheral tension 
was excessive compared with central tension. We 
attempted to find reducing lobes that enabled 
tension to be assumed evenly through the wound. 
Sixty percent produced even tension. Sixty-five 
percent reducing lobes produced slightly greater 
peripheral to central tension.  
 
This crude modeling with the gauge on skin hooks 
was then applied to patients and their defects. In 
clinical application, the 60 % principle held up well. 
Some additional refinement of this model may 
produce further improvements in this technique. 
 
We also tried models with variable percentage 
reductions. This increased the complexity of the 
overall repair without apparent improvement in the 
distribution of tension through the wound. 
 
By way of comparison, primary elliptical closure, 
by its very nature, involves maximum wound 
tension centrally with very low wound tension 
peripherally. This places the centre of a tightly 
closed ellipse at considerable dehiscence risk. 
 
The ROM flap can be applied to defects resulting 
from Mohs micrographic surgery or from defects 
based on a clinical margin of normal skin. We 
recommend that the specimen is marked to indicate 
its most cephalic point. We prefer use of a suture 
marker at this point. This allows easy correlation 
between the specimen and the wound should any 
revision be required. (Figure 9) 
Post operative care: 
Our patients are generally advised to restrict 
walking for two days to meet essential needs. From 
that point onward, we allow a gradual increase in 
walking capacity. We advise elevation of the leg 
when seated or lying. We do not require patients to 
spend lengthy periods with strict elevation. Most 
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patients have returned to full duties by day 4, - 
except that we continue to ask them to elevate the 
leg when seated. 
 
Figure 10 shows the same wound seven days 
following repair. Note that the semicircular incision 
loops have considerably lengthened and now appear 
as lines with waves either side of the wound centre. 
This effect is similar to a Z plasty effect. The 
wound is lengthened and subsequent contracture 
risk is reduced. The Z effect also allows tension in 
the healing to be assumed in multiple planes, 
reducing the risk of sudden tension in the plane 
perpendicular to the principle wound axis causing 
dehiscence. 
 
All wounds have an occlusive dressing applied 
following surgery. We ask patients to leave this 
dressing intact for at least 4 days. We review the 
patient after one week and apply a further occlusive 
dressing. We review patients a week later for 
removal of sutures. Figure 11 shows the same 
wound eighteen days following repair. Healing is 
progressing. Figure 12 shows the wound one month 
after surgery. 
Discussion: 
A number of techniques have been tested to allow 
medium sized low leg defects to be closed 
satisfactorily without the need for a graft. Blair et 
al.164 describe how a long established technique 
involving opposing island pedicle advancement 
flaps can be applied to this clinical scenario. 
Delayed healing and wound infection still affected 
15% of cases studied. Local subcutaneous flaps 
without an axial blood supply can produce poor 
perfusion compared with random pattern flaps. 
Penington et al86 describe a variation on this 
technique whereby a single V  - Y advancement 
flap is effected rather than two flaps. Delayed 
healing and partial flap necrosis remain issues with 
this technique. 
 
The risk of partial flap necrosis can be reduced by 
shortening the distance of the random pattern of 
vasculature to the end of the flap. The ROM flap 
involves a very favorable length to base ratio of 
approximately 0.5:1. (Figure 13) 
 
Complex axial flaps have proved successful in 
numerous lower leg deficits.165, 166  These flaps 
involve mobilizing skin and deeper structures on a 
neurovascular pedicle. In particular, trauma that 
results in loss of much deep tissue as well as skin 
can be closed with good results using microvascular 
flaps, often based on the saphenous or sural 
systems. Most skin cancer deficits, however, on the 
lower leg involve only a skin defect along with 
subcutaneous tissue. Deeper structures are less 
commonly resected. With muscle planes and 
structures intact, disrupting same to close a skin 
defect is rarely appropriate.  
 
Bilobed flaps were initially popularized for nasal 
defects following excision of non melanoma skin 
cancer. Indeed this technique has considerable 
advantages for nasal repairs.128, 167 A bilobed flap 
allows excess skin around the bridge of the nose to 
be transposed through two lobes to a lower nasal 
defect. 
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Bilobed flaps have more recently been used as a 
means of closure for elective lower leg deficits. 
Bilobed flaps traditionally involve minimal if any 
reduction in lobe diameter as the flap is affected. As 
such, this technique can displace the wound tension 
when applied to the leg rather than spread the 
wound tension throughout the repair. 
 
The bilobed concept and the axial flap concept have 
also been combined regarding large lower leg 
defects168. This technique is perhaps more relevant 
to very large defects or defects involving much 
deeper structures than the medium sized defect 
resulting from skin cancer excision from the lower 
calf. A  T type and O  Z type flap repairs 
have also been used to close low leg defects. 
 
Motley et al169 describes an alternate method of 
adapting an established random pattern flap 
technique for usage on the lower leg. This involves 
meshing an advancement flap. This useful technique 
can result in the unsightly fish scale effect that 
follows skin meshing. 
 
Cross leg flaps have also been used to close leg 
defects170. This results in prolonged incapacity and 
immobilization, and is suggested by the authors as 
being a consideration when considerable bone is 
exposed. This technique is not applicable to 
common leg defects following skin lesion excision 
from the leg. 
 
Conclusion: 
Although to date we have only performed this 
technique on twenty patients, we feel the reducing 
opposed multilobed flap repair offers another 
alternative when the dermatologic surgeon is faced 
with a medium sized defect on the low leg. To date, 
we have not experienced a patient suffering wound 
infection, flap necrosis or delayed or non-healing of 
their wound. Further, the dermatologic surgeon may 
be able to handle additional low leg cases in the 
surgery without the need for hospitalization. 
 
Table 1 compares the theoretical benefits and 
disadvantages of the ROM flap with traditional 
primary closure and split skin graft for low leg 
defects. A larger trial is needed to compare the 
ROM flap closure with existing methods of closing 
medium sized low leg defects. The authors have 
commenced such a trial. 
 
Figure 1 
 
Flap 
Flap 
Elective 
deficit 
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Figure 2: 
 
Figure 3: 
 
Figure 4: 
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Figure 5: 
 
Figure 6: 
 
Figure 7: 
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Figure 8: 
Figure 9: 
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Figure 10: Seven days post operative 
 
Figure 11: 
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Figure 12 One month following ROM flap repair of a defect following excision of invasive SCC from low calf 
 
 
 
Figure 13 
 
  
Length 
Base 
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Table 1. Comparison of ROM flap to traditional techniques for closure of low leg defects. 
Feature ROM Flap Primary Closure Split Skin Graft 
Role closing elective 
medium defect size on low 
leg 
Can often close with 
acceptable tension, avoiding 
graft 
Closes small defects, 
medium defects close 
with considerable skin 
tension 
Can be used even on very 
large defects 
Difficulty of technique Most difficult Simplest technique Intermediate  
Donor site required No No Yes 
Elevation post op 1  4 days 2  5 days Can be weeks 
DVT risk through 
immobilization 
Low Low  High 
Dehiscence risk closing 
medium sized defect 
Low High Low 
Cosmetic outcome Good Excellent if heals 
uneventfully, poor with 
breakdown or dehiscence 
Poor, often depression at graft 
site, skin quality can be poor. 
Graft often has poor color and 
texture match 
Return to normal duties Quick Slower Slowest 
Possible need for deep 
anchor sutures 
Slight High No 
Follows natural skin lines 
of tension 
No Yes No 
Post op care required Average Average Heavy. Numerous dressings to 
both sites. Significant nursing 
care.  
Wound length Large for deficit Shorter Deficit length (& width) 
Skin wastage 
Ease of identifying site for 
revision of a margin 
Minimal 
Easy-if specimen oriented 
and marked 
Can be considerable 
Same 
Minimal 
Same 
Wound tension in multiple 
planes 
Semicircular incisions result 
in tension assumed in 
multiple planes 
No, - All tension in a 
single plane 
Graft assumes the negligible 
tension in wound 
Coping with friction in post 
operative period 
Small movement of 
negligible concern 
Small movement of slight 
concern 
Movement can interfere with 
graft taking 
Z effect in repair to 
achieve wound lengthening 
and counter future wound 
contracture 
Semicircular incisions 
lengthen wound in healing 
phase, - contracture risk 
greatly reduced 
No lengthening possible, 
wound contraction can be 
disabling 
Graft contracture risk  
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Summary 
This chapter described the development of and design principles of the ROM flap.  
 
The manuscript describes a theory but does not evaluate whether this theory works. The idea of the 
ROM flap may or may not result in legs that heal better than closures using traditional techniques. 
 
This introductory paper describes outcomes on only 20 patients. Greater numbers and data comparing 
patients who have undergone a ROM flap with those closed with other techniques are needed to 
validate the novel technique. Chapter 4 details my retrospective data on this ROM flap technique, 
detailing to what extent the theoretical advantages were realized.  
 
62 
 
 Chapter 4 Reducing opposed multilobed flaps result in fewer 
complications than traditional repair techniques when closing 
medium sized defects on the leg following excision of skin 
tumour 
Chapter 3 describes the reducing opposed multilobed (ROM) flap and the potential it has to reduce 
complications based on its design. It was incumbent upon me to determine whether or not this novel 
technique delivered on the theoretical advantages. It remained simply an idea until it was trialled.  
 
With this in mind, we subjected the ROM flap technique to a retrospective study once the procedure 
had been used for twenty months. By this time I had closed 140 defects with the novel technique. To 
evaluate the procedure, we compared outcomes from this procedure to outcomes from other below 
knee procedures from the time my extensive database commenced, (July 2002).  
That is, the final 15 months of closing mid-sized leg wounds with other techniques was compared to 
the first 20 months of ROM flap usage. 
This study was a sequential series of all techniques used prior to flap development to usage of the 
ROM flap thereinafter. The trial was published in Dermatologic Surgery in July 2006171 and the full 
text of the manuscript is as follows: 
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Abstract: 
Method: This retrospective  study compares 140 
defects closed with a reducing opposed multilobed 
(ROM)) flap141 with 85 defects closed with 
traditional techniques. 
Results:  
A total of 225 defects between 11 and 44 mm in 
diameter were excised over 3 years from July 1st 
2002. 
There were 140 defects closed by ROM flap and 85 
non ROM closures including 29 O-to-Z flaps and 
12 bilateral transposition flaps. A total of 111 
squamous cell carcinomas, 64 basal cell carcinomas, 
and 11 melanoma were excised. 
ROM flap closures developed 20 complications 
(14.3%) 13 infections, 5 partial wound dehiscence, 
and 2 partial end flap necrosis. 
Non-ROM closures developed 27 complications 
(31.8%):13 infections, 6 partial end flap necrosis, 4 
partial dehiscence, 2 wound depression, 1 
hemorrhage, and 1 persisting pain. Three ROM and 
7 non-ROM   cases suffered two complications. 
The total complication rate was significantly lower 
with ROM flaps (P=.003), including lower end flap 
necrosis incidence. (P=.027) 
Conclusion:  
The ROM flap results in fewer complications than 
traditional techniques when closing defects 11 to 45 
mm in size on the leg and foot. In particular, end 
flap necrosis incidence is lower with ROM flap 
closure. 
Introduction: 
Managing skin cancers below the knee poses special 
problems for the surgeon. Wounds heal poorly 
compared with other skin sites on the body. Skin is 
often tight, especially on the shin, limiting its 
mobilization to close an adjacent defect. Circulation 
is often reduced or poor. Infection rates can be 
higher than elsewhere on the body. 
 
Small defects (less than 11 mm in diameter) are 
usually able to be closed directly. Larger wounds 
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become increasingly difficult to close directly due 
to skin tension. 
 
Skin grafts can be used to close large leg wounds. 
Grafts do not suffer the tension issues faced with 
direct closure. However, grafts have their own 
difficulties, including failure to take and poor 
aesthetic outcomes. Wound depression is so 
common in skin graft closures that it is almost an 
expectation.  Further, skin grafts on the leg require 
considerable periods of elevation and 
immobilization and the associated health risks such 
as deep venous thrombosis (DVT). Nevertheless, 
Skin grafts remain the most common realistic 
closure technique for large leg defects, (> 45 mm 
diameter).163  
 
But what of medium sized defects, 11  45 mm in 
diameter? These defects are often too large to close 
directly, yet it would be disappointing to subject the 
patient to a graft for a defect of this size. 
 
Many random pattern skin flaps such as rotation, 
advancement, transposition and island pedicle flaps 
have been used for these medium sized defects163, 
164, 172
. Bilobed type random pattern skin flaps, 
though initially described for nose defects128, 167, 
have found usage elsewhere including below the 
knee. End flap necrosis rates can be high, however, 
with delayed healing and wound breakdown 
common. Patients may spend lengthy periods before 
returning to normal ambulation and activity. 
Other techniques including cross leg170 and 
meshed169 flap techniques have been described, but 
have significant functional and / or aesthetic 
disadvantages for the patient and may be more 
appropriate for larger defects. 
Axial, fascio-cutaneous and related flaps remain an 
option for large defects but have the disadvantage 
that subcutaneous sheath and tissues are incised and 
mobilized86, 166, 168, 173, 174. These flaps are also 
predominantly for usage in other circumstances and 
for larger defects.  
 
Defects can be left to heal by second intention. This 
often results in lengthy periods of leg elevation as 
well as delays in returning to normal ambulation 
and activity. Further, patients with wounds healing 
by second intention can suffer non healing and 
chronic ulceration problems. 
 
The reducing opposed multilobed (ROM) flap141 
was developed from first principles to attempt to 
address the traditional problems associated with 
random pattern skin flaps and second intention 
healing below the knee. (Figure 1) Using the ROM 
technique, all skin flaps have a low Length to-Base 
ratio of 0.5. (Figure 2) Further, there are no up-
hill flaps involved in this closure where the base of 
the flap is distal to the end of the flap. For these 
reasons the end flap necrosis rate and wound 
breakdown risk should be reduced when below knee 
defects are closed using this technique. 
 
Skin wastage is also an issue in below knee defect 
closures. An elliptical closure can result in up to 
twice as much skin being excised as would be 
required for excising the lesion with an appropriate 
margin alone. If several skin lesions are excised, 
then the increasing loss of otherwise normal skin 
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compounds the patients ongoing skin loss 
problems. 
 
The ROM flap technique involves no skin wastage 
while enabling the patient to mobilize the same day 
as the surgery. While the theoretical benefits of the 
ROM flap are encouraging, evidence is needed to 
identify whether this translates into benefits for the 
patient. 
 
The aim of the retrospective analysis was to 
ascertain whether theoretical benefits from the 
usage of the ROM flap below the knee were borne 
out by improved outcomes and fewer complications. 
Method: 
We retrospectively analyzed all patients treated at a 
dedicated skin cancer surgery unit over three years 
between July 1st 2002 and June 30th 2005. 
We excluded all tumours managed by non surgical 
means. Only lesions excised and defects closed with 
suture were included. We also excluded any defect 
smaller than 11mm in size or larger than 45 mm in 
size. All skin sites below the knee were included. 
This includes the foot. 
 
There were no exclusions based on medical 
conditions, including diabetes, peripheral vascular 
disease, peripheral neuropathy, Alzheimers disease 
and peripheral edema. Further, a tight or inflamed 
skin character did not lead to exclusion. 
 
The age and sex of each patient was noted as well as 
whether they were diabetic, a smoker or were on 
anticoagulant therapy. In keeping with 
recommended practice175, anticoagulants would not 
be ceased other than in the event that INR levels 
were over the therapeutic range. 
 
The retrospective study involved consecutive 
sequential series of patients. Non ROM techniques 
were used from July 2002 until October 2003. With 
the introduction of the ROM technique in October 
2003, all medium sized defects were then closed 
with ROM flaps. The change of practice in October 
2003 followed frustration with complication rates 
from existing techniques and the identification of 
significant theoretical advantages with the ROM 
technique. Other than the change in closure 
technique, no other change in management was 
implemented. Post operative antibiotics were only 
given if infection was apparent. Preparation and 
dressing protocols were consistent throughout. No 
patient received preoperative prophylactic 
antibiotics. 
 
The ROM technique has been described previously 
by us141. Briefly it involves a series of semicircles 
extending strictly in a cephalic and caudal direction 
from the primary defect, (Figure 3). Semi circles 
closest to the defect are 65% of the diameter of the 
primary defect. Each subsequent semi circle is 65% 
of the diameter of the previous semicircle. The 
process of reducing semi circles continues until a 5 
to 8 mm semicircle is planned. 
 
The technique involves a series of transpositions. 
The outer smallest semi circles are transposed into 
the adjoining semicircular defect. This process 
continues until the largest semi circular flaps are 
joined together to close the central defect. The 
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resulting wound appears as a zig-zag type line 
running cephalo-caudal down the leg. (Figure 4) 
 
All surgery was undertaken by one surgeon. All 
wounds were closed with polyamide interrupted 
cutaneous sutures. No wound closures involved 
deep, subcutaneous or intradermal suturing. While 
such deep sutures can be useful in approximating 
skin edges, they are not the usual practice of this 
surgeon when closing defects below the knee. 
Surgery was undertaken with sterile gloves, 
equipment and drapes. The surgeon wore mask and 
gown. All wounds were occlusively dressed post 
suturing. A follow up of at least 4 weeks was 
undertaken on every case by consultation with the 
surgeon. They were also followed up by phone by 
nursing staff. Alternate sutures were removed two 
weeks after surgery with the remaining sutures 
removed five to seven days later. 
 
All ROM patients were allowed to walk the same 
day as surgery but were asked to minimize walking 
for the first 24 hours following surgery. They were 
then progressively allowed to increase ambulation. 
When seated over the first three days following 
surgery, patients were encouraged to elevate legs 
where possible. 
 
All non ROM closure patients were asked to avoid 
any walking for 2 days and were then advised to 
slowly return to normal ambulation. Skin graft 
patients were further advised to elevate their leg for 
at least 7 days where possible. 
 
In the event that a wound dehisced or broke down, 
healing by second intent was effected, with minimal 
debridement undertaken when appropriate. All 
complications were assessed and recorded. Analysis 
was on an intention to treat basis. 
 
All complications noted at any stage were recorded. 
Specifically, infection, haemorrhage, pain, 
dehiscence, end flap necrosis, oedema, delayed 
wound healing, chronic ulceration, elevation, 
depression, contour distortion, etc were all 
specifically assessed in the convalescence period. 
Infection was assessed clinically based on finding 
three out of the following four clinical measures ; 
induration, erythema, pain and discharge. Any 
patient experiencing wound pain three months 
following surgery was deemed to have persistent 
pain.  
 
Statistical methods: 
We calculated that we needed at least 74 cases and 
controls in order to have a power of 0.8 to detect a 
reduction in the complication rate by 50% from 
40% to 20% with a p value of < .05 
Descriptive statistics regarding subjects were 
presented as mean values. Differences in 
proportions of complications between groups were 
assessed using Chi square test. 
Results: 
A total of 417 below knee post excision closures 
were effected on below knee wounds in the skin 
cancer surgery centre from July 1st 2002 until June 
30th 2005. No tumor required excision of tissue 
beyond fat and surrounding subcuticular soft tissue 
structures. 
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A total of 189 defects were below 11 mm in size 
and were closed directly. Three defects were more 
than 45 mm in size and were closed with partial 
thickness skin grafts. 
 
A total of 225 defects were medium in size 
(between 11 and 45 mm in diameter) and were 
hence included in this analysis. The diagnoses 
managed to produce these 225 defects are detailed 
in Table 1.  
A total of 111 were squamous cell carcinoma and 
64 were basal cell carcinomata. 
 
A total of 140 medium sized defects were repaired 
with ROM flaps. Of these, 135 defects were fully 
closed while the remaining five defects were 
reduced in size by at least 80% by incompletely 
closed ROM flaps. Two of these residual defects 
had a graft applied. Three residual defects were left 
to heal by second intent. The largest size of the five 
residual defects was 13 x 12 mm in size. These five 
cases were included with the other ROM flaps in 
analysis on an intention to treat basis. 
 
Eighty-five medium sized defects were closed with 
procedures other than the ROM flap. Twenty-two of 
these defects were closed directly. Sixty-one defects 
were closed with random pattern skin flaps that 
were not ROM flaps. Twenty-nine of these flaps 
were O to Z type closures. Six defects were 
closed with simple transposition flap repairs. 
Twelve defects were closed with bilateral 
transposition flap repair. An additional six defects 
were closed with bilobed type transposition flap 
repairs. The remaining 8  random flap closures 
were; 1 A to T repair, 2 rhombic transposition 
repairs, 2 simple rotation flaps, 1 V to Y type 
island advancement flap and 1 triple transposition 
flap repair. 
 
There were no significant differences in the 
characteristics of the two groups of patients. ROM 
flap patients had a mean age of 58.0 years compared 
with non ROM patients whose age was 59.8 years 
on average. There were 104 defects on men and 121 
defects on women included in the study. Nine per 
cent of patients were on Warfarin therapy while 
24% were on Aspirin therapy. Fourteen per cent of 
patients were diabetic and 15% of patients were 
smokers. 
 
The range of defects closed with ROM flaps varied 
from 11 to 44 mm in diameter. Defects closed by 
other techniques varied from 11 to 31 mm in 
diameter. There were no defects between 31 and 45 
mm in this study until the ROM technique was 
being used. 
 
This is a consecutive series. All non ROM closures 
were undertaken between July 1st 2002 and October 
2003. All ROM flap closures were undertaken 
between October 2003 and June 30th 2005.  
 
In both groups wounds that suffered infection, 
wound dehiscence or end flap necrosis were 
allowed to heal by second intent. No wound 
underwent flap / scar revision. 
 
Two defects were electively closed with split skin 
grafts. Both of these developed wound infections. 
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As there were few split skin grafts and as graft 
outcomes are known to be different to closures 
where skin edges retain their blood supply at 
closure, the skin grafts were excluded from further 
analysis. 
 
Complications experienced (Table 2) 
A total of 140 ROM flap closures experienced 20 
complications in 17 closures. Three ROM closures 
suffered both infection and partial wound 
dehiscence. 
 
Eighty-three non ROM closures (closed either 
directly or by non ROM random pattern flaps) 
experienced 24 complications in 18 closures. Six 
non ROM closures suffered two complications. 
 
Partial end flap necrosis was low in the ROM group 
with only two cases experienced (1.4%). In contrast, 
six non ROM closures suffered partial end flap 
necrosis, (7.2%). This difference was significant. (p 
= 0.024) 
 
Post operative infection was experienced in 13 
ROM cases, (9.3%) versus 11 non ROM closures, 
(13.3%) p=0.36 
 
All but one of the wound infections resolved with 
oral Dicloxacillin 500mg four times daily. One 
ROM flap wound infection did not respond to 
Dicloxacillin but responded subsequently to 
Ciprofloxacin 750 mg twice daily for 10 days. 
 
Partial wound dehiscence was experienced in five 
ROM cases (3.6%) versus four non ROM cases 
(4.8%) This difference was not significant (p=.65). 
No dehiscence extended the full length of the 
wound. 
 
While post operative infection and dehiscence rates 
were not significantly different, the trend favored 
ROM flap repairs. This contributed to an overall 
complication rate of 20 (14.3%) in ROM cases and 
24 (28.9%) in non ROM cases. This difference is 
highly significant. (p=.008) 
 
Seventeen ROM wounds suffered one or more 
complications, (12.1%). In contrast, 18 non ROM 
wounds suffered one or more complications 
(21.7%). (p=.06) 
 
We effected a sub-analysis of O  Z repairs given 
they were the most common of the non ROM 
techniques used in this series. The 29 cases closed 
with O  Z type flap repairs suffered a total of 7 
complications (24.1%). These were two infections, 
three cases of end flap necrosis, one persistent pain 
and one wound dehiscence. Although O  Z 
closures suffered a lesser percentage of 
complications than the other non ROM flaps, the 
difference was not significant, (p=0.25). 
 
There was no case of intra-operative bleed beyond 
100ml and no case of postoperative bleed in those 
patients continuing to take anticoagulants. No 
patient had a pre-operative INR in excess of 
therapeutic range. As such, none of the 72 patient 
taking Warfarin and / or aspirin discontinued their 
medication. There was no case of lymphoedema 
experienced. 
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All ROM patients tolerated the procedure well, with 
no patient expressing concern or disapproval with 
their surgery. In contrast one patient following skin 
graft, one patient following bilateral transposition 
repair and one patient following O  Z repair 
complained of the slow healing and length of time 
to return to full mobilization. All ROM patients had 
excellent final cosmetic outcomes, including the 
five cases that did not fully close with the ROM 
technique alone. There was no ROM closure that 
resulted in an unsightly scar, wound depression or 
elevation. 
Discussion: 
Patients with defects closed with ROM flaps 
suffered significantly fewer complications while 
walking early post surgery, - the same day. 
 
The theoretical modeling of the ROM flap 
suggested wounds would have less tension, 
increased end flap perfusion, and quicker healing. 
This expectation of the ROM flap, with its low 
length-to-base ratio and lack of up-hill flaps was 
borne out by the significant reduction in the 
incidence of end flap necrosis in ROM patients. 
 
Although the trend for ROM patients having lower 
infection and other complications did not reach 
statistical significance, they contributed to the 
overall significantly lower complication rate 
experienced by ROM patients.  
 
ROM flaps were used to manage larger defects than 
the non ROM group. The largest ROM defect was 
44 mm compared with 31 mm in the non ROM 
group. The apparent ROM procedure advantage is 
perhaps further supported by its better results 
despite this larger defect size range. The ROM 
procedure was well tolerated with excellent patient 
acceptance.  
 
As no bleeding complications were experienced in 
any patient, the policy of not ceasing anticoagulants 
for this type of surgery is supported. Reduced 
ambulation following surgery below the knee places 
patients at increased risk of DVT. Continuing 
anticoagulant prophylaxis / therapy minimizes such 
DVT risk. 
 
While no case of DVT was experienced in this 
series, the early mobilization of patients following 
ROM closure should theoretically further reduce 
risk of this complication. A much larger study 
would be required to identify whether this 
theoretical reduced DVT risk is realized. 
 
This study has some significant limitations. There 
was no randomization. This consecutive series 
involved only one surgeon. As a consecutive series, 
there is the possibility that improved experience for 
both surgeon and nursing staff contributed to the 
better outcomes of ROM cases. As a new procedure, 
however, the surgeon had no experience with ROM 
flaps before this study. Further, the surgeon had 
considerable experience before the first excision in 
this trial, having excised and closed over 8000 skin 
lesions prior to the commencement of this study. 
There were several nursing staff changes over the 
study period. At all times during the study both, 
experienced and inexperienced nursing staff was 
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involved in patient management. Although most 
patients were followed up for many months, not all 
were available for longer term follow up. 
Not all skin cancers below the knee require surgical 
excision to manage the tumor. Other treatments 
include; curette (with or without electrodessication), 
imiquimod ointment, photodynamic therapy and 
cryotherapy. Further, clinicians can leave post 
excision wounds to heal by second intention 
following excision of tumor. Second intent healing 
can produce excellent results for defects below the 
knee, but recovery time and time spent with leg 
elevation can be considerable, with the subsequent 
disadvantages to patient. ROM flaps enable prompt 
return to walking and normal activity. 
Conclusion: 
Patients with medium sized defects (11  45 mm) 
below the knees closed with a ROM flap 
experienced significantly fewer complications than 
patients with the similar sized defects closed by 
other means. 
In this consecutive series study, end flap necrosis 
rates were also significantly lower in defects closed 
with ROM flap versus those closed with other 
techniques. 
Although this study is not randomized, it 
demonstrates that in the hands of this surgeon, 
defects below the knee between 11 and 45 mm in 
size should be closed with a ROM flap hereinafter. 
Dermasurgeons should consider adopting this 
technique. 
A future prospective random control trial by other 
surgeons would further evaluate the role of the 
ROM flap in closing medium sized elective defects 
on the leg and foot after skin lesion excision. 
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Table 1:Diagnoses of all lesions excised producing defects 11 to 45 mm in diameter. 
Diagnosis Number Percentage 
Invasive SCC 79 35.1 
Nodular / Invasive BCC 38 16.9 
SCC in situ (Bowens Disease) 32 14.2 
Superficial BCC 26 11.6 
Keratoacanthoma 12 5.3 
Invasive malignant melanoma 10 4.4 
Lentigo maligna melanoma 1 0.4 
Hyperkeratotic actinic keratosis 10 4.4 
Other benign lesions 17 7.6 
TOTAL 225 100 
SCC = squamous cell carcinoma; BCC = basal cell carcinoma. 
 
 
Table 2: Complications experienced with various closures (excluding 2 split skin grafts) 
Type of wound closure Infection Partial 
Dehiscence 
Other complications Total 
ROM flap (N = 140)** 13 (9.3%) 5 (3.6%) 2 (central flap necrosis) 
(1.4%) 
20 (14.3%) 
Ellipse & close direct (N = 22) 
(Non ROM) 
3 (13.6%) 1 (4.5%) 1 (wound depression) 5 (22.7%) 
Other skin flap (N = 61) 
(Non ROM) 
8 (13.1%) 3 (4.9%) 8 in total comprising 
 6 flap necrosis 
 1 persistent pain 
 1 post operative bleed 
19 (31.1%) 
Total Non ROM closures 
(N = 83) 
11 (13.3%) 4 (4.8%) 9 (10.8%)  24 (28.9%) 
TOTAL (N=223) 24 (10.8%) 9 (4%) 11 (4.9%) 44 (19.7%) 
** 5 ROM flaps did not close completely, leaving residual defect up to 20% of original size 
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Figure 1: The layout for the reducing opposed multilobed (ROM) flap repair.  
  
 
Figure 2 : Being a semicircle, the length to base ratio of ROM flap is 0.5 
 
 
Figure 3: Larger ROM flap layout demonstrating no up hill flaps. 
 
 
Figure 4: Following surgery as planned in Figure 3 
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Summary 
This manuscript describes the extent to which the ROM flap delivered on its potential to reduce 
complications following skin cancer surgery below the knee. Chapter 1 identified that infection 
incidence is higher below the knee. Chapter 2 revealed that mupirocin ointment did not lower this risk. 
Chapter 3 and 4 identified that while the ROM flap assisted other outcomes, no improvement in the 
infection incidence was identified. 
 
While the ROM flap did not reduce the incidence of wound infection to statistical significance, the 
technique did result in reduced incidence of flap necrosis, and overall complication incidence. This trial 
helps validate the ROM flap technique for usage closing defects below the knee from 11 to 45 mm in 
diameter.  
 
This study was retrospective, - the only retrospective study in this suite of studies for PhD by 
publication. This is a major limitation of this study. A randomized controlled trial would remain useful in 
the future to validate further the ROM flap technique. 
 
There was but one case of post operative bleeding noticed in this entire below knee wound trial, 
(0.4%). This contrasts with post operative bleed incidences reported on the literature of around 3%.51  
This raises the question as to whether the leg is a region of unusually low post operative haemorrhage 
risk or whether our overall incidence of bleeding was lower than suggested figures. This question 
could be answered through my concomitant prospective study of bleeding complications, a study that 
had been in progress since my database commenced. 
 
The next chapter describes the first of my two bleeding studies. They focus primarily on the issues 
surrounding patients taking warfarin and aspirin medication at the time of their skin surgery. We 
planned to identify when and whether an increased bleeding incidence might eventuate such that 
temporary ceasing of warfarin and / or aspirin may be advisable.  
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Chapter 5 Bleeding complications in skin cancer surgery are 
associated with warfarin but not aspirin therapy  a prospective 
study 
 
Chapters 1 and 2 pertain to the issue of infection complications following skin surgery. Chapters 3 and 
4 deal with the ROM flap and how it can result in reduced skin surgery complications. Now we change 
focus from an emphasis on infection to post operative bleeding complications following skin cancer 
surgery. Such is the subject of chapters 5 and 6. These studies were designed to address some of the 
other questions that had arisen concerning bleeding complications.  
 Should patients cease warfarin for skin surgery?  
 Should aspirin be ceased?  
 Do some body regions bleed more than others? 
 Does the technique to close the wound alter the post operative bleeding risk? 
 Does gender or age alter bleeding risk? 
 
From the outset of my randomized controlled trial of ointments125, my approved protocol included the 
regarded policy that warfarin and aspirin should not be ceased for skin surgery unless the INR is over 
3.0.140, 176   
 
Our prospective study of bleeding complications was designed to address some of these questions.  
The full manuscript as published in British Journal of Surgery177 is as follows: 
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Abstract: 
Method:  
This was a prospective study of 5950 skin lesions 
excised on 2394 patients. No patient stopped taking 
aspirin or warfarin unless the international 
normalized ratio (INR) exceeded 3.0.  
 
Objective:  
The aim was to identify risk factors for post 
operative bleeding following skin cancer surgery. 
 
Results: The rate of post operative bleeding was 0.7 
per cent overall and  2.5 per cent in the 320 patients 
taking warfarin. The rate of bleeding was 1.0 per 
cent for skin flap repairs, 0.4 per cent for simple 
excision and closure, and 5.0 per cent for skin 
grafts. 
Diabetic patients and smokers were not at increased 
risk of bleeding. There were four independent risk 
factors for bleeding: age 67 years or older, odds 
ratio (OR) 4.7 (95per cent confidence interval, 1.8 
to 12.2); P=0.002, warfarin therapy (OR 2.9, (1.4 to 
6.3); P=0.006), surgery on or around the ear (OR 
2.6 (1.2 to 5.7); P=0.012) and closure with a skin 
flap or graft (OR 2.7 (1.4  5.3); P=0.004). Aspirin 
therapy was not an independent risk factor for 
bleeding. 
 
Conclusion: Warfarin therapy, increasing age, 
surgery on or around the ear and closure with flap or 
graft are independent risk factors for post operative 
bleeding complications in skin cancer surgery. Most 
postoperative bleeds were inconvenient but not life 
threatening, unlike the potential risk of 
thromboembolism after stopping warfarin or aspirin. 
There was no case for discontinuing aspirin before 
skin surgery, but the INR should be monitored in 
patients taking warfarin. 
Introduction: 
Some patients who require minor surgery for skin 
cancer will be taking antithrombotic medication 
such as aspirin or warfarin. Their management 
varies greatly from surgeon to surgeon; some 
routinely stop these drugs before surgery, whereas 
others continue them.178 
Several studies have reported no increased risk of 
bleeding associated with continuing warfarin or 
aspirin. All but one of these studies were very small, 
with fewer than 100 patients on aspirin or non 
steroidal anti-inflammatory (NSAID) and up to 16 
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patients on warfarin74, 179-181. The largest  involved 
286 patients taking aspirin or NSAIDs and 26 taking 
warfarin176. The power of these studies would have 
only allowed the detection of a large difference in 
bleeding risk and would have been limited by other 
confounding risk factors. Bleeding  is the 
commonest complication of skin surgery (incidence 
of 3 per cent), and use  of anticoagulants or 
immunosuppressant drugs is a risk factor.51 
 
In recent years surgeons have been encouraged to 
continue warfarin and / or aspirin therapy before 
excision of skin tumours140, 176, 180-187, accepting an 
international normalized ratio (INR) of up to 3.5.183 
Stopping antithrombotic drugs risks life threatening 
thromboembolic sequelae, even when medication is 
stopped only for a short period. 175, 178, 188, 189. 
   
Other forms of surgery have some data available to 
guide surgeons in their decision whether or not to 
stop antithrombotic medication. There is mixed 
advice regarding continuing warfarin and aspirin in 
patients having ocular surgery190, 191. Safe 
continuation of antithrombotics has been reported 
for dental192, prostate193 and cardiac surgery194. 
 
The aim of this prospective study was to monitor 
bleeding complications in a referral based skin 
cancer centre, and to identify risk factors for this 
complication. 
 
Method: 
This study involved patients managed from 1 July 
2002 to 28 February 2006 at a skin cancer surgery 
referral centre in Geelong, Australia. Patients 
antithrombotic medications were not altered either 
before or following skin cancer surgery unless the 
INR was over 3.0. 
Consecutive patients who were treated during the 
study interval were included. Surgical procedures 
included modified Mohs micrographic surgery16; 
small and large excision and closure of lesions; 
curettage (with or without electrodessication); skin 
flaps; full  and partial thickness skin grafts, and 
wedge excision surgery. Patients on warfarin 
therapy must have had an INR test within a week of 
planned surgery, usually within two days. 
Patients who stopped their antithrombotic 
medication before surgery were excluded, as were 
patients with an INR above 3.0. Other exclusions 
were lesions managed entirely by cryotherapy 
patients who had more than 15 lesions treated (to 
avoid over representation), and partial and full 
thickness skin graft donor sites.  
One surgeon performed all procedures. All 
procedures were performed under local anaesthetic. 
Bipolar diathermy was used to effect haemostasis 
where appropriate. The site of all removed lesions 
was recorded and specimens underwent 
histopathological examination. All full thickness 
wounds were closed with interrupted nylon skin 
sutures. Absorbable deep sutures were used only if 
layers deep to the skin required direct closure. 
Occlusive wound dressings were used unless patient 
allergy made this impractical. 
In patients with multiple tumours, the main lesion 
was removed first and a sub analysis of first lesions 
excised was carried out. 
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Patients had follow - up at least until removal of 
sutures. Patients who attended elsewhere for 
removal of sutures were contacted by telephone. 
Post operative bleeding: 
Any post operative haemorrhage or haematoma was 
recorded. A haematoma was regarded as small (up 
to 5 ml), medium (5 to 50 ml) or large (over 50 ml). 
A haemorrhage was regarded as small (up to 25 ml), 
medium (25 to 100 ml), or large (over 100ml). 
Haemorrhage was further classified as delayed (1 to 
24 hours after surgery) and late (more than 24 
hours). 
Statistical Analysis: 
To detect an increased incidence of bleeding of 2.5 
per cent compared with 1 per cent, with a sensitivity 
of 0.05 and a power of 0.8, it was calculated that the 
study would require 280 procedures on patients 
taking warfarin. Recruitment continued until at least 
280 procedures had been performed on patients 
taking warfarin and 280 on patients taking aspirin. 
 
Demographic details were presented as percentage 
or mean (s.d.) as appropriate. Chi-square analysis 
was used to test the significance of differences 
between proportions and categorical variables. This 
method was also used to assess the invariable risk of 
bleeding, with results  presented as odds ratio with 
95 per cent confidence interval.(c.i.) Multivariable 
analysis  using binary logistic regression (forward 
and backward) was used to identify independent 
risk factors for bleeding, and odds ratio beta-
coefficients with 95 per cent were recorded. 
Receiver - operator characteristic (ROC) curves 
were used to determine the age cut off value that 
represented the best combination of sensitivity and 
specificity for risk of a bleeding complication. SPSS 
version 14.0.2 (SPSS, Chicago, Illinois, USA) was 
used for all statistical analysis. P < 0.050 was 
considered statistically significant. 
 
Results: 
Participants 
A total of 5950 skin lesions from 2394 patients were 
treated by excision or curettage in the 44 months. 
Twenty-four patients (29 lesions) were excluded as 
anticoagulant therapy was stopped before they 
attended. A further three patients with an INR over 
3.0 were excluded. One patient had more than 15 
lesions and all lesions after the 15th were excluded 
from the study. 
The mean age of the patients was 64 (17) (median 
67) years; with 55.3 per cent were men. The 5950 
lesions managed included 3175 malignant lesions; 
1436 squamous cell carcinomas (24.1 per cent), 
1381 basal cell carcinomas (23.2per cent), 166 
melanomas (2.8 per cent), 24 lentigo maligna (0.4 
per cent) and 168 other cutaneous malignancies (2.8 
per cent). The 2775 benign lesions excised 
comprised; 1098 benign actinic lesions (18.5 per 
cent), 137 dysplastic melanocytic naevi (2.3 per 
cent) and 1540 other benign lesions (25.9 per cent). 
Twelve patients were not seen at the time of, or 
after, removal of sutures and were followed up 
through telephone contact. All others were seen by 
the surgeon or nursing staff. 
Post operative bleeding 
Forty bleeds were recorded (0.7 per cent) among 
5950 lesions treated. There were 14 haematomas, 
ten small and four medium collections.  Twenty-six 
patients had a haemorrhage recorded; there were 
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twenty-two delayed and four late bleeds. Fifteen of 
the haemorrhages were small, ten were medium and 
one was large.  
The latter occurred 3 weeks after surgery while the 
patient was on warfarin therapy. Although the INR 
was therapeutic at the time of surgery, it rose in the 
following weeks to 7.4. This was the only person 
admitted to hospital with post operative bleeding. 
Management involved stopping warfarin and wound 
compression. 
Three patients (two on warfarin) required wound 
exploration to control bleeding. One patient 
required vessel ligation and bleeding in the other 
two was controlled with bipolar diathermy, and 
compression. Two patients (neither on warfarin) had 
a haematoma evacuated. Bleeding complications in 
all other patients were managed conservatively. 
 
Predictors of increased risk of bleeding 
There was no difference in the bleed rate between 
men and women (0.7 versus 0.6 per cent 
respectively, p= 0.550), but those with bleeding 
complications were significantly older than the 
remainder (75 ± 9 versus 64 ± 17 years; p<0.001). 
ROC curve analysis demonstrated that age 67 years 
provided the best cut-off value for the risk of a 
bleeding complication. 
There were six bleeds (2.1 per cent) among 285 skin 
cancer procedures undertaken in 67 patients 
receiving warfarin therapy only (Table 1).  This 
incidence was significantly higher than in patients 
not on warfarin) (P<0.001). A total of 829 skin 
cancer procedures were undertaken on 334 patients 
taking regular oral aspirin. Nine instances of 
bleeding were documented (1.1 per cent), and the 
incidence was higher than in patients who were not 
on aspirin (p=0.032). There were two bleeds among 
35 skin cancer procedures in 11 patients managed 
with both warfarin and aspirin. The incidence of 
bleeding was significantly higher than in patients 
not on antithrombotics, (P < 0.001).  
A sub-analysis of the first procedures revealed a 
significantly increased rate of bleeding in those on 
warfarin but not those receiving aspirin, (Table 1). 
The rate of bleeding after each surgical technique is 
summarized in Table 2. Only skin grafts were 
associated with a rate over 4 per cent. Bleeding was 
least common when wounds were closed directly, 
(0.4 per cent) or managed by curettage, (0.2 per 
cent). 
Bleeding was not more frequent in diabetics (1.5 per 
cent; two of 135 first procedures) (P=0.86). 
Similarly the rate in smokers (0.4 per cent; one of 
287) wasnt different (P=0.491).  
Univariable analysis showed that a number of 
factors were associated with an increased risk of 
bleeding complications after surgery;  age of 67 
years or greater, warfarin therapy, aspirin therapy, 
flap or graft closure, and surgery on or near the ear, 
(Table 3). 
Binary logistic regression revealed that aspirin was 
not an independent factor as older patients were 
more likely to take aspirin. The remaining four 
variables were independent predictors of bleeding 
complications (Table 3). 
 
Discussion: 
Bleeding complications were increased in patients 
taking warfarin, but not in those taking aspirin. 
There does not appear to be a case for stopping 
79 
 
aspirin before skin procedures. Three other 
independent risk factors for bleeding were age 67 
years or more, surgery in the area of the ear, and 
flap or graft closure. 
The marginal reduction in bleeding incidence risk 
that might be associated with stopping warfarin 
therapy cannot be justified uniformly when 
balanced against the risk of a serious thrombo-
embolic event188, 189. 
This risk has been variously estimated between one 
in 278 and one in 11,500175, 195. The variation in 
these estimates makes it difficult to quantify the 
proportional risk of minor haemorrhage that a 
patient would suffer by stopping antithrombotic 
drugs. 
 
The risk of a major thromboembolic event is 
estimated at 1 per cent per day if the patient has 
suffered a deep venous thrombosis or pulmonary 
embolism within one month of  temporarily 
stopping warfarin cessation.195 
Additional precautions to reduce the risk of 
bleeding may be appropriate when operating on 
patients taking warfarin. The INR should be at the 
lower end of therapeutic range, especially when 
several additional risk factors are present. A fixed 
INR recommendation cannot be made as the 
therapeutic range recommended for patients 
depends on the indication for anticoagulation.183, 195 
There was no life threatening bleeds in this study. 
All were managed with relatively simple measures 
and bleeding complications experienced were 
mainly an inconvenience and did not cause 
significant morbidity. This contrasts with more 
invasive surgery. Deep cavity and organ bleeding 
following major surgery may be occult until 
substantial blood loss has occurred.  In particular, 
abdominal and thoracic cavity bleeding can be life 
threatening, so the findings of this study cannot be 
extrapolated to major surgery. 
This study has some limitations. No NSAIDS or 
other anticoagulants were considered. Newer 
antithrombotics such as ticlopidine188 and 
clopidogrel were rarely being taken by patients 
during the design phase of this prospective study, 
although their usage has increased since. These 
recommendations regarding aspirin and warfarin 
cannot be extrapolated to other antithrombotics.  
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Table 1 Incidence of bleeding complications in patients on warfarin and aspirin 
 Warfarin 
therapy 
Aspirin 
therapy 
Both warfarin & 
aspirin therapy 
Patients on neither 
warfarin nor aspirin 
Total 
Number of patients 67 334 11 1982 2394 
Total no. skin cancer 
procedures 
 
Total no. of bleeds 
285 
 
 
6(2.1)* 
829 
 
 
9(1.1)**** 
35 
 
 
2(6)* 
4801 
 
 
23(0.5) 
5950 
 
 
40(0.7) 
Haemorrhage 3 8 2 13 26 
Haematoma 3 1 0  10 14 
No. of bleeds on first 
procedures 
3(4)** 2(0.6) 1(9)*** 14(0.7) 20(0.8) 
 
Values in parentheses are percentages. *P<0.001, **P=0.002, ***P=0.003, ****P=0.032 versus patients 
receiving neither warfarin nor aspirin (x2 test). 
 
Table 2: Bleeding incidence following different skin closure techniques 
 Operations Post operative 
bleeding 
P  * 
Direct primary closure 3364 14 (0.4) 0.006 
Skin flap repair 1958 20 (1.0) 0.021 
Skin graft 101 5 (5.0) <0.001 
Curette 488 1 (0.2) 0.230 
Wedge excision and repair 39 0 (0) 0.610 
Total 5950 40  
 
Values in parentheses are percentages. * Versus other closure techniques (x2 test). 
 
 
  
81 
 
Table 3: Odds ratios are presented for individual factors found to be associated with  bleeding  and results of 
binary logistic regression.. 
 
  individual factors Binary logistic regression 
 
Odds 
ratio 
Confidence 
intervals 
P * Odds 
ratio 
Confidence intervals P 
Age ≥ 67 years 7.2 (2.8 , 18.4) <0.001 4.7 (1.8 , 12.2) 0.002 
Warfarin therapy 5.1 (2.4 , 10.7) <0.001 2.9 (1.4 , 6.3) 0.006 
Flap or graft 4.1 (2.1 , 7.5) <0.001 2.7 (1.4 , 5.3) 0.004 
Ear surgery 3.8 (1.8 , 8.0) <0.001 2.6 (1.2 , 5.7) 0.012 
Aspirin therapy 2.2 (1.1 , 4.4) 0.026 1.4 (0.69 , 2.9) 0.349 
 
Values in parentheses are 95 per cent confidence intervals. *x2 test. 
  
82 
 
Summary 
In this study we identified four independent risk factors for bleeding in skin cancer surgery: age 67 or 
older, warfarin therapy, surgery on or around the ear, skin flap or skin graft closure. My results suggest 
that a 4% or higher incidence of post operative bleeding in skin cancer surgery is only likely in patients 
with three or more of the four risk factors.  
Given the life threatening thrombo-embolic sequelae that can follow short term cessation of warfarin, it 
should not be routinely ceased for skin cancer surgery and should never be ceased within a month of 
a patient suffering deep venous thrombosis or pulmonary embolus. 
 
There is a limitation in this study that again the predominant analysis was undertaken on lesions rather 
than patients. The independence issue arises again. 
 
Since my trial was published, an interesting and significant study on the risks of ceasing 
antithrombotics was published by Garcia in the Archives of Internal Medicine.196 The investigators 
aimed to assess the frequency of thromboembolism following ceasing antithrombotics. The 
prospective observational cohort study included 101 sites. A total of 1293 episodes of warfarin therapy 
interruption in 1024 individuals were included. The most common procedures were colonoscopy, oral 
and ophthalmic surgery. Heparin replacement was used in only 8.3% of cases overall. Seven patients 
(0.7%) experienced post procedure thromboembolism within 30 days. None of the 7 patients who 
experienced thromboembolism received heparin. 23 patients (2.2%) had post operative bleeding. 14 
of these 23 received peri-procedural heparin or low-molecular-weight heparin. 
The authors conclude that short term interruption of anticoagulants poses a low but statistical risk of 
thromboembolism. 
 
Together with my study specific to skin surgery, the Garcia work substantially increases our 
knowledge of the place for ceasing warfarin short term for skin surgery.   
My incidence of bleeding whilst on warfarin was 2.5%, similar to the patients in the Garcia study. Our 
patients may also face a thromboembolism risk in the order of 0.7% if they had their warfarin therapy 
interrupted. None of our patients had a serious bleed compared with 6 patients having eye, mouth or 
colonoscopy surgery. 
 
Skin surgery appears to have a lower risk of serious post operative bleeds than the minor surgery 
studied in the Garcia trial. Given that lower risk of a serious bleed, the case for ceasing warfarin is 
increasingly difficult to justify for skin surgery against the possible 0.7% incidence of thromboembolism 
that might result from such short term medication alteration. 
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The other risk factors we have identified, age, closure method and location must be factors into any 
decision regarding short term warfarin ceasing. 
 
Doctors managing skin lesions could benefit from more specific details of bleeding risk in all parts of 
the body and more details of risks faced with different surgical procedures and closures.  
 
Further expansion of this more detailed analysis may be useful to clinicians managing skin lesions 
with surgery. The next chapter details the post operative bleeding incidence we identified on different 
regions of the body. 
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Chapter 6 Skin cancer surgery to the ear risks increased 
bleeding complications  a prospective study 
 
Chapter 5 gave us an overall view of risk factors for bleeding following skin surgery. Chapters 1 and 2 
addressed infection complications. Chapters 3 and 4 addressed surgery below the knee. Further 
questions regarding bleeding complications remain. 
 
We have demonstrated that age, more complex skin surgery and patients taking warfarin are risk 
factors for post operative bleeding. My earlier work did not detail sites on the body that may vary in 
bleeding incidence. Doctors manage skin lesions in all skin locations. Specific risks and information on 
individual sites can assist management decisions. Certain body locations have been considered to be 
at increased risk of bleeding complications. In each case the consideration is not based on substantive 
data. Sites on the head and neck have been considered  to have an increased risk of bleeding 
following skin surgery.197 Elsewhere, the ear has been said to share bleeding risk with other sites 
undergoing cutaneous surgery.198 
 
There has been no large prospective data to assist the physician in recognizing which regions face 
greater or reduced bleeding complication risks. With this in mind, we compiled a prospective study of 
body sites and their individual bleeding complication risks. This manuscript has been published in the 
Journal of Plastic, Reconstructive and Aesthetic Surgery in April 2008.199 The published study is as 
follows: 
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Skin cancer surgery to the ear risks increased increasing bleeding 
complications  a prospective study  
Authors: 
A. Prof. Anthony J. Dixon1, MBBS FACRRM 
FACSCM 
Mary P. Dixon2, B Appl Sci (Nursing) 
A. Prof. John B. Dixon3, MBBS FRACGP PhD 
Abstract: 
Method: Prospective study of 5950 skin lesions 
excised on 2394 patients.  
Objective: To identify body sites at increased risk of 
post operative bleeding following skin cancer 
surgery procedures.  
Results: Post operative bleeding incidence was 
0.67% overall (40/5950). The incidence was 
increased at 2.16% when surgery was on or near the 
ear (9/416). (p<0.001) Bleeding incidence on the 
pinna was 2.24% (7/313) and the immediate post 
auricular incidence was 3.03% (1/33).  
The only other body sites demonstrating a bleeding 
incidence over 1% were the nose (6/571), neck 
(3/199) and temple (2/137) regions. In each of these 
sites the increase was not significant compared to 
elsewhere on the body. 
No bleeding complication was life threatening and 
most bleeds were managed with pressure and 
dressings. Only three patients required wound 
exploration to manage ongoing post operative 
bleeding. 
Limitations: This study involved a single surgeon in 
Southern Australia and may not be indicative of 
broader skin surgical practice. 
Conclusion: Postoperative bleeding following skin 
surgery is uncommon and is usually able to be 
managed conservatively. 1 in 2000 procedures 
might come to wound exploration due to ongoing 
bleeding. The ear, including immediate pre-
auricular and post auricular sites are the only body 
regions demonstrating an increased incidence of 
post operative bleeding following skin cancer 
surgery. Attention to haemostasis during surgery 
and care with dressings following surgery may be 
more important when excisions are planned in and 
around the ear. 
Introduction: 
There is limited data to identify sites of skin that 
may be at higher risk of bleeding complications. It 
has been reported that surgery to the outer ear 
shares the bleeding risk with other parts of the 
body.198 Elsewhere, ear nose and throat surgery has 
been identified as at higher risk of unexpected 
readmission with bleeding complications cited as 
one such reason.200 
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Aim: 
Through a prospective study we identified incidence 
of post operative bleeding following skin surgery 
for all body sites to identify locations that may be at 
increased risk.  
Method: 
This study involved patients managed from 1 July 
2002 to 28 February 2006 at the skin cancer referral 
centre, Skincanceronly, Geelong, Australia. 
Patients aspirin was continued and warfarin was 
not altered either before or following skin cancer 
surgery unless INR was over 3.0. In the event that 
post operative haemorrhage occurred, pressure, 
dressings and wound exploration were implemented 
as appropriate. This trial was approved by the 
Barwon Health Research and Ethics committee.  
Surgical procedures included: modified16 margin 
control surgery12, 201; direct excision and closure of 
lesions; curettage; skin flaps; full thickness and 
partial thickness skin grafts; and wedge excision 
surgery. 
Patients were excluded if they ceased their warfarin 
or aspirin prior to attendance or recorded a 
preoperative INR level over 3.0. Bipolar diathermy 
and ligatures were available for all cases. All full 
thickness wounds were closed with nylon or 
polyamide interrupted skin sutures. Absorbable 
deep sutures were used in closure only if sheath, 
cartilage, muscle or other layers were breached or if 
dermis and epidermal closures would benefit from 
separate closure. 
Patients were followed up at least until removal of 
sutures. Expanded details of the methodology have 
been previously published.177  
Statistical Analysis: 
Demographic details were presented as percentage 
or mean ± standard deviation (SD) as appropriate. 
Analysis was univariate (Chi-square method) and 
multivariate; tested using binary logistic regression 
(forward and backward) and odds ratio beta-
coefficients with 95% confidence intervals are 
shown. The SPSS 14.0.2 statistical software was 
used for all statistical analysis. A p-value of less 
than 0.05 was considered statistically significant. 
Results: 
Participants 
A total of 5950 skin lesions from 2394 patients were 
treated by excision or curettage. There were 28 
exclusions. Lesions managed included 3175 
malignant lesions; 1436 SCCs (24.1%), 1381 BCCs 
(23.2%), 166 melanoma (2.8%), 24 lentigo maligna 
and 168 other cutaneous malignancies (2.8%). 
 
Post operative bleeding 
 40 bleeds were recorded (0.67%). There were14 
haematomas and 26 haemorrhages recorded.  
There was one large bleed three weeks post surgery. 
The patient on warfarin had a therapeutic INR at the 
time of surgery but it rose to 7.4 in the weeks 
following surgery. He was the only person 
hospitalized due to post operative bleeding. 
Management involved ceasing warfarin and wound 
compression. 
Three patients (two on warfarin) required wound 
exploration to control bleeding. One patient 
required vessel ligation and the other two patients 
had bleeding controlled with bipolar diathermy, 
Kaltostat ® and compression dressings. Two 
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patients (neither on warfarin) with haematoma had 
their collection evacuated. All other patients had 
bleeding complications managed conservatively; 
pressure dressings and review. 
  
Bleeding in relation to surgical technique 
The lowest bleeding incidence was seen with 
wounds closed directly, (0.42%) and those managed 
by curettage, (0.20%) 
Skin flap closure results in an increased bleeding 
risk, odds ratio (OR) 2.6, (1.4  4.9) P=0.02. 
The types of skin flaps (n=1958) undertaken were; 
488 transposition (24.9%), 341 bilobed (17.4%), 
296 O to S (15.1%), 201 reducing opposed 
multilobed (ROM)141, 171 (10.3%), 103 A to T 
(5.3%), 100 V  Y (5.1%),  429 others (21.9%). 
Skin grafts revealed a higher risk of bleeding of OR 
8.5 (3.3  22) P<0.001. 
 
Bleeding in relation to site on body 
The bleeding incidence at different sites on the body 
is detailed in Table 1. 
Procedures on and around the ear showed an 
increased incidence of bleeding complications, 
2.24% (p<0.001) Ear bleeds were greater for all 
procedure types or whether taking warfarin or not, 
(Table 2). 
 
Surgery on the ear was combined with surgery 
adjacent to the ear as frequently defects on the ear 
were repaired with skin grafts or flaps involving 
adjacent skin. 
No other body site demonstrated a statistical 
increased incidence of post operative bleeding. 
Table 1: The bleeding incidence following surgery to various body regions 
 Operations % of all sites Post operative bleeding Percent P value to rest * 
Head and neck 3436 57.7% 27 0.78% NS P=0.23 
Ear 313 5.3% 7 2.24% P<0.001 
Preauricular 70 1.2% 1 1.43% NS** 
Postauricular 33 0.6% 1 3.03% NS** 
Ear + pre & post auricular 416 7.0% 9 2.16% P<0.001 
Nose 571 9.6% 6 1.05% NS P=0.24 
Scalp 327 5.5% 1 0.31% NS** 
Neck 199 3.3% 3 1.51% NS P=0.14 
Forehead 428 7.2% 3 0.70% NS P=0.94 
Temple 137 2.3% 2 1.46% NS P=0.25 
Cheek & Zygoma 683 11.5% 2 0.29% NS P=0.20 
Chin & lips 218 3.6% 1 0.35% NS ** 
Eyelids 97 1.6% 0 0% NS p=0.37  
Trunk 1063 18.0% 7 0.66% NS p=0.95 
Back 574 9.6% 4 0.70% NS p=0.93 
Chest 266 4.5% 2 0.75% NS p=0.87 
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Pectoral 170 2.9% 1 0.59% NS** 
Abdomen 38 0.6% 0 0% NS p=0.58 
Buttock 15 0.3% 0 0% NS p=0.75 
Lower limb 653 11.0% 3 0.46% NS p=0.48 
Thigh and groin 111 1.9% 1 0.90% NS** 
Leg 468 7.9% 2 0.43% NS p=0.50 
Foot 58 1.0% 0 0% NS p=0.53 
Toes 16 0.3% 0 0% NS p=0.74 
Upper limb 798 13.4% 3 0.38% NS p=0.27 
Arm 185 3.1% 0 0% NS p=0.26 
Forearm 214 3.6% 1 0.47% NS**  
Hand 336 5.6% 2 0.60% NS p=0.86 
Fingers 63 1.1% 0 0% NS p=0.52 
Total 5950 100% 40 0.67% 
 
* P values determined using chi square test comparison to other body locations 
** Single bleeds preclude chi square analysis 
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Table 2: Comparison of procedure on and near the ear with procedures elsewhere.  
Procedure 
 
Total ear 
procedures# 
Ear bleeds % 
 
Total non ear 
procedures  
Non ear  
bleeds 
% P value 
Ellipse 159 3 1.9% 3191 11 0.3 P=0.003 
Graft 65 4 6.2% 31 1** 3.2 ** 
Flap 168 2 1.2% 1770 18 1.0 NS 
on warfarin 27  1 **  3.7% 258 5 1.9 ** 
not  on warfarin  389 8  2.1% 5276 26   0.5 P<0.001 
    
9    
Chi square analysis-**Chi square test not possible with only a single bleed. 
# includes procedures on the ear as well as immediate pre and post auricular. 
Table 3: The percentage of bleeding complication for patients grouped by the number of bleeding risk factors. 
 Overall bleeding 
rate 
Percent of all 
cases managed 
0 risk factors 0.1% 36% 
1 risk factor 0.4% 34% 
2 risk factors 1.2% 23.8% 
3 risk factors 4.3% 4.6% 
4 risk factors** 5.6% 0.3% 
** Only 1 bleed experienced in patients with all 4 independent risk factors 
Risk factors were age 67 or older, warfarin, ear location, and flap or graft closure 
Discussion: 
There is an increased risk of bleeding in patients 
having skin cancer surgery in and around the ear. 
Our analysis was multivariate and demonstrated that 
all procedure types were associated with a greater 
bleed incidence on and near the ear. 
Among ENT surgery cases, ear surgery has been 
regarded as low risk of requiring unexpected post 
operative admission due to complications.202 
Applying firm pressure dressings to defects closed 
on and around the ear often proved challenging. 
We have previously identified three additional 
independent risk factors for bleeding complications 
following skin surgery by multivariate analysis177; 
age 67 or older, warfarin administration  and closure 
with flap or graft. The risk of post operative 
bleeding is 1/1000 with no risk factors, 4/1000 with 
1 risk factor and 12/1000 with 2 risk factors. 
Bleeding risk then escalates with 3 risk factors, 
(43/1000) and all 4 risk factors, (56/1000). 
   A blinded study has demonstrated that even 
experienced surgeons cannot predict whether 
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patients are on warfarin or aspirin at the time of 
operating. 203  
Surgeons should consider anticoagulant 
management and INR levels prior to operating. This 
study involves a single surgeon working in two 
surgical venues in one southern Australian regional 
city.  The bleeding incidence reported may not 
reflect practice elsewhere. 
Conclusion: 
The only  site where post operative bleeding risk 
was found to have increased risk followed excision 
on or immediately adjacent to the ear. An increased 
attention to haemostasis and dressings may be 
considered when surgery to the ear is planned. 
Curettage results in a similar bleeding risk to simple 
surgical excision and closure. 
Bleeding following skin procedures is likely to be 
little more than an inconvenience and manageable 
with steps such as pressure, dressings and review. 
Occasionally (1:2000) the patient may come to 
wound exploration. 
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Summary 
Chapters 5 and 6 combine to provide substantial information on the risks of post operative bleeding 
following skin cancer surgery. In this chapter we found the ear and the skin adjacent to the ear were 
the only body sites where the clinician can predict an increased bleeding risk based on my data.  
Chapters 1 and 2 addressed several infection questions. Chapters 3 and 4 addressed several 
questions regarding surgery below the knee. Now some post operative bleeding questions have been 
explored. 
 
While we strive hard to minimize poor outcomes in skin lesion excision surgery, it is the patients who 
suffer as a result of these complications. It is the patients who must deal with the prolonged healing 
time, the pain, delays in returning to normal duties and the potential diminished aesthetic outcomes. 
 
Chapter 7 takes a new direction. Rather than identifying skin surgery complications and their risk 
factors, we now look at the patients perspective. Do patients feel less satisfied with their clinician if 
they suffer complications such as bleeding or infection? Or are there other aspects of the skin cancer 
surgery service that influence patients perceptions to a greater extent? 
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Chapter 7 Prospective study of long term patient perceptions 
of their skin cancer surgery 
 
The studies thus far described in chapters 1 through 6 focus on complications of skin cancer surgery 
and their risk factors. But how do patients view experiencing such surgical complications? 
 
These complications can result in increased pain, delayed healing, increased visits to the doctor, 
delays returning to normal duties, poorer aesthetic outcome and many other adverse impacts on our 
patients. But how do the patients view these complications? 
 
The medical profession frequently associates lack of complications as a measurement of success of 
surgical interventions. 51 Regarding skin surgery, complications are frequently visible and readily 
apparent to the patient. It is not well known whether infection, bleeding, scar and wound complications 
affect the patients perceptions of the skin surgical service. Does success from the clinicians view 
equate to success from the patient perspective? Or does the patient see other aspects of the service 
provided by the physician as more important to them. 
 
Further, pain is another aspect of wound management we have not adequately addressed thus far. It 
has been considered that wounds that heal quickly generally involve less pain.158 
 
We specifically sought feedback from my patients on the pain they experienced and their perceptions 
of our service through a prospective trial. We sought permission from patients prior to their service 
including advice that we would be surveying them 6 to 9 months after their surgery to determine their 
views on complication, pain and the service provided. 
This prospective trial has been published in the Journal of American Academy of Dermatology.204 The 
complete manuscript of this trial is as follows: 
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Prospective study of long term patient perceptions of their skin cancer 
surgery 
Abstract: 
Background:  We identified factors that influence 
patient perceptions of their skin cancer surgery 
through a prospective study of patients referred to a 
single surgeon during 18 months. 
Method: Patients having surgery resulting in 
a wound sutured and dressed were surveyed 6 to 9 
months later. Monitoring for complaints continued 
for three years. 
Results: In all, 74% of patients returned the 
survey (576 of 778). A total of 250 (43%) rated 
their scar excellent, 177 (31%) very good, 72 
(12.5%) good, 40 fair (6.9%) and 14 (2.4%) poor or 
very poor.  Age, sex, diagnosis, or closure method 
did not result in a variation in scar perception. 
In all, 27.3% of scars (21 / 77) on the trunk were 
rated neutral or negative compared with 6.9% (33 / 
476) of scars elsewhere, (p<.001) and 5% (15 / 305) 
of head and neck scars (p<.001).  Complications did 
not change scar or overall evaluation ratings. 
In all, 393 (68%) rated the overall service excellent, 
145 (25%) very good, 22 (4%) good and 3 (0.5%) 
fair. No patient rated the service poor or very poor. 
Patients rating the service lower were most 
dissatisfied with scar appearance, time waiting 
before surgery, pain from the local anaesthetic, 
nursing care, follow up care, cost and written 
material. 
In all, 99% of patients who rated their scar very 
good or excellent rated the overall service 
optimally, compared with only 85% of patients who 
rated their scar as good or worse.  
Limitations: A single experienced surgeon in a 
southern Australia locale might not reflect the 
perceptions in other clinicians locations. 
Conclusion: Complications and patient 
complaints do not identify patient dissatisfaction 
from cutaneous surgery. The patients perception of 
their scars markedly influences their overall service 
perception. Patients experienced more 
dissatisfaction with repairs on the trunk. 
Introduction: 
Patient perception of skin cancer surgery is poorly 
understood. We have previously described a 9.8% 
incidence of neutral or negative response to long 
term scar appearance125. Others have described a 
similar 13% neutral or negative wound assessment 
after excision of basal cell carcinoma.205 Skin 
cancer is still predominantly managed by surgical 
excision and repair, and cosmetic outcomes from 
such procedures are usually well accepted, even in 
comparison to non operative procedures such as 
radiotherapy205. Using a randomized trial format the 
authors  have previously demonstrated that the 
application of ointment to a wound does not change 
the overall patient assessment of cosmetic 
outcome.125 Many other wound management 
methods have been adopted with the hope of 
improving scars but have shown no significant 
benefit in formal randomised control trials.206, 207 
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Wounds repaired under some tension are 
predominantly closed with sutures, with similar or 
somewhat improved results when compared with 
wounds closed with glues208-212, staples145, 213 or 
tapes214-219. 
 
Little is known of the aspects of skin cancer surgery 
that might result in a higher risk of the patient 
feeling neutral or negative toward their treatment 
experience or their scar. Patient perceptions of the 
outcomes of skin cancer management can differ 
from objective assessments220. It is not known how 
age, sex, diagnosis, type of procedure or 
complications affect patient satisfaction. It is 
possible that other aspects of skin cancer 
management might also alter patients perception of 
service; waiting period before surgery, pain, 
dressing type, local anaesthetic, the operation, 
nursing care, procedure counselling, pathology 
counselling,221 or even cost222, 223. 
Outcomes of wounds assessed over weeks rather 
than months are less likely to demonstrate a 
significant difference as wound healing progresses 
over several months. Study of wound healing 
perception should extend out  at least three months 
to allow for scar remodeling156. 
Methods:  
Through a prospective longitudinal study, we 
sought to investigate whether patient demographics, 
diagnosis or treatment might influence a neutral or 
negative response to skin cancer surgery. This 
prospective study was conducted in accordance with 
the Declaration of Helsinki and was approved as 
part of a larger trial by the Barwon Health Research 
& Ethics Committee. 
Inclusion criteria 
Newly referred patients who attended a dedicated 
skin cancer surgery centre between July 1st 2002 
and December 31st 2003 were offered enrolment in 
the prospective trial. Inclusion criteria required that 
the patient: 
Be referred for management of skin lesion. 
Have incisional or excisional surgery. 
Have treatment resulting in a wound that was closed 
with sutures and to which a dressing was 
subsequently applied. Suturing was predominantly 
simple interrupted, with usage of vertical and 
horizontal mattress sutures at times where 
appropriate. Buried deep absorbable sutures were 
used sparingly before polyamide, particularly on 
larger defects or those with increased tension. 
Exclusion criteria 
Patients were excluded if the skin was contaminated 
or infected before surgery, the surgical site was not 
amenable to a moist occlusive dressing (eg. eyelid, 
lip), or the patient had a known allergy to the 
occlusive dressing. 
Any patient who had more than one procedure 
during the trial period had the trial pertain to the 
first procedure only. Where patients had multiple 
tumours needing excision, the most concerning 
tumour was excised first.  
One dermatologic surgeon (A.J.D) performed all 
procedures in one of two operating rooms. All 
surgery was undertaken using sterile surgical 
gloves, drapes and equipment. The surgeon wore a 
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surgically clean gown and a face mask. The site of 
all removed lesions were recorded and all 
specimens sent for histopathological examination. 
The dressings were moist and occlusive in nature108, 
109
 and were applied by an experienced nurse who 
chose a dressing appropriate to site and patient 
considerations. Each patient was given a detailed 
postoperative instruction sheet, highlighting wound 
management and warning signs for complications. 
Patients who had a large excision and / or flap or 
graft were contacted by telephoned the day after 
surgery. Wounds were followed up clinically until 
wound healing was complete, at least until removal 
of sutures, and longer if there was skin flap or graft 
surgery involved or a complication was 
experienced. 
Patients were counseled verbally and in writing, 
including a one page information sheet. 
Complications record: 
Any infected wounds were recorded and classified 
in the following predetermined groupings: purulent 
site, suture abscess, cellulitis, infective necrosis, 
large subcuticular abscess, regional lymphadenitis 
and septicemia. Wound infections were assessed 
clinically unless there was abscess formation or 
evidence of involvement beyond the local site. In 
these circumstances, a wound swab for culture was 
taken. In the absence of suppuration, a wound was 
considered infected if three of the following were 
present: discharge, pain, erythema, or induration. 
All wound infections were treated with oral 
Dicloxacillin (500mg four times daily) unless 
sensitivity or allergy deemed this to be 
inappropriate. 
Complications were detailed and recorded. Adverse 
scar outcomes were classified as, wound spread, 
suture marking, hypertrophic scar, keloid, 
hyperpigmentation, hypopigmentation, wound 
depression, wound elevation, pronouncement of dog 
ears, and scar contracture. 
Other adverse outcomes recorded included post 
operative bleeding, contact allergy to dressing, 
contact allergy to skin preparation, other contact 
dermatitis, recurrence of tumor, nodal or distant 
metastasis, dehiscence, pruritus, and persistent pain 
or nerve damage. Other adverse outcomes to be 
noted were; ectropion, nodal involvement, and 
distant metastases. 
Questionnaire: 
Six months after surgery, each patient was mailed a 
one-page survey to complete and return. (Figure 1) 
Patients not returning surveys were sent a repeated 
survey at 8 - 9 months after surgery. Patients who 
had multiple surgeries were asked to rate only their 
first procedure so as to minimize confusion. 
All complaints either verbal or written, made by a 
patient about the doctor or the skin cancer surgery 
centre either direct or through a third party was 
documented for at least 36 months after each 
surgery. 
Statistical Analysis: 
All key outcome incidences were analyzed using the 
chi-square test and the positive responders were 
compared with neutral or negative responders 
individually using 2 x 2 tables. The same process 
was used when examining other hypotheses. The 
only exception was our analysis of overall service 
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perceptions. There were no negative responders to 
this question so we compared very good and 
excellent (optimal) responses with good and fair 
(sub optimal) responses with, chi-square test with 2 
X 2 tables. 
Results: 
A total of 926 patients were referred for surgery 
between July 1st 2002 and December 31st, 2003. A 
total of 148 patients were excluded from the study 
for the following reasons: wound sites were not 
amenable to a dressing (n=96), allergy to dressings 
(n=25), contaminated wounds at time of surgery 
(n=8), patient declined (n=13), age under 18 years 
(n=4) and patient unable to understand (n=2). The 
study group consisted of 778 patients with an 
average age was 59.3 ± 18 years. 
These 778 patients had a total of 1801 surgical 
procedures during the 18 month study period.  
In all, 69.4% of wounds were closed with elliptical 
excisions and direct closure. In all, 29.9% involved 
a random pattern skin flap and 0.7% required a skin 
graft. 
Complications: 
Post operative complications are detailed in Table 1. 
There were a total of 32 wound infections, (1.8%). 
Infections were predominantly local abscesses and 
cellulitis, and were treated with and responded to 
oral antibiotics, predominantly Dicloxacillin. There 
were no abscesses that needed draining; no 
infections required intravenous antibiotics, or 
hospitalization. No patient had more than one 
wound that became infected. 
A sub-analysis of the excision region found a 
significant increase in the risk of wound infection in 
lower limb lesions. There were 225 lower limb 
lesions with an infection incidence of 4.4% 
compared with 1.4% for the remaining body areas 
(p<.001). 
A sub-analysis of the first lesion versus second or 
subsequent lesions managed on each of the 778 
patients revealed no significant difference in the 
incidence of skin infection, wound problems, 
bleeding and total complications between groups. 
(data not shown) 
Survey at 6-months 
A total of 576 patients returned the survey (74%). In 
all, 65.5% of men patients returned the survey (274 
out of 418) compared with 83.9% of women (302 
out of 360)  (p<.001). Non-responders were not 
significantly different from responders with regard 
to age, sites of wounds or complication incidence. 
Scar satisfaction: 
Of the 576 respondents, 250 patients (43.4%) rated 
their scar as excellent, 177 (30.7%) rated their scar 
very good and 72 (12.5%) rated their scar as good. 
A further 40 patients (6.9%) rated their scar fair, 8 
(1.4%) poor and 6 (1.0%) very poor. Sex and age 
did not correlate with the likelihood of rating a scar 
neutral or negatively, with responders in each age 
quartile demonstrating around a 10% neutral or 
negative scar assessment. 
 
We analysed all the responses of patients who rated 
their wound neutral or negatively. (Table 2). Of 
note, scars to the trunk were more likely than scars 
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elsewhere to be rated as fair or worse. In all, 21 out 
of 77 trunk wounds (27.3%) were rated fair, poor or 
very poor compared with 33 out of 476 (6.9%) 
elsewhere on the body (p<.001). In all, 4.9% of 
patients (15 of 305) with surgery to the head and 
neck rated their scar fair or worse compared with 
9.2% of lower limb scars (6/65) and 12.4% on the 
upper limb (12/97). 
Analysis of face and head wounds was noteworthy 
for the high level of long term wound satisfaction. 
Of 305 head and neck wounds, 149 (48.9%) were 
rated excellent, 91 (29.8%) were rated very good, 
41 (13.4%) good, 13 (4.3%) fair and 2 (0.7%) poor. 
No head and neck scar was rated very poor. 
Patients were more likely to rate a scar neutral or 
negative if they were unhappy with the time taken 
to undertake surgery or that the pathology 
explanation was suboptimal. When a patient was 
unhappy with their scar they were more likely to be 
unhappy with the overall service. (Table 2).  
Larger defects were more likely to be closed with a 
flap or a graft than direct closure. However, the 
choice or reconstruction did not affect patient 
satisfaction. 
The presence or absence of complications in the 
post operative period did not correlate with a 
subsequent dissatisfaction. Patients with malignant 
and benign tumour surgery had equal rates of 
satisfaction. Patients assessment of the duration 
before the first appointment with the doctor did not 
correlate with subsequent wound assessment. 
Details of the patients assessment of the quality of 
practice explanations and timeliness of the service 
are in Table 3. 
Wound pain: 
Of the 576 respondents, 187 (32.5%) reported no 
post operative pain, 221 (38.4%) reported minimal 
pain that required no analgesia, 135 (23.4%) 
reported pain that was controlled with paracetamol, 
16 (2.8%) required analgesia stronger than 
paracetamol and 4 patients (0.7%) described severe 
pain that did not respond to combined oral 
analgesics.  
Dressing feedback: 
In all, 284 of the 576 respondents (49.3%) found the 
dressing to be no inconvenience to them. 259 (45%) 
rated the dressing as a nuisance while only 12 
patients (2.1%) found the dressing to be disruptive 
or intolerable. 
Overall assessment: 
When asked for their overall assessment of the 
service 6 to 9 months after surgery, 393 of the 576 
(68.2%) rated the service excellent, 145 (25.2%) 
very good, 22 (3.8%) good, and 3 (0.5%) fair. No 
respondent described the overall service as poor or 
very poor. 
We sought to further analyse aspects that resulted in 
the 25 patients rating the service good or fair 
(suboptimal) rather than very good or excellent, 
(optimal). 
Answers to questions from the 25 respondents who 
rated service as suboptimal were compared with 
those rating the service optimally. (Table 4).The 
following characteristics correlated with a 
suboptimal rating: male sex, perceived undue time 
taken between consultation and surgery, assessment 
of the local anaesthetic, rating of the actual 
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operation, nursing care assessment, follow up care 
rating, cost of service rating, rating of written 
material provided and self scar assessment.  
There were four aspects of service that were 
consistently and repeatedly highlighted by those 
rating the overall service as suboptimal. These were 
scar assessment, cost of service, follow up care, and 
written material provided. In each of these 4 
parameters, over two thirds of respondents 
providing a suboptimal rating came from the 25 
patients who rated the overall service as suboptimal. 
In contrast, less than one third of respondents 
providing a suboptimal rating for these parameters 
came from the 538 patients that considered the 
overall service optimally. In each case the 
difference was highly significant. 
No patient rated the overall service as suboptimal 
unless at least two of these four aspects were rated 
sub optimally. Four patients nominating the service 
as good indicated two areas in which their 
assessment was suboptimal. Five patients 
highlighted 3 of these 4 parameters as suboptimal, 
thirteen listed all 4 parameters. The three patients 
who rated the overall service as fair indicated all 4 
parameters were suboptimal. 
Complaints: 
Aside from the surveys, no complaints were made 
by any patient during the trial period up or until 
December 31st
 2006. There was no verbal or written 
complaint to the doctor or the staff. Further, no 
complaints were made to any third parties about us 
and then forwarded or reported to us. The survey 
invited respondents to add comments after the 
specific questions. (Figure 1) No patient chose to 
make a complaint within the comments section. 
Discussion: 
Just more than 90% of patients in this study rated 
their long term scars as excellent, very good or 
good. This is consistent  with previous smaller 
studies.205 These data showed that more than 99% of 
patients who rated their scar very good or excellent 
also rated the overall service very good or excellent. 
In contrast, only 85% of patients who rated their 
scar good, fair, or worse rated the overall service 
very good or excellent. It is clear that end points for 
quality can be very different from end points of 
service as assessed by the patients. Although 
surgeons are conscious of complications such as 
tumour recurrence and strive to minimise such 
adverse outcomes, patients did not associate 
complications with suboptimal scars or poor quality 
of service. 
 
This study demonstrated that patients were more 
likely to consider the scar suboptimal when it was 
on the trunk, including the chest, back and 
abdomen. In contrast, patients were overwhelmingly 
very satisfied with surgical scars to the face and 
head.  
In response to these findings, we have developed a 
fact sheet explaining the characteristics of scars to 
the trunk, including the higher and problematic 
incidence of hypertrophic scars, wound spread and 
keloid formation.  
 
Surgeons excising lesions from the trunk may 
consider using reconstructive techniques that reduce 
the incidence of widened scars, hypertrophic scars 
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and keloids. These include the modified buried 
vertical mattress suture79and the incorporation of 
both deep subcuticular and epidermal sutures. Such 
deeper sutures have been demonstrated to result in 
better patient scar acceptance when used after 
abdominal224, hip225, 226 and leg surgery145. Other 
studies, however, have not found such an 
advantage.129, 213  
 
The infection incidence and distribution of infection 
in this study is consistent with previously published 
data in a larger study.122 Patients scheduled for 
excisions below the knee can be advised that they 
are subject to higher rates of infection and that more 
prolonged and involved post operative care can be 
expected. 
 
Other than location on the body, this study 
demonstrated that patients were more likely to rate a 
scar poorly with a perceived delay before surgery or 
if they were not fully satisfied with the explanation 
of the pathology results. Patients expressed 
dissatisfaction with delays as short as several days 
between learning that a skin lesion needed excision 
and the eventual surgery.  
 
There were several instances when the patient scar 
assessment did not correlate with our assessment. 
For example, there were two patients seen over six 
months after surgery who rated their scar as poor 
despite the fact that the study investigators had to 
check photographic records to identify the site of 
surgery as no visible scar was apparent. Similarly, 
there were patients who rated their scar excellent 
when the surgeon would have preferred a more 
aesthetic result. A more formal analysis of patient 
versus clinician assessment of scar was not possible 
as relatively few patients were examined 6 to 9 
months after their procedure. 
Two thirds of the patients did not require analgesia 
after excision of skin lesion. Those who required 
analgesia predominantly controlled their pain with 
paracetamol. Wound dressings were well tolerated 
by patients with few regarding dressing as more 
than just a minor nuisance. 
 
The study has many limitations other than reliance 
on patient scar assessment in the absence of an 
independent evaluator. The study involved only a 
single experienced skin cancer surgeon in a 
southern Australian temperate climate. Wound 
infections can be substantially higher in more 
tropical regions, including northern Australia.227 
The study surgeon may be more experienced and 
skilled at facial surgery than trunk surgery, possibly 
accounting for the large discrepancy in wound 
satisfaction between trunk scars and other scars. 
Women were more likely to return the survey than 
men. It is unclear whether this had any effect on the 
validity of the study. 
 
Five patients who had no out of pocket expense for 
their skin cancer management rated the cost of the 
service as fair. These were pensioners who assigned 
the total cost of their treatment to the public health 
system (Medicare Australia). They may have chosen 
to describe the cost as fair in the belief that a fair 
cost for pensioners is that Medicare Australia should 
meet the entire account. As such, the wording of our 
cost question may have been inadequate. 
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Conclusion: 
To maximise patient satisfaction with respect to 
surgical skin cancer services, the surgeon needs to 
consider aspects of service beyond minimising 
tumour recurrence, minimising complications and 
addressing complaints if and when they are made. 
 
The most important factor influencing a patients 
overall assessment of a skin cancer service is their 
perception of the final aesthetic outcome of the 
wound. 
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Table 1: Complications experienced  
 Total 
Number of patients 778 
Number of operations 1801  
Average age of patients, y 59.3 ± 18 
Male  418 (53.7%). 
Average operations per patient 2.3 
Wound infection 32 (1.8%) 
Suture abscess 11 
Cellulitis 17 
Infective necrosis 2 
Purulent sutured wound 2 
Lower limb excisions (n=225)) 10 
Scar complications - other 12 (0.7%) 
Skin necrosis 7 
Hypertrophic scar 3 
Wound elevation 1 
Wound depression 1 
Post operative bleed 12 (0.7%) 
Wound dehiscence 13 (0.7%) 
Other complications 10 (0.6%) 
Total complications 79 (4.4%) 
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Table 2: Comparison of patients who perceived scar positively versus neutral or negative patient self assessment 
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Sex Male 261 232  88.9 29 11.1 5 NS 
Female 292 267  91.4 25 8.6 8 
Age, y 58 or older 300 271 90.3 29 9.7 6 NS 
 
Under 58 253 228 90.1 25 9.9 7 
Past skin cancers Yes 73 66 90.4 7 9.6 3 NS 
No 480 433 90.2 47 9.8 10 
Skin site Trunk 77 56 72.7 21 27.3 0 P<.001 
Limbs or head & neck 476 443 93.1 33 6.9 13 
Benign or malignant Benign 272 245 90.1 27 9.9 7 NS 
 
Malignant 281 254 90.4 27 9.6 6 
Analgesia Required analgesia 149 131 87.9 18 12.1 5 NS .27 
No analgesia 402 366 91.0 36 9.0 0 
Complications Yes 33 28 84.8 5 15.2 0 NS 0.28 
No 520 471 90.2 49 9.8 13 
Operation Direct closure 400 362 90.5 38 9.5 9 NS 
Other 153 137 89.5 16 10.5 4 
Dressing experience No issue 276 249 90.2 27 9.8 0 NS 
Nuisance or negative 275 250 90.9 25 9.1 5 
Assessment of time to 
appointment 
VG or excellent 514 463 90.1 50 9.9 2 NS 
Good or fair 36 32 88.9 4 11.1 3 
Assessment of time to 
surgery 
VG or excellent 515 477 93.8 38 6.2 5 P<.001 
Good or fair 33 17 51.5 16 48.5 0 
Rating of surgery 
explanation 
VG or excellent 507 457 90.1 50 9.9 5 NS 
Good or fair 40 36 90.0 4 10.0 0 
Rating of pathology 
explanation 
VG or excellent 497 454 91.3 43 8.7 5 .003 
Good or fair 50 39 78.0 11 22.0 0 
Overall assessment VG or excellent 498 455 91.4 43 8.6 0 .006 
Good or fair 54 43 79.6 11 20.4 0 
 
NS, Not significant. 
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Table 3: Patient assessment of the timeliness and quality of explanation of services 
 
Excellent Very good Good Fair Poor Very poor Did not 
answer 
Time until first 
appointment with 
doctor 
359 (62.3%) 167 (29.0%) 34 (5.9%) 3 (0.5%) 0 0 13 
Time until operation 
was undertaken by 
doctor 
323 (56.1%) 204 (35.4%) 33 (5.7%) 3 (0.5%) 0 0 13 
Procedure explained 265 (46.0%) 254 (44.1%) 35 (6.1%) 9 (1.6%) 0 0 13 
Pathology explained 275 (47.7%) 238 (41.3%) 41 (7.1%) 6 (1.0%) 3 (0.5%) 0 13 
Written explanations 
provided 
280 (48.6%) 239 (41.5%) 40 (6.9%) 9 (1.6%) 4 (0.7%) 1 (0.02%) 13 
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Table 4: Comparison of patients who rated overall service very good or excellent (optimal) versus those who 
rated the service as suboptimal 
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Sex  Male 266 249 93.6 17 6.4 .033 
Female 297 289 97.3 8 2.7 
Age 58 or older 304 289 95.1 15 4.9 NS .54 
Under 58 259 249 96.1 10 3.9 
Past skin 
cancers 
Yes 75 71 94.7 4 5.3 NS .68 
No 489 468 95.7 21 4.3 
Skin site Trunk 84 79 94.0 5 6.0 NS .46 
Limbs or head & 
neck 
479 459 95.8 20 4.2 
Benign or 
malignant 
Benign 274 264 96.4 10 3.6 NS .37 
Malignant 289 274 94.8 15 5.2 
Analgesia Required 
analgesia 
155 148 95.5 7 4.5 NS .96 
 
No analgesia 408 390 95.6 18 4.4 
Complications Yes 34 31 91.2 3 8.8 NS .2 
No 529 507 95.8 22 4.2 
Operation Direct closure 405 390 96.3 15 3.7 NS .72 
Other 159 149 93.7 10 6.3 
Dressing 
experience 
No issue 280 271 96.8 9 3.2 NS .16 
Nuisance or 
negative 
283 267 94.3 16 5.7 
Assessment 
time to 
appointment 
V G or excellent 524 502 95.8 22 4.2 NS .21 
Good or fair * 34 31 91.2 3 8.8 
Assessment 
time to surgery 
V G or excellent 521 501 96.2 20 3.8 .004 
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Good or fair  * 35 30 85.7 5 14.3 
Surgery 
explanation 
V G or excellent 518 497 95.9 21 4.1 .08 
Good or fair * 40 36 90.0 4 10.0 
Pathology 
explanation 
V G or excellent 508 485 95.5 23 4.5 NS 
Good or fair * 50 48 96.0 2 4.0 
Rating of local 
anaesthetic 
V G or excellent 500 484 96.8 16 3.2 .001 
Good or lower 61 52 85.2 9 14.8 
Rate the 
operation 
V G or excellent 511 502 98.2 9 1.8 .001 
Good or lower 49 33 67.3 16 32.7 
Nursing care 
assessment  
V G or excellent 545 532 97.6 13 2.4 .001 
Good or fair * 18 6 33.3 12 66.7 
Follow up care 
rating 
V G or excellent 507 502 99.0 5 1.0 .001 
Good or lower 51 31 60.8 20 39.2 
Cost rating V G or excellent 427 422 98.8 5 1.2 .001 
Good or lower 135 115 85.2 20 14.8 
Written 
material rating 
V G or excellent 486 478 98.4 8 1.6 .001 
Good or fair ** 72 55 76.4 17 23.6 
Scar 
assessment  
V G or excellent 426 422 99.1 4 0.9 .001 
Good or lower 138 117 84.8 21 15.2 
 
 NS, Not significant 
* There were no patients rating this category or overall service as poor or very poor. 
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Figure 1 Survey of participants 6 to 9 months following lesion excision.  
 
How would you rate the wound discomfort from the 
time of the surgery? 
No pain 
Minimal discomfort that did not require pain killers 
Mild pain, relieved by Panadol, Panamax or Herron 
Paracetamol 
Moderate pain that required stronger pain killers to 
gain relief 
Bad pain that could not be relieved with pain killers 
The worst pain I have ever experienced 
 
How would you rate the inconvenience of the 
dressing from the time of the surgery? 
No inconvenience 
A nuisance, but did not interfere with things 
Very disruptive or embarrassing to me 
Could not tolerate the dressing 
 
Rate our performance as either:  
Excellent, Very Good, Good, Fair, Poor or Very 
Poor to the following 12 questions: 
 
How would you rate the time taken from being 
referred to Skincanceronly Clinic until the time you 
were assessed by our Doctor? 
How well was the procedure explained to you in 
advance? 
How would you rate the time taken to have your 
skin surgery? 
How effective was the local anaesthetic? 
How would you rate the actual operation? 
How would you rate the nursing / reception staff? 
How well was the pathology result explained to 
you? 
How good was the follow up care by 
Skincanceronly Clinic? 
How good was the final look of the scar? 
How would you rate the cost of your treatment at 
Skincanceronly Clinic? 
How good was any written material provided? 
Overall, how do you rate our service? 
 
Please feel free to add any comments: 
 
  
107 
 
Summary: 
While chapters 1 through 6 expanded our knowledge base of skin surgical complications, they did not 
provide information on the patients view regarding suffering such complications. We now have further 
information regarding how patients view their skin cancer surgery. The patients viewpoint differs from 
that of the clinician. Suffering complications did not result in an increased likelihood of patient 
dissatisfaction.  
 
26% of the patients did not return the survey. These patients may have been more dissatisfied that 
those who responded. Also, patients who had more than one lesion excised may have had difficulty 
recalling which lesion was excised first in their reflections on the skin service. 
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 Chapter 8  Other publications 
Chapters 1 through 7 describe the original studies that comprise the core works of this thesis. Other 
manuscripts have been published designed to assist doctors in better understanding management of 
skin cancer including managing complications of skin surgery.228-236 They do not include original 
research.  
 
Australian Family Physician published 13 peer reviewed and published manuscripts for which the 
author was Dr. Anthony Dixon. 
These included the 23 Golden Rules of Managing Skin Cancer229 as well as 12 pieces geared at 
providing a broad update on managing skin cancer for the general practitioner audience.228, 230-243 
These manuscripts are reproduced in full in the Appendix to this thesis. 
 
Two other manuscripts have been published providing a short literature review on two separate 
controversies in cutaneous oncology. One manuscript reviewed the role of sentinel node biopsy in 
managing melanoma. The second discussed the possible role or arc welding as an ultraviolet source 
that might lead to skin cancer production.  
 
The role of sentinel node biopsy in managing melanoma was published in CML Dermatology in 
2006.244 The full text of this manuscript follows:  
MSLT spells a halt to sentinel lymph node biopsy 
Background 
In 1892 Dr. Herbert Snow observed that melanoma 
patients who developed lymph node involvement 
invariably died of their malignant melanoma. Ever 
since that time, clinicians and researchers have been 
trying to find a way to turn this observation into a 
better outcome for our patients. Snow proposed that 
all melanoma patients have their regional lymph 
nodes resected245. However, several subsequent 
random control trials have failed to demonstrate a 
survival advantage from elective lymph node 
dissection (ELND). 
 
80% of the nodes resected through ELND had no 
melanoma involvement. Patients were being 
subjected to considerable morbidity for no apparent 
benefit. ELND has long been abandoned from 
routine management of malignant melanoma. But if 
we knew which 20% of patients had the melanoma 
in their nodes, maybe these melanoma patients 
could be selected for lymph node dissection.  
 
Sentinel node biopsy described: 
100 years later, Dr. Donald Morton described 
sentinel lymph node biopsy (SNB); a method of 
identifying patients that have early node 
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involvement such that these patients could then be 
offered completion lymphadenectomy (CL)246. 
Mortons approach promised three advantages for 
patients: improved survival, enhanced patient 
information and guidance for future management. 
 
SNB involves the use of lymphoscintography and / 
or dye to identify the sentinel node (SN). The 
identifier is injected around the site of the primary 
melanoma, enabling the material to be carried 
through the lymph system to the SN. Dissection of 
the node basin can then identify this SN and it is 
removed leaving adjacent nodes in place. 
Involvement of melanoma in the processed SN 
would then direct management to CL. 
 
Lens247 identified that the likelihood of melanoma 
involvement in SNs is proportional to the Breslow 
thickness of the primary tumor. 1% of tumors below 
Breslow 0.75mm will have SN involvement. 8.3% 
of patients with Breslow 0.75 to 1.5 mm 
melanomata will have positive SNs, 22.7% of 
patients with Breslow 1.5 to 4 mm and 35.5% of 
more advanced tumors. 
 
The original idea of SNB involved resection of the 
SN at the time of resection of the primary tumor. In 
two separate studies, Leong248 and Evans249 have 
identified that outcomes are not different if the 
primary tumor excision is undertaken before the 
SNB. Given the only management of melanoma that 
improves outcome is prompt wide local excision 
(WLE), a lengthy delay for tumor resection just to 
enable simultaneous SNB is not justified. 
 
Multicenter trial of SNB 
After developing the concept of SNB, Morton went 
on to test the efficacy of this technique through a 
well designed and powered random control trial 
known as the Multicenter Selective 
Lymphadenectomy Trial (MSLT  1). This trial was 
based at the John Wayne Cancer Institute in Santa 
Monica California. The multinational centers 
involved in the trial included Sydney Australia 
where a large number of patients were recruited for 
the trial. 
 
MSLT excluded melanomata with Breslow below 1 
mm. This has proved an appropriate exclusion given 
the low incidence of positive SNs in patients with 
early tumors. 
 
In this study, 1200 patients were randomized to 
SNB with all those having positive nodes 
proceeding to CL. There were 800 controls who did 
not have SNB performed, but had 
lymphadenectomy if and when nodes became 
subsequently involved. The survival data from the 
MSLT  trial has now been presented at the 
American Society of Clinical Oncology meeting in 
May 2005. This same data has also been presented 
to the 6th World Congress on Melanoma in 
September 2005 and American Society for 
Dermatologic Surgery Annual Meeting in October 
2005. 
 
The five year survival for patients in the SNB group 
was 87%, versus 86% in the control group (p=0.4). 
The sentinel node patients gained no survival 
benefit. 
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Sub-analysis: 
Unfortunately a flawed sub-analysis of this study 
has created more interest than the core data. Morton 
showed that SNB positive patients demonstrated a 
22% 5 year survival advantage over patients who 
later developed tumor involved nodes. Such a so-
called advantage is hardly surprising. This simply 
reminds us those patients likely to develop involved 
lymph nodes fare better than patients who have 
proven lymph node involvement. 
 
At the end of the day, the one comparison that is 
valid in the MSLT study is the primary outcome for 
which the study was designed, the 5 year survival of 
treatment versus control arms. Their outcomes are 
the same. 
 
An earlier study by Kretschmer250 has suggested an 
outcome benefit for SNB patients. This paper is 
much quoted but flawed. The study compared SNB 
patients with those who later developed positive 
clinical nodes and had delayed lymph node 
dissection (DLND). 5 year survival for DLND 
patients was 50.2% compared with 62.5% for SNB 
positive patients. 
However, the study did not involve patients who did 
not have SNB and did not develop clinical nodes. 
As such, the study simply compared those who 
might develop metastatic nodal involvement with 
those that did develop involved nodes. The 
discussion within this manuscript goes to some 
length to explain how lead time bias was factored 
into the analysis. Lead time bias was not the 
predominant flaw in the analysis, rather it was the 
failure to compare patients on an intention to treat 
basis. 
 
How much melanoma in the SN?: 
In the MSLT trial, any melanoma in the SN meant it 
was deemed positive and CL was offered. But there 
is increasing evidence that small amounts of 
melanoma within the SN may not be of great 
concern. Vuylesteke251 demonstrated that patients 
with Breslow thickness less than 2.5 mm who had 
positive SNs with tumor load of less than 0.3 mm 
did not have additional nodes involved with 
melanoma. They had excellent survival prospects 
and did not need to have CL. 
 
The significance of a small amount of melanoma 
involvement in a node (or micrometastasis) was 
further questioned by Giblin et al252. If there are tiny 
foci of melanoma in SNs then it is difficult to justify 
further offering the patient CL. At times there will 
be pockets of melanoma in peripheral sinuses of 
SNs which, apparently for immunological reasons, 
do not progress to metastasis. It would be 
devastating to effect a block dissection and cause 
morbidity such as lymphoedema only to find 
predictably uninvolved nodes in the large dissection 
specimen. 
 
Starz253 data demonstrates any SN involvement of 
less than 1 mm has no adverse prognostic 
significance. Spanknebel254 demonstrated that 
micrometastases identified only on 
immunochemical staining have no adverse 
prognostic significance. 
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We can no longer justifiably advise all our SN 
positive patients to proceed to CL. Cochran255 has 
demonstrated that only one third of patients with 
positive SNs will have melanoma in adjacent nodes. 
Indeed proceeding to CL may only be appropriate if 
the original tumor had a large Breslow thickness, 
there was considerable volume of melanoma in the 
SN and also dense dendritic cells in the SN. It is 
difficult to justify advising a patient with an early 
Breslow tumor to have the SNB procedure if we 
would not then advise proceeding to CL even when 
the SN contained melanoma. 
 
Complications of SNB: 
The MSLT trial demonstrated that 10.1% of patients 
who undergo SNB, develop complications.256 
Indeed the complication rate rose to 37.2% in those 
patients who were SNB positive and went on to CL. 
SNB complications are such a problem on the head 
and neck that some centers exclude patients who 
have primary head and neck tumors. For example, 
some 25% of these SNs are located within the 
parotid gland, with dissection to identify and 
remove the node risking facial nerve damage.257 
 
If SNB provides no survival benefit but is 
associated with such concerning morbidity figures, 
there must be some other reason to justify patients 
undergoing this procedure. 
 
Information for patients: 
Mohrle et al258 studied 283 SLN patients finding 
that these patients gained no benefit in survival 
time. While these findings supported the MSLT 
data, this paper also raised again the value of SNB 
as a means of providing accurate advice for our 
patients. 
 
Zogakis47 demonstrated that 9% of SNB negative 
patients developed tumor recurrence. Similarly, 
Gershenwald259 demonstrated 13% of patients who 
were SNB negative would develop recurrence 
somewhere else within three years. Clearly SNB 
negative patients are surviving poorly compared 
with patients who did not have SNB and did not 
subsequently develop nodal involvement. 
 
SNB negative patients can be advised that they are 
less likely to develop later metastatic disease. But 
they cannot be advised that metastatic disease has 
been ruled out. The advice that ones SN is negative 
simply means a slightly lower risk, not a removed 
risk of mortality from the malignancy. Melanoma 
can spread via the circulatory system. Melanoma 
patients need careful follow up even if they have a 
negative SNB. 
 
Melanomata with large Breslow thickness are 
associated with increased risk of mortality and 
increased risk of SN positivity. As such, to what 
extent is that added risk that comes with having a 
SN positive merely reflect the underlying Breslow 
thickness? 
 
Roka260 undertook a multivariate analysis of risk 
factors for survival in malignant melanoma. The 
analysis was able to separate the predictive value of 
Breslow thickness from the predictive value of SNB 
status. Roka found that SNB was not predictive of 
overall survival. Rather, Breslow thickness was the 
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only independent predictor of overall survival. In an 
analysis of disease free survival, Breslow thickness, 
SNB status and ulceration were all predictive. 
Breslow thickness remains the single most 
important detail of a melanoma when it comes to 
providing information and advice to our patients. 
 
In transit melanoma: 
Thomas et al101 raised the concern that the SNB 
procedure may increase our patients risk of 
subsequent in transit and loco-regional metastases. 
These same investigators published the excellent 
random control trial of 1 cm versus 3 cm clearance 
for high risk melanoma in the New England Journal 
of Medicine261. In this metanalysis101, they 
demonstrated an incidence of in-transit metastasis in 
SN positive patients following CL was 4  5 times 
that expected for that mean Breslow thickness. In 
other words, it is doing synchronous or near-
synchronous wide excision and completion 
lymphadenectomy, while melanoma cells are still in 
transit, which may cause the increased incidence of 
in-transit disease. 
 
Others have not confirmed this in transit risk262. Van 
Poll 263 demonstrated Sydney patients were not 
more likely to develop in transit disease following 
SNB. Kretschmer 264 refuted Thomas concluding 
that SNB and CL avoid later tumor recurrence and 
prolong disease free survival in melanoma patients. 
Unfortunately this study has the same intention to 
treat problems that were characteristic of their 
earlier work250. 
 
Regardless of whether or not SNB leads to an 
increased risk of in transit and loco-regional disease 
or not, the vital impact for our patients is whether 
they will live longer through the SNB procedure. 
The MSLT study demonstrates they will not. As a 
sufficient number of authors, independently, have 
now described an increased incidence of in-transit 
metastasis, all patients considering this operation 
should be warned of this possible risk. 
 
Does SNB guide future management?: 
We do not have treatments for metastatic melanoma 
that prolong life. Chemotherapy, radiotherapy and 
other approaches have not demonstrated improved 
long term survival for our melanoma patients. We 
cannot even justify CL in SNB positive patients 
with tumor load in the SN beneath 1 mm. 
 
This situation might change in the future. Emerging 
treatments such as B RAF inhibitors265 may provide 
a future management for patients with early nodal 
disease. If such treatments are demonstrated to 
improve patient survival, then we may have a 
reason to identify early metastatic disease through 
the SNB procedure. 
 
Abandon SNB?: 
Medalie and Ackerman266 consider that SNB now 
lacks any value to the extent that it should be 
abandoned. Thomas101 does not suggest the 
technique be abandoned, but does consider the 
technique should no longer be used outside of 
randomized control trials (RCTs). Indeed given the 
lack of benefit of SNB and the significant morbidity 
that comes with the procedure, it is now difficult to 
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justify the test outside of RCTs. At best SNB 
provides some extra advice for patients with 
melanomata between Breslow 1 and 3 mm in 
thickness.  
 
Conclusion: 
SNB promised three things; improved survival, 
enhanced patient information and guidance for 
future management. SNB does provide added 
information for patients who have tumors with 
Breslow thickness between 1 and 3 mm. In all other 
respects the SNB procedure has not delivered on its 
promise. 
SNB may have a role in the future if and when an 
adjuvant melanoma therapy is developed that 
improves survival in patients with demonstrated 
early metastatic involvement.  
The MSLT results are very helpful. If a 
pharmaceutical product performed as poorly as SNB 
as shown in MSLT the product would never achieve 
FDA approval, but rather it would be abandoned or 
invited to proceed to phase iii trials. Why should a 
surgical management be regarded any differently?  
It is now difficult to justify ongoing usage of the 
SNB procedure other than in the context of an RCT 
to evaluate possible future medical or surgical 
interventions for melanoma patients. SNB is 
certainly not a standard of care for melanoma 
patients. 
 
Another original manuscript shedding light on non solar causes of skin cancer was published in the 
Medical journal of Australia in 2004.267 Specifically, we discussed the possible role of ultraviolet from 
arc welding being a contributing cause in skin cancer development. The full manuscript published is as 
follows: 
Ultraviolet radiation from welding and possible risk of skin and ocular malignancy 
Introduction: 
The overwhelming majority of skin cancers are 
caused by exposure to ultraviolet radiation (UVR) 
from the sun. However, there are non-solar sources 
of UVR that may also cause cancer. The purpose of 
this review is to explore the evidence that radiation 
from the welding arc may also be a significant risk 
to welding trades people, people near arc welding 
trades people and to occasional users of arc welding 
processes such as mechanics, sculptors and farmers.  
A literature search was conducted using Pubmed 
and Synergy. The key words used in the search 
were: basal cell carcinoma, squamous cell 
carcinoma, skin cancer, melanoma, weld, 
welding arc, radiation and ultraviolet.  
 
Ultraviolet Radiation and Cancer: 
The full spectrum of UVR can be classified into 
three groups based on wavelength. Ultraviolet A 
(UVA) spans UVR with the longest wavelength 
(400  315 nm). Over 98% of solar UVR exposure 
is UVA. UVA penetrates the skin more deeply than 
Ultraviolet B (UVB) or Ultraviolet C (UVC), 
but is less associated with DNA damage and the 
formation of pyrimidine dimmers. 268 269 
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UVB includes UVR with shorter wavelengths (315 
 280 nm). UVB accounts for less than 2% of our 
solar UVR exposure because much of it is absorbed 
in the upper atmosphere. UVB accounts for most of 
the DNA damage within skin cells and most of the 
resultant skin cancers. 268 269 
 
UVC covers the range of UVR with the shortest 
wavelength (280  100 nm). UVC exposure is 
insignificant for most people because solar UVC is 
readily absorbed in the atmosphere before the 
damaging radiation reaches the earths surface. 
Knowledge of the effects of UVC on skin is less 
clear. However, UVC may be as dangerous to skin 
as UVB. 269 270 
 
Arc welding produces the full spectrum of UVR. 
The short distance between the arc and the welders 
skin may not be sufficient to absorb most of the 
UVB and UVC. Arc welders may be at significantly 
increased risk of developing actinic skin damage 
including malignant melanoma and non-melanoma 
skin cancer (NMSC), particularly if they have 
inadequate protection.  
Apart from producing UVR, arc welding can also 
produce thermal burns on the skin of welders. Such 
burns may also contribute to skin developing skin 
cancer.271 
 
Review of evidence 
Table 2 summarizes the limited studies into the risk 
of skin cancer from arc welding. The only formal 
case control study was by Emmett and co-workers 
272
, who studied 77 welders, 75 other workers 
exposed to welding and 58 non-exposed workers. 
Emmett did not find a link between welding and the 
development of cancer on the skin of welders. 
 
A number of features of the Emmett study are 
noteworthy. They studied one workplace, described 
by Emmett as a plant where both management and 
workers were careful to maintain hygienic practices. 
. . well-run welding operations which use and 
enforce current safety standards. . . He also said 
that;  it is not believed these results can be 
extrapolated to welding operations which do not 
employ good practices. 
 
The study looked at relatively young people. The 
average age of the workers examined was 45. The 
average age of welders was 43 and they had been 
working for the same employer for an average of 
16.9 years. Skin cancer often occurs decades after 
the significant UVR exposure. It is conceivable that 
the UVR skin damage experienced by those workers 
had not manifested as actinic changes because they 
were relatively young. 
 
The Emmett study involved workers welding 
predominantly with mild steel. Higher intensity 
welding such as welding aluminium was not 
explored. Formal medical histories of those 
examined were not available.  
 
Furthermore, the Emmett study did not include 
examination for naevi. At the time the relationship 
between atypical naevi and malignant melanoma 
was not understood. We now recognize that 
multiple atypical naevi are associated with a 
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significant increase in the subsequent incidence of 
malignant melanoma.273 
 
The evidence linking ocular melanoma with 
welding is contradictory (Table 2). In an overview 
on the topic, Tenkate 274, 275 postulated that UVR 
from arc welding was one of the most intense 
artificial sources of optical radiation. 
 
Effect of Welding Technique on UVR Exposure: 
Lyon 276 describes common welding techniques and 
variables and the relative radiation exposure from 
each. These variables and their impact on UVR are 
summarized in Table 3. 
UVR is associated with arc welding processes 
which include manual metal arc, gas metal arc 
(GMA) and gas tungsten arc welding. GMA 
welding generally produces the most radiation of 
the common welding processes and aluminium is 
generally welded by GMA welding. (Table 4) 
It should be noted that not all welding processes 
involve striking an arc. These forms of welding 
produce minimal UVR. Welding processes and their 
UVR emissions are summarized in Table 5. 
 
Skin protection is essential to minimize UVR 
exposure. Suitable protection while arc welding 
includes wearing suitable gloves as well clothing 
over the arms and forearms down to the gloves. For 
welding trades-people working in an uncomfortable 
environment, operator comfort and convenience are 
a major factor. In particular, the radiant heat from 
welding can be quite uncomfortable and welding on 
a hot day compounds the problem. The temptation 
is to discard heavy welders clothing in favour of 
light, summer clothing. The wearing of short 
sleeved shirts and / or no gloves while welding 
places the skin of the forearm and hand at 
considerable UVR exposure. Many welders 
recognize the red triangle that develops over the 
manubrium. This erythema commonly results from 
the welder forgetting to fasten the top shirt buttons 
before welding. 
Aside from full time welders, there are many trades-
people who perform welding as a small part of their 
occupation (eg; motor mechanics) and these people 
often find it inconvenient to put on protective 
clothing in order to undertake a quick job.  
A third group of welding workers, sculptors and 
trades-people doing highly intricate work, also 
experience difficulties in achieving fine details with 
heavy clothing over their forearms and thick gloves 
on their hands. 
Furthermore, while trades-people are invariably 
educated in health and safety issues when learning 
to weld, other workers in the same workplace may 
not be. It is common to see welders working in a 
factory with thick clothing and a suitable mask 
while other people in the vicinity have little or no 
skin protection. Sometimes these are assistants 
supporting the metal being fused. Exposure to UVR 
of all people working in the area of a welding arc 
should be considered. 
 
Recommendations: 
While there remain many unanswered questions 
regarding arc welding and skin cancer risk, there are 
some principles that we can consider in prevention 
of skin cancer. These include: 
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When skin cancer patients deny a significant history 
of sun exposure, arc welding should be considered a 
possible cause.  
Welders can be advised regarding appropriate 
clothing and be encouraged to choose sunscreens 
that include UVC protection. Workers welding 
aluminium risk the highest exposures to artificial 
UV and can be so advised. 
The lack of quality studies means there is 
uncertainty about the risk of skin cancers from arc 
welding operations and further investigations are 
needed. 
Issues that should be considered in any future study 
include: 
 Examining workers who commenced 
welding at least 25 years prior to the study.  
 Workers using varying arc welding 
processes, shielding gases and metals. 
 Part time welders who do not adequately 
protect themselves. 
 Examining for atypical naevi as well as 
actinic keratoses, NMSC and malignant 
melanoma.  
 Obtaining histology on any suspicious 
lesions.  
 Background actinic damage from solar 
UVR. 
 Similarly, other risk factors such as skin 
type need consideration.  
Table 1: Evidence linking development of cutaneous malignancy with arc welding 
Investigator Finding Level of evidence 
Emmett et al 272 Case control study of 77 welders and 133 other workers in 
the same factory. Welders more frequently suffered 
erythema and cutaneous burns. Neither welders nor controls 
were found to have NMSC. The only melanoma identified 
was in a non welder. Only seven workers demonstrated 
actinic keratoses.  
Level III.2 
Currie & Monk 277 Review five cases of NMSC in welders  advise that this 
non solar source of UVR should not be overlooked 
Level IV 
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Table 2:   Evidence linking development of ocular malignancy with arc welding 
Investigator Findings Level of evidence 
Holly et al 278 Case control study of 221 patients with uveal melanoma. 
Welding exposure increases the risk of developing 
intraocular melanoma 
Level III.2 
Guenel 279 Case control study of 50 patients with uveal melanoma. 
Identified increased risk through welding and considered 
ultraviolet the likely cause 
Level III.2 
Pane 280 Assessed risk factors in 125 patients with ocular melanoma. 
Wearing sun glasses did not reduce risk. Lifetime UVB 
exposure was not associated with greater risk 
Level IV 
Vajdic 281 Case control study of 290 patients with ocular melanoma. 
Total UVR exposure, especially prior to age 40 increases 
life risk of ocular melanoma 
Level III.2 
 
 
Table 3: Factors that increase UVR exposure whilst arc welding 276 
Factor Effect 
Working close to arc Radiation dose is inversely proportional to the square of the distance from 
the arc 282 
Increased Arc energy Increases UVR  
Duration arc is struck Increases UVR  
Increasing electrical 
current 
Greater current produces increased UVR 
Metal being welded Aluminium arc welding produces high levels of UVR. Stainless steel 
welding produces intermediate levels. Arc welding iron produces still less 
UVR 
Shielding gas used Helium absorbs more UVR than argon. Shielding with helium thus reduces 
skin exposure to UVR 
Angle of plate  Emission is maximum at 50  60 degrees from the surface of the plate 
being welded 282 
Welding with no arc Other forms of welding produce minimal if any UVR. Non arc welding 
techniques include; oxy-acetylene welding, resistance welding, friction 
welding, laser and electron beam welding, friction stir welding 
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Table 4: Factors contributing to the high levels of UVR emission when welding aluminium 283 
Factor Effect on UVR emissions 
High Conductivity Aluminium is 4  5 times as conductive as steel, requiring higher arc energy 
to concentrate sufficient power to effect a weld 
Shiny surface Aluminium is more reflective than steel 
Technique required Welders using high radiation techniques such as gas metal and gas tungsten 
arc welding 
 
Table 5: Welding processes and UVR emission produced by each 276 283 
Level of UVR emission Welding processes 
High Gas metal arc welding  Gas tungsten arc welding 
Medium Most arc welding processes including domestic units 
Low Submerged arc welding 
Minimal or nil Oxy-acetylene welding  Resistance welding  
Friction welding 
Laser and electron beam welding Friction stir welding 
 
Figure 1: (welder hands.jpg) 
Welder with multiple squamous cell 
carcinomata (SCC) on the hands despite 
denying a history of outdoor exposure. All 
five lesions marked were proven SCC on 
histology.  
 
 
 
Figure 2: (welding tubes.jpg) 
 
Tradesman using gas metal arc welding with a 
relatively high current. His unprotected left hand is 
very close to the welding arc.  His head is closely 
over the arc risking welding fumes into his lungs. 
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Abstract: 
Most skin cancers are caused by solar ultraviolet 
radiation (UVR) and it is believed that the most 
dangerous part of the UVR spectrum is Ultraviolet 
B (UVB) (315  280 nm).  Fortunately, most of 
UVB is screened from the earth's surface by the 
outer atmosphere.  Arc welding produces the full 
spectrum of UVR, including UVB. It is therefore 
likely that welders will be exposed to a greater risk 
of skin cancer than the rest of the population. 
Nevertheless, there has been minimal exploration to 
determine whether the UVR from arc welding is 
causing skin cancer. 
The only major study of skin cancer from arc 
welding involved examining welders who were 
careful to protect themselves. The workers did not 
demonstrate an increased incidence of skin cancers 
in this study. Cancers may take years to develop and 
there was no follow-up of these workers to see if an 
increased incidence of cancers developed over time. 
Further, the radiation protection observed by these 
welders may not be typical of the welding industry 
as a whole. As such, the study cannot be 
extrapolated beyond this safe workplace and these 
young welders. Further studies are needed 
examining welders in their senior years, ensuring 
there is a lengthy time for their skin to have 
developed cutaneous malignancies. In contrast to 
cutaneous malignancies, there is evidence that 
welding increases the risk if ocular malignant 
melanoma. Just as we urge the public to protect 
themselves from UVR, we need to consider similar 
advice to arc welders.  
 
Another manuscript alerting general practitioners to the possible large ultraviolet doses than can be 
endured while arc welding was published in Australian Family Physician.238 
 
In May 2008236 a short letter on melanoma update was published in the British Medical Journal. It 
reads as follows: 
Sentinel lymph node biopsy: Let's get back to basics in managing melanoma  
I find the debate about sentinel node biopsy 
puzzling.1 Clinicians are getting bogged down with 
this question while the fundamentals of managing 
cutaneous melanoma are being neglected. A recent 
Australian study284 showed that doctors perform 
poorly in key aspects of managing this aggressive 
tumour.  
 
Only a third of doctors excised cutaneous melanoma 
with the margins recommended by the Australian 
guidelines - a third used larger margins and, more 
worrying, a third used narrower margins. Most 
doctors failed to check the skin at follow-up, and 
they often diagnosed suspicious lesions by biopsy 
not local excision. Australian surgeons are slow to 
acquire dermoscopic skills that improve early 
diagnosis of melanoma. A patient with a thin 
melanoma is more likely to develop another 
cutaneous primary than metastatic disease. Yet 
dermoscopy and skin checks are often neglected.  
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If surgeons used time spent doing the sentinel 
lymph node biopsy in routinely examining the skin 
at follow up, there would be a tangible gain for our 
patients. In contrast, a procedure with a 10% 
incidence of complications256 which does not 
improve five year survival,285 is hardly a tangible 
gain.  
 
Let us get back to the basics. Lets offer our patients 
skin checks for life, ensure dermoscopy is a routine 
part of this examination, and excise suspicious 
lesions rather than biopsy them to gain histology. 
Most importantly, lets give our patients with 
invasive melanoma a minimum 10 mm margin of 
normal skin rather than skimp.  
 
 
Other published works in the field of skin cancer have also been completed, again not specifically 
related to complications of skin surgery.244, 267, 286-288 
These publications have collectively provided further education and information for general 
practitioners managing skin cancer including the management and minimization of complications 
associated with skin lesion excision. 
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Chapter 10 Conclusions 
This thesis comprises seven original published studies.122, 125, 141, 171, 177, 199, 204, 289 Supporting the seven 
substantive works is a number of other informative and educational published manuscripts. 
The predominant conclusions of the seven trials are as follows: 
1) Infection prospective study: 
Our data suggest there are limited circumstances in skin lesion surgery where an infection incidence 
of over 5% could be expected. The area of greatest risk was below the knee. This includes the shin, 
calf foot and toes. Infection incidence was significantly higher below the knee than above the knee. 
There is a case for routine preoperative systemic antibiotics for all skin surgery procedures in this 
region.  
Risks of antibiotic resistance would need to be considered in any decision to routinely administer 
antibiotics prior to skin surgery. Other circumstances where an infection incidence over 5% was noted 
include: wedge resections of lips and ear and skin grafts. Skin surgery in the groin may result in a 
similar increased risk. My data was too limited to make a conclusion in this region.  
Skin flap repairs resulted in a fivefold increased incidence of infection compared with direct closure. 
Nevertheless, the only site where skin flap repairs resulted in an infection incidence of over 5% was 
below the knee. As such, expected closure is not, per se, an indication for preoperative antibiotic 
prophylaxis. This study was limited by a lack of multivariate analysis. Given multiple risk factors were 
apparent, such an analysis would have been preferable. Further, age was not considered as a 
possible confounder in this study. 
 
2) RCT of ointment on wounds prior to dressings 
There appears to be no value in applying ointment to wounds prior to occlusive dressing. Neither the 
application of sterile paraffin nor mupirocin ointment resulted in a significant difference in post 
operative complications. In particular, infection incidence was not altered by the administration of 
these agents. Pain, wound discomfort and aesthetic outcome were also not altered by usage of such a 
single application of ointment. 
Of concern was an unexpected risk of skin necrosis in the mupirocin arm of my trial. Topical antibiotics 
can also result in contact dermatitis and antibiotic resistance. Topical antibiotics are contraindicated 
following the sutured closure of clean skin surgical wounds.  
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3) & 4) Retrospective trial of the reducing opposed multilobed (ROM) flap repair 
The ROM flap is a novel flap for closures below the knee. Based on first principles it was designed to 
meet the ideal requirements to minimize complications in this at risk site. 
The subsequent retrospective trial of ROM flaps demonstrated reduction in the incidence of end flap 
necrosis but wound infection was not significantly reduced with this technique. Overall, complication 
incidence was reduced when this repair technique is used to close defects 11 to 45 mm below the 
knee when compared with traditional closure techniques. 
 
5) The effect of antithrombotics on post operative bleeding complications 
There are limited circumstances when warfarin should be ceased prior to skin cancer excision. We 
identified four independent risk factors for bleeding following skin lesion excision: warfarin, age ≥ 67, 
surgery on or adjacent to the ear and closure by skin flap or graft. Only when 3 or more out of four risk 
factors are present can a post operative bleeding incidence of greater than 4% be predicted.  
Given the life threatening thrombo-embolic sequelae that can follow short term cessation of warfarin, 
my data suggest it should not be routinely ceased for skin cancer surgery and should never be ceased 
within a month of a patient suffering deep venous thrombosis or pulmonary embolus.  In general, my 
data shows short term stoppage of warfarin should only be considered when two or more further 
bleeding risk factors are present. 
Care should be taken to ensure INR levels are within reference range and below 3.0 both prior to skin 
surgery and in the post operative period.  
Aspirin was not demonstrated to be an independent risk factor for post operative bleeding and should 
not be ceased for skin lesion excision based on my data.  
 
6) Body sites and bleeding risks 
The ear and skin immediately adjacent to the ear is the only site where an increased incidence of 
bleeding complications can be predicted based on my data. Added care with haemostasis is needed 
when operating in this area. Most post operative bleeding complications can be managed 
conservatively and outcomes are invariably excellent following the interim setback. We found only one 
case in 2000 can one expect to have to reopen a wound to manage active bleeding in the post 
operative period.  
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7) Patient perceptions of their skin cancer surgery 
The trunk is the only body site we identified where the aesthetic outcome of the wound was least 
accepted by patients. 
Patients did not associate suffering surgical complications with a more adverse perception of the skin 
cancer service. Patients accept that complications can happen and this did not result in itself in a poor 
assessment of the skin cancer service.  
In monitoring the quality of service provided, the surgeon needs to consider aspects of service beyond 
minimising tumour recurrence, minimising complications and addressing complaints if and when they 
are made.  
If a patient feels his / her wound is less aesthetic than their expectations, we found they are more 
likely to consider the surgeon and the experience as suboptimal. Patients saw perceived 
overcharging, poorly explained pathology and waiting for surgery as problematic.  
 
8) Findings and features that pertained to several studies: 
We did not find that smokers or diabetics suffered increased complication rates compared with non 
smokers or non diabetics. However, the infection data was not multivariate and a further analysis with 
binary logistic regression would be useful to confirm that smoking and diabetes do not alter infection 
incidence in my data. 
Bleeding complications and infective complications occur largely in different wounds in different 
locations. One rarely leads to the other. 
Interestingly, patients taking warfarin, whilst at greater risk of post operative bleeding complications, 
were not at increased risk of post operative infection. We did not find any increased complication 
incidence in patients taking aspirin. Aspirin appears to be a safe medication that can be continued for 
skin surgery.  
Two thirds of patients do not require analgesia following excision of skin lesion and those that require 
analgesia are predominantly controlled with paracetamol. Wound dressings are well tolerated by 
patients.  
 
All of the studies undertaken were single institution studies involving a single surgeon in temperate 
southern Australia. This is a substantial limitation of all the studies undertaken. These findings might 
not be applicable to other clinicians in other locations and other climatic conditions. 
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9) Regions of the body: 
We identified that different regions of the body are associated with different post operative 
complications.  
Infection is greatest below the knee, bleeding is greatest on or near the ear, yet patients perceive 
wound outcomes the worst following surgery to their trunk. It was interesting that outcomes varied 
considerably in relation to the parts of the body being managed. 
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Chapter 11  Where to from here? 
This program of studies is not complete. Further studies in the program are in press, pending or 
envisaged.  
Further research questions identified: 
The findings of all studies could be best validated by multi centre future trials involving more than one 
clinician and with more climates and circumstances involved. 
Data on infection risk factors could be further analyzed using a multivariate approach. Age should be 
considered as a confounder in such an analysis. Diabetes and smoking as possible risk factors for 
infection should also be considered in such a multivariate approach. 
Further studies could be undertaken with patients rather than lesions as the predominant subject for 
examination. 
A future randomized controlled trial would be required to determine whether routine systemic 
antibiotics prior to skin surgery below the knee makes sufficient difference in post operative infection 
incidence to justify the antibiotic administration. 
While we assessed mupirocin ointment on closed wounds, other antibiotic ointments were not trialled 
and there is prospect that other agents may provide a benefit that was not shown with mupirocin. 
A further prospective randomized controlled trial of ROM flap closures below the knee would provide a 
greater level of evidence than the retrospective trial published.  
It is often suggested that complications are linked to each other. For example, some suggest that 
haematoma often leads to abscess. Infection is also said to be associated with wound dehiscence. To 
date we have not specifically examined such linkages, though the database is robust enough to do so.  
A further study looking at situations where multiple complications occur in single wounds could be 
drawn from the existing database. This would help identify whether patients who suffered a post 
operative bleed were more prone to infection than those who did not.  
 
Research with no funds: 
It is noteworthy to reflect on the basis of the seven original studies that comprise this thesis. There 
was no University, Government, Corporate or any outside funding source for any of these studies. 
They were undertaken within the context of a small single doctor private medical practice. The costs to 
effect these studies were entirely borne by Dr. Anthony Dixon from revenue derived from his private 
practice of managing skin cancer. Even the mupirocin ointment required to effect the ointment study125 
was privately purchased from the local pharmacy.  
126 
 
Yet these publications comprise the largest, (by patient number) studies of infection, perception, skin 
flap and bleeding complication trials ever undertaken in dermatologic surgery.  
The Future: 
Further studies are planned or have been completed to draw from the existing database. Such studies 
include: 
Do smokers fare worse than non smokers in skin surgery?  Our existing database suggests 
they fare no differently to non smokers. However, a multivariate analysis of smoking with respect to all 
complications has not been evaluated. My existing infection study122 was univariate. We have now 
completed a multivariate analysis of data regarding our smokers and non smokers. This study has 
been published in the British Journal of Dermatology290. 
 
Do patients with diabetes fare worse than non smokers in skin surgery?  Again my existing 
study regarding infection risk factors did not evaluate Diabetes as a risk factor with a multivariate 
approach122. My bleeding study was multivariate and found Diabetes was not predictive of post 
operative bleeding177. But what of other complications? We have completed a manuscript of Diabetes 
and skin surgery complications using a multivariate approach. This study has been accepted for 
publication by Dermatologic Surgery. 
 
Age and skin surgery complications? We have identified that age over 66 is a predictor of 
bleeding complications177. But what of other complications? Age was not considered in my analysis of 
wound infections. Age may be predictive of infection and other complications. We envisage a further 
analysis of my data to specifically address whether or not age is predictive of any other complications.  
 
Does haematoma lead to infection? Does infection lead to dehiscence? A close examination 
of patients with multiple complications within a single wound has not been explored. We envisage a 
further analysis and publication of skin surgery wounds that suffer two or more complications. 
 
The program of seven studies completed within this thesis will drive further studies within this small 
private single doctor practice. The studies have substantially altered my practice with improvements 
for the benefit of my patients. We hope the studies may assist many practices. We hope it may inspire 
other doctors to initiate, effect and publish clinical trials within the context of their private practice. 
Clinicians can undertake research in their own small practice leading to large studies that are 
disseminated internationally for the benefit of all patients. 
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Multiple superficial
basal cell carcinomata
Topical imiquimod versus curette 
and cryotherapy
Treatment options for BCC
Topical imiquimod
In the largest trial of topical imiquimod for
superficial basal cell carcinomas (SBCCs),
Geisse1 demonstrated 82% histologic clear-
ance rate when applied five times per week.
This is in keeping with earlier studies.2,3
Imiquimod also has a role in treating large
and long standing SBCCs.4 Limited experi-
ence managing nodular BCCs with imiquimod
has failed to demonstrate satisfactory clear-
ance rates.3
Side effects are not uncommon and include
erythema, scabbing, oedema, induration,
itching, pain, erosion, and secondary infection.
Pain varies with frequency of application.1–3
Following imiquimod treatment the skin
can have an erythematous and slightly thick-
ened appearance. Unfortunately, SBCCs can
have a similar appearance. Superficial BCCs
on the torso are often misdiagnosed as an
inflammatory skin condition; malignancy
considered only after the ‘rash’ fails to
respond to topical corticosteroid and/or anti-
fungal management. 
Curette with cryotherapy
Curette with cryotherapy (C&C) is an estab-
l ished approach to managing SBCCs.5
Kokoszka6 undertook a meta-analysis of treat-
ment of BCCs with cryotherapy showing cure
rates of around 90%. Most studies excluded
difficult BCCs such as recurrent and mor-
pheaform tumours. Many authors
recommend curettage before cryotherapy as
it defines and debulks the tumour. I favour
this approach using a blunt curette, cleaving
the BCC in one direction before a second
curettage cleaving perpendicular to the first.
A blunt dermal curette is cheap, able to be
sterilised and reused. 
Bleeding may be a problem following
curettage. Spot monopolar electrocautery is
my preferred approach to this predicament.
Haemostatic dressings can also be used.
Anthony J Dixon, MBBS, DipRACOG, FACRRM, is a dermasurgeon and Director, Skincanceronly, Geelong, Victoria.
anthony@skincanceronly.com 
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BACKGROUND
Superficial basal cell carcinoma can be
successfully managed by means other than
surgical excision. Nonexcisional approaches
include topical imiquimod, and curette and
cryotherapy (C&C). 
OBJECTIVE
This article discusses the management of an
insulin dependent diabetic man aged 52 years
presenting with 17 torso basal cell carcinomas
(BCCs); mostly superficial BCCs (SBCCs). 
DISCUSSION
Half were treated with topical imiquimod.
The remaining lesions were treated with
curette and cryotherapy. All lesions resolved
with proven histologic clearance. The
patient considered C&C caused him less
discomfort and disruption. He developed a
late secondary infection in some sites
treated with imiquimod. At 12 months there
was no evidence of recurrence though new
nodular BCCs and SBCCs had developed
elsewhere on his upper torso. He has
elected to have future SBCCs managed with
C&C. While excisional surgery remains the
benchmark management for nonmelanoma
skin cancer, topical imiquimod and C&C are
important options for treating SBCCs.
Case history
PF, aged 52 years, is an airline engineer
and an insulin dependent diabetic. He pre-
sents with a large ulcerating nodular basal
cell carcinoma (BCC) on his right leg. A
wound infection followed its excision.
Examination of his skin elsewhere
revealed 17 further BCCs located on his
pectoral, trunk and arm regions. He was
keen to explore nonexcision treatment
for these BCCs.
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Table 1. Summary of managing SBCC with surgery versus imiquimod versus C&C
Surgical excision Topical imiquimod 5% Curette and cryotherapy
Recurrence rate 5% or lower with experience Around 20% Around 10% 
Pain Not often a problem. Oral Varies with frequency of Typically uncomfortable for a
paracetamol for a few days application and can continue week or so
meets needs of most for 6 week duration of treatment  
Cost to patient Gap payment above Medicare for Expensive script. Many scripts Gap payment for curette 
surgery item numbers may be needed to treat multiple/ item numbers
large SBCCs
Scarring Generally least, though wound Usually noticeable post-treatment, Hypopigmentation or
spread, hypertrophy and keloid can but keloid and wound spread discolouration may occur
be issues on the upper torso not considered issues
Experience required Large wounds on the upper torso Skills recognising the erythema The physician needs to learn
by treating doctor may need deep sutures and/or flap and induration associated with the feel of using a skin curette,
repairs to ensure satisfactory treatment are required, enabling identifying the different
outcomes including acceptable suitable counselling to patients. character of scraping friable
wound spread incidence A treatment ‘break’ often helps SBCC tissue versus normal
distressed patients underlying dermis
Histology Mandatory Strongly recommended in all Always send any curetted
cases. Clinical diagnosis is tissue for histologic
insufficient confirmation
Bleeding Haemostasis required at time Not an issue Control spot bleeds with
of surgery. Postoperative bleeds diathermy or haemostatic
can occur dressings
Keloid prone patient Avoid surgery, especially on torso Recommended Less keloid risk than excision
(imiquimod is being used by 
some to treat keloid)
Healing time Predictable Six weeks plus, due to effects of Predictable and prompt
imiquimod locally
Patient involvement Usually minimal Involved with ointment application Usually minimal
in own treatment and wound care
Nodular BCCS Treatment of choice Contraindicated Not recommended for difficult
Recurrence rates unacceptable BCCs such as morpheaform, 
ulcerating and sclerosing BCCs 
Recurrent BCCs Excision required. Referral for Contraindicated based on Contraindicated based on
Mohs micrographic surgery should evidence to date evidence to date
be considered
Face and ears Treatment of choice. Scars on face Avoid. Very little data. Avoid as pigmentation changes
generally less noticeable than on Not endorsed for face can be more noticeable than 
torso surgical wounds
Anticoagulants Increased bleeding risk. Extra care Must be considered given the Haemorrhagic blistering can
with haemostasis. Ceasing warfarin/ absence of bleeding issues occur. More care needed with
aspirin in advance is no longer spot diathermy
common in cutaneous oncology
Dark skinned patients Caution. Keloid formation or poor Must be considered given minimal Avoid. Hypopigmentation can
scarring can be accentuated keloid and hypopigmentation be striking and distressing  
concerns to patient
Very large SBCC Surgery could be major with Can be used on even large SBCCs Very useful technique, even on
large scarring flexural regions
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Cautery should be minimal as it is associated
with more scar risk than curette and/or
cryotherapy. I no longer treat nonmelanoma
skin cancer (NMSC) with curette and broad
based cautery in view of these scar risks. 
Reported complications of C&C include
ulceration, hypopigmentation, blistering, 
scarring, oedema, pain, secondary infection
and recurrence. 
Surgery
Excisional surgery generally produces less
pain, quicker healing and more aesthetic
scars than less invasive alternatives. Most
authors only recommend nonexcisional
approaches for managing simpler BCCs.
Indeed, SBCC is the only skin cancer for
which imiquimod treatment is approved in
Austral ia. National Health and Medical
Research Council guidelines7 regard surgical
excision as the ‘gold standard’ for manage-
ment of NMSC against which nonsurgical
treatments should be judged. 
Nonsurgical approaches to managing
SBCCs are reserved for when surgery is
considered inappropriate. Excision is often
more convenient for patients with fewer
visits to the doctor and less self manage-
ment of the wound. 
Management of patient
Every lesion on PF’s body suggestive of
NMSC was numbered and punch biopsied
(Figure 1, 2). Nineteen biopsies revealed 17
BCCs, mostly SBCCs. Lesions eight and 10
were actinic keratoses and treated with
cryotherapy, BCCs one through seven and
nine were treated with C&C. This included
all back lesions given the logistics of accu-
rately applying cream to these sites, BCCs
11 to 19 were treated with imiquimod.
Lesions selected for C&C were curetted
until no apparent tumour remained. The
base and 4 mm of surrounding skin was
then treated with a 15 second freeze/120
second thaw/10 second freeze liquid nitro-
gen cryospray. Moist occlusive dressings
were then applied to each site. PF was
instructed to carefully apply imiquimod 5%
w/w cream accurately and very sparingly, 4
days per week for 6 weeks to the sites
selected for imiquimod therapy. Following
Geisse’s1 study, five applications per week
for 6 weeks is now the generally recom-
mended regimen. 
At 2 weeks, PF commented that the
imiquimod sites were very itchy, especially
his left shoulder (Figure 3). Discomfort was
most marked an hour after application.
Pruritus subsided 24 hours following appli-
cation. Some sites treated with C&C bled
for up to 2 days following treatment; sites
were all uncomfortable for 3–4 days. 
Three weeks later PF complained of
increased imiquimod site pain, swelling,
lethargy, fever and generally feeling poorly.
He had impetigo with tender left axillary
lymphadenopathy. Oral dicloxacillin resolved
his skin infection. At this stage (week 5), all
his C&C treated sites were healed (Figure 4)
and he commented that he had been ‘no
longer aware’ of these sites since week 2. 
Results
At 6 weeks, each site was biopsied confirm-
ing no evidence of residual BCC at any site.
At 10 weeks all sites felt the same to PF
and looked clinically indistinguishable (Figure
5). PF considered that the problems he
experienced with imiquimod treatment
would ensure he chose C&C to manage
future SBCCs. Note that despite Figure 2
demonstrating BCCs and Figure 5 demon-
strating resolved BCCs, both present as
similar erythematous macular regions on his
torso. This further highlights the difficulties
that can be experienced in diagnosing
SBCCs. 
At 6 months follow up, PF had developed
two new SBCCs. One had developed in the
right pectoral region where similar lesions
had been treated with C&C (Figure 6). The
other SBCC had developed in the left
(imiquimod) pectoral region. Both were
treated with C&C. 
At 12 month follow up, two new nodular
BCCs had developed, again one on each
shoulder. Both were surgically excised
(Figure 7). Follow up to 12 months therefore
demonstrated an equal propensity to
develop BCCs in the regions treated with
each modality. These new BCCs were at
new sites on his torso. They were not recur-
rences of previously treated lesions.
Figure 1. Upper back with multiple SBCCs
numbered – note previous scars from previously
excised skin tumours
Figure 2. Chest and arms. All but lesions numbered 8
and 10 are BCCs
Figure 3. Two weeks into treatment. Note scabs on
C&C sites and erythema at imiquimod sites
Figure 4. After 5 weeks. C&C sites healed. Secondary
impetigo affects some imiquimod sites
Discussion
Each of PF’s 17 truncal, pectoral and arm
BCCs were successfully treated with either
C&C or topical imiquimod. Following treat-
ment, all sites settled and the final cosmetic
results were indistinguishable. Neither treat-
ment prevented new BCCs developing in
nearby sites. Recurrence remains a possibil-
ity. Given the extent of his BCC disease to
date, further tumours are very likely. Given
the data to date, PF was fortunate to have
histologic clearance of all tumours. 
PF will choose C&C to manage future
SBCCs. In my experience, many patients
find the lengthy 6 week discomfort that can
be associated with imiquimod treatment to
be t iresome. Other patients are much
happier applying a cream than having their
skin ‘scraped and frozen’.  Many f ind
imiquimod treatment to be very effective
without the adverse effects noticed by PF.
A summary of further differences between
imiquimod, excision and C&C is outlined
in Table 1. 
In special circumstances, these less inva-
sive treatments may have a more prominent
role, eg. young people, high keloid prone
patients, diabetic patients, those with numer-
ous tumours, immunosuppressed patients,
those on warfarin, or those with a pace-
maker. In these circumstances, the clinician
may seek to avoid excisional surgery.
Conclusion
Excisional surgery remains the benchmark by
which all skin cancer management must be
compared. Both C&C and topical imiquimod
treatment are effective means of managing
superficial BCCs and should be considered in
patients with multiple superficial BCCs.
Clearances rates with imiquimod are around
80% versus 90% with C&C. 
Conflict of interest: none declared.
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Figure 7. At 12 months, two further superficial BCCs
had appeared on the left and right pectoral regions
Figure 6. Left shoulder. One of two new nodular
BCCs that developed 6 months post
imiquimod/C&C treatment. The other nodular BCC
developed on the right shoulder
Figure 5. Ten weeks following clearance biopsies
AFP
1.  Suture rule – if  histology indicates 
further treatment is needed, leave  
sutures in
If histology reveals that more surgery is 
needed, don’t remove sutures. They are a 
marker of the location and direction of the 
initial surgery. One does not need to worry 
that sutures left a long time might cause a 
reaction – the skin is set to go in subsequent 
surgery. Early suture removing can lead to 
later head scratching! 
2.  Melanoma rule – cut it out early and 
cut it out widely
Only two things have been demonstrated 
to improve outcome/survival for melanoma 
patients: cut it out early and cut it out widely. 
In short, chemotherapy, radiotherapy, lymph 
node dissection, sentinel node biopsy, 
immune therapy, BCG therapy and anything 
else tried has not been demonstrated to 
improve patient outcome/survival. 
3.  Basal cell carcinoma rule – BCCs  
ain’t BCCs
There are three broad groups of basal cell 
carcinoma (BCC):
• superficial BCCs (SBCCs)
• simple nodular BCCs, and 
• tough BCCs (Figure 1). 
The latter include morphoeic, desmoplastic, 
recurrent, and micronodular BCCs, as well 
as those previously partly treated with 
cryotherapy many times or photodynamic 
therapy (PDT). Other than surgery, options 
for SBCCs include imiquimod ointment, 
curette, cryotherapy and PDT. We would 
never consider these options for tough BCCs. 
In contrast, Mohs surgery is benchmark 
management for tough BCCS, but elaborate 
overkill for SBCCs. 
4.  Squamous cell carcinoma rule – SCCs 
can spread
Invasive SCCs can go to nodes and further. 
Squamous cell carcinomas at greater risk of 
spread include: 
• recurrent SCCs 
• tumours on lip, ear and scalp 
• large tumours, and 
• aggressive poorly differentiated or spindle 
malignancies. 
Think beyond 'cut it out early and cut it out 
widely' with these tumours. 
5.  Dysplasia rule – dysplastic naevi need to 
be diagnosed (not necessarily excised)
A patient with multiple dysplastic naevi is at 
high risk of developing malignant melanoma. 
However, removing the dysplastic naevi does 
not remove the risk. The melanoma is more 
likely to develop elsewhere on skin that now 
From their  col lect i ve exper ience in  Austra l ia  and the USA, 
dermasurgeons Anthony Dixon and Scott Hall have compiled a list of 
‘golden rules’ for general practitioners to help reduce errors and 
problems with skin cancer management. It is anticipated that these tips 
will provide a brief yet informative reference when faced with skin cancer 
management concerns in general practice. 
Anthony J Dixon, MBBS, DipRACOG, FACRRM, is a dermasurgeon, and Director of  Research, Skin Alert Skin Cancer 
Clinics, Geelong, Victoria. anthony@skincanceronly.com
Richard Scott Hall, MD, is a dermasurgeon, Cookeville Regional Medical Centre, Cookeville, Tennessee, USA.
Managing skin cancer
23 golden rules 
Figure 1. Patient with two seemingly innocuous 
actinic keratoses on the right side of  the nose. 
They were in fact linked under the skin as a large 
morphoeic BCC, requiring Mohs surgery
Procedures • CLINICAL PRACTICE
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looks ‘normal’. The emphasis of treatment is 
photography, surveillance and dermoscopy, 
not excising everything looking dysplastic.
6.  Hole rule – think first of  the mole, 
next of  the hole
Recurrence rates are the key outcome 
indicator in cutaneous oncology. The biggest 
factor leading to high recurrence rates is 
surgery with inadequate margins. First work 
out what margin each tumour needs. Then 
work out whether you will be able to close 
that defect, or refer the patient. 
7.  Examination rule – with bright light 
and magnification, less tumours will 
be missed
The jeweller's loupe, natural light and 
good artificial lighting, all help the close 
examination of suspicious skin lesions. A 
digital camera and a dermoscope are also 
vital tools. Patients often ask you to glance 
at a lesion at the end of a consultation on 
another matter. Avoid the temptation to have 
a quick glance with poor lighting and no 
equipment. A melanoma will not be found if it 
is not carefully looked for.
8.  Dermoscopy rule – dermoscopy 
diagnoses dark dudes
Accuracy in diagnosing melanoma and other 
dark skin lesions improves dramatically 
with dermoscopic skills (Figure 2). This 
means having a dermoscope at the ready, 
and using it repeatedly to build familiarity. 
Education on what to look for will enhance 
skills and accuracy. Further, even when the 
dermoscope does not provide the answer, 
it often helps to decide whether a punch 
biopsy, shave biopsy, curette or excision is 
appropriate. Large brown macules are often 
best shaved; this way you sample widely 
without a full thickness scar. Don’t simply 
freeze undiagnosed pigmented lesions. 
Remember ‘ABCD’ with pigmented lesions: 
Asymmetry, Border, Colour, Diameter.
9.  Histology rule – send it to the lab, not 
the bin
Among others, medical defence organisations 
warn us against treating skin cancer without 
histology. Surprises happen (Figure 3). 
Some malignant melanomata look nothing 
like melanoma. If every specimen goes to 
histology, many surprises can be discovered. 
I f  the pathology report seems odd, 
consider another biopsy. A commonwealth 
agreement means extra histology does not 
increase government spending on histology. 
If in doubt, have little hesitation in sending 
specimens for histology.
10.  Nerve rule – perineural invasion on 
histology means radiotherapy consult
Perineural invasion is an important warning 
sign on histology reports. Tumour can 
‘skip’ down the nerve. This means that a 
tumour may have continued well beyond 
histologically clear margins. Options include 
further surgery and radiotherapy. Where a 
radiotherapy service is available, offer it to 
the patient. 
11. Follow up rule – examine rest of  skin
In following up a skin cancer patient, the 
most important aspect of the consultation is 
examination of the remaining skin. Melanoma 
patients have a high risk of a second tumour. 
A patient who has had one nonmelanoma 
skin cancer has a two out of 3 chance of 
developing another. A patient who has had 
three skin cancers nearly always grows 
more skin cancers – and the next might be 
malignant melanoma. 
12.  Research rule – we are supposed to 
be scientists
While adjuvant therapy for melanoma 
is limited thus far, we can’t find that 
breakthrough unless current and future ideas 
are trialled. Many tertiary centres in Australia 
are trialling future melanoma treatments. In 
the meantime, as scientists, we must be 
prepared to cease techniques that were once 
popular and have been found wanting in more 
recent larger long term trials. 
13. GP rule – GPs rule! 
Most skin cancers in Australia are managed 
by GPs. Australian GPs are among the best 
doctors in the world at recognising skin 
cancer. Further, GPs know when lesions are 
beyond their expertise and other doctors 
need to be involved. Patients need to have 
the advice and confidence that their own GP 
is the doctor they should see to have their 
skin checked and skin cancers treated, and 
that their GP knows exactly who is best to 
treat them if their skin cancer is too difficult.
14.  Photography rule – two or more: 
number and photograph them
Photography is increasingly useful in 
cutaneous oncology.  Qual i t y  d ig i t a l 
photography is affordable and images can 
be easily downloaded into clinical software. 
When removing or sampling many lesions, 
photography becomes invaluable. Mark 
the skin and photograph each lesion in 
advance (Figure 4). Remove them in order 
as numbered. When histology returns, it 
becomes easy to determine which report 
relates to which anatomical site. 
Figure 2. This small lesion had suspicious features 
on dermascopy: blue-white veil, pseudopods and 
dots and globules throughout the lesion. The 
patient had recently been examined by a ‘skin 
cancer detection machine’ and advised that he  
did not have a melanoma (see Rule 15)
Figure 3. Apparent epidermal cyst ready for excision. 
Histology revealed a dermal melanoma
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15.  Computer rule – an Australian GP 
beats any machine at diagnosing  
skin cancer
There are numerous computer programs 
claiming to diagnose skin cancer by linking 
software to a scanner (Figure 2). They are 
heavily marketed to the public, especially in 
Queensland and New South Wales. Slogans 
such as, ‘Be scanned be sure’ are grossly 
misleading. Patients are better off seeing 
their own GP (see Rule 13).
16.  Experience rule – the more we see 
and treat, the better we get
Accuracy in skin cancer management comes 
with experience. The best are those who see 
and manage the most. Unlike most areas in 
medicine, we have a constant ‘supervisor’ 
continually checking and rechecking our 
skill and accuracy on everything we do in 
cutaneous oncology. It is called histology. Take 
a stab at the diagnosis every time and write it 
down in the notes. The learning never stops. 
17.  Dressing rule – wounds heal better 
occluded
Sutured wounds have better cosmetic 
outcomes if covered with an occlusive 
dressing for at least 4 days. Uncovered 
wounds have more scab formation, more 
infection and worse scarring. Cover every 
wound and urge the patient to keep the 
dressing on as long as possible. The wound 
may ‘smell’ when the dressing is removed. 
Smell is not infection. 
18.  Time rule – if  you only ask one 
question, make it: ‘How long has it 
been there?’
‘Months’ is the key. Changes or growth over 
days or weeks are often due to inflammation. 
It may soon change back or disappear. If it has 
not changed for years then it probably won’t 
change any time soon. If the patient says 
the lesion is changing or growing and staying 
changed for months, be quick to biopsy. 
19.  Orientate rule – mark or stitch one edge 
of  tumour for orientation purposes
It is unfortunate when histology says, 
‘incompletely excised at one lateral margin’. 
It helps when that margin can be identified. 
A ‘nick’ or stitch at one point can be denoted 
12 o’clock for pathology. The report back 
from histology might then say, ‘incompletely 
excised at ## o’clock’. The result is the 
affected margin can be identified and 
addressed without having to excise further in 
every direction. 
20.  Pink rule – persisting pink ‘pimple’ 
might be nodular melanoma
Nodular melanoma accounts for 15% of 
malignant melanoma, but 50% of melanoma 
deaths. They are often amelanotic and 
difficult to diagnose. Many are described as 
a pink pimple that grew and didn’t go away 
(Figure 5). Nodular melanomas do not have 
classic dermoscopic features. A short fuse to 
histology is essential. 
21.  Efudix rule – GPs pick lesions for 
Efudix, not patients
5-fluorouracil (Efudix) is used for benign 
actinic lesions, not skin cancer. Never 
prescribe 5-fluorouracil for self administration 
by the patient. This can lead to nightmare 
malignancies. It should only be prescribed 
after careful examination by a physician to rule 
out existing cancers. Treat only for a specified 
period under close medical supervision.
22.  Location rule – tumours on eyelids, 
nose and ear require considerable 
expertise
Banal looking tumours in bad locations can 
require aggressive and disfiguring treatment 
to save vital structures and/or life. Consider 
referring BCCs located near the nose, ears 
and eyes. Even small BCCs can invade the 
nasal vault or the orbital rim. Orbital rim 
involvement is very dangerous and difficult 
to treat. Basal cell carcinomas on the ear 
can be much larger than apparent. For SCCs 
be aware of the temples, around nerve 
foramens such as the infra-orbital nerve and 
pre-auricular areas. They can be much larger 
or deeper than clinically suspected. 
23.  Curette rule – careful technique 
produces best results when curetting 
SBCCs or Bowen tumours
When treating a skin malignancy with curette, 
scrape from multiple angles, otherwise some 
edges will get less pressure. Curetting a 
BCC needs a sharp curette that you ‘trust’ 
as it lifts off the tumour. Continue until 
normal tissue is ‘felt’, even if the naked 
eye  suggests  o ther wise .  Cons ider 
cryotherapy to help destroy residual tumour 
cells following curettage. 
Conflict of interest: none declared.
Figure 4. Skin lesions numbered and photographed 
before excision
Figure 5. Persisting ‘pink pimple’. This lesion 
persisted for several months, slowly enlarged and 
became irregular. Histology revealed a nodular 
melanoma
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The upper basal cell carcinoma (BCC) is approached 
first. Given the difficulties determining tumour border, 
this BCC is managed using micrographic surgery, a 
margin control approach sometimes termed 'Mohs' 
or ‘slow Mohs’ surgery (Table 1). In this technique 
the excision specimen is sent for urgent paraffin or 
frozen section examination. The defect is not closed 
until there is confirmation of margin clearance. 
This produces minimal recurrence rates in BCCs 
that would otherwise result in unacceptably high 
tumour recurrence risk. A critical aspect of this 
approach is careful mapping and orientation of the 
specimen (Figure 2). If further excision is required, 
one must be confident of the exact site on the 
patient’s face.
	
Histology	 demonstrates	 BCC	 extending	 inferiorly,	
confirming	 these	 two	 lesions	 are	 in	 fact	 a	 single	 BCC.	
Second	 stage	 slow	Mohs	 is	 undertaken	 the	 day	 after	
the	 first	stage	excision.	This	 involves	excising	 the	entire	
lower	 lesion	and	extending	the	dissection	to	 include	the	
involved	 border	 of	 the	 first	 stage	 excision.	The	 defect	
following	this	second	stage	is	shown	in	Figure 3.	
	 Histology	 confirms	 the	 tumour	 is	 now	 fully	 excised.	
This	 leaves	 a	 sizeable	 defect	 to	 be	 filled.	The	major	
part	 of	 this	 defect	 is	 closed	 using	 a	 forehead	 flap.	This	
flap	 is	 based	 on	 the	 contralateral	 supratrochlear	 artery.	
Case history
A woman aged 42 years, who works as a hairdresser, presents with 
two apparent actinic lesions on the right of her nose (Figure 1). 
Close clinical examination reveals the lesions are likely to be 
infiltrating basal cell carcinomas (BCCs). The lesions are firm with 
similar nontender indurations surrounding each site. Infiltrating 
BCCs can extend beyond the poorly defined clinical borders. 
Could these two lesions be the one tumour?
One lump or two?
A case study of infiltrating BCC on the nose
Anthony Dixon 
MBBS, FACRRM, is 
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Figure 1. Two nose lesions, highlighted 
by black pen
Table 1. Mohs micrographic surgery 
Mohs micrographic surgery is an established benchmark method of 
managing difficult nonmelanoma skin cancer.1 Its usage is typically for 
difficult BCCs on the head and neck. The tumour may be selected for 
Mohs surgery because it is a morphoeic, micronodular, or infiltrative 
BCC, because it has poorly defined margins, or because it is recurrent 
BCCs previously failing treatment with other modalities such as 
imiquimod, photodynamic therapy, curettage, or cryotherapy are often 
selected for Mohs surgery because the previous treatment clouds 
determination of where residual tumour starts and stops 
Sites where Mohs surgery is most often considered are: 
• eyelids
• nose
• ear
• lips, and 
• areas of the face near these organs 
Classic Mohs micrographic surgery involves frozen section histology 
whereby the surgeon is also the histologist. Further sections are taken 
the same day until clearance is confirmed. This is frequently undertaken 
by dermatologists who have completed a post fellowship Mohs training 
program over 1–2 years
In ‘slow Mohs’ surgery, the dermatopathologist and surgeon work in 
partnership, and stages may take place over several days 
Mohs surgery is readily available in most areas of the United States. 
In Australia the service is limited to a small number of major centres. 
General practitioners and patients would benefit from establishing if 
there is a Mohs or slow Mohs service in their area 
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The	 flap	 folds	 down	 onto	 the	 nose	 (Figure 
4).	The	 patient	must	wear	 this	 ‘trunk’	 across	
her	 nose	 for	 2–3	 weeks.	 Considerable	
preoperative	 counselling	 is	 required	 regarding	
the	unsightly	trunk.
	 The	 trunk	 is	 excised	 during	 the	 final	 stage	
of	 surgery	 (Figure 5).	 Note	 that	 the	 upper	
part	 of	 this	 defect	 has	 been	 left	 to	 heal	 by	
secondary	 intention.	 Secondary	 healing	 can	
be	effective	in	certain	circumstances.	Concave	
regions	 with	 a	 firm	 base	 lend	 themselves	
to	 secondary	 healing.	 Classic	 sites	 where	
secondary	healing	may	be	considered	are:
•	conchal	bowl	of	the	ear
•	near	the	inner	canthus,	and	
•	the	lower	leg.	
Seven	 months	 later,	 the	 area	 has	 healed	
reasonably	 for	 a	 large	 defect	 (Figure 6).	 A	
‘web’	of	skin	near	the	canthus	may	result	from	
allowing	this	area	to	heal	by	secondary	 intent.	
This	can	be	later	revised.	
Summary of important points 
•	Infiltrating	 BCCs	 can	 appear	 with	 the	
majority	 of	 the	 tumour	 hidden	 under	
apparently	normal	looking	skin.	
•	Where	two	new	BCCs	appear	close	to	each	
other,	consider	they	may	be	one	tumour.
•	Where	borders	of	BCCs	are	impossible	to	
clinically	determine,	consider	micrographic	
controlled	surgery.	
•	Secondary	 intent	healing	can	be	effective	
in	certain	circumstances.	Concave	regions	
with	 a	 firm	 base	 lend	 themselves	 to	
second	intent	healing.
•	Skin	 grafts	 are	 now	 rarely	 used	 on	 the	
nose.	An	array	of	 flaps	 invariably	produce	
more	acceptable	results.	
•	Management	 of	 BCCs	with	 cryotherapy,	
imiquimod,	 or	 fluoruracil	 cream	 (rather	
than	 obtaining	 histology),	 could	 lead	 to	
delay	 in	 diagnosis	while	 the	 large	 deep	
tumours	 invade	 further	 into	 the	nose	 and	
risk	vital	structures.
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Figure 5. Post second stage repair
Figure 6. Seven months after second stage repairFigure 3. Post second stage excision
Figure 4. Post first stage repair
Figure 2. Layout for first stage margin control surgery
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Dermoscopy of his dysplastic melanocytic naevi (DMN) 
showed pigment patterning that was often disrupted with 
brown dots frequently seen erratically placed through 
a naevus. Many of the DMN were irregular in shape, 
asymmetric, had variable colouration and had borders 
that were at times sharply defined and at times poorly 
defined. Mr BS therefore has two significant risk factors 
for the development of a second primary melanoma: a 
past history of melanoma and DMN syndrome. 
	
Digital	 dermoscopic	 images	 of	Mr	BS’s	 remaining	DMN	
were	 taken.	 He	 also	 had	 digital	 clinical	 photography	 of	
most	 of	 his	 skin	 demonstrating	 the	 existing	 lesions.	
Dermoscopic	 images	were	 labeled	with	 numbers	 on	 the	
body	 photographs.	All	 photographs	were	 stored	 on	 his	
computer	medical	record	file.
	 Mr	BS	was	reviewed	every	4–6	months	and	his	skin	was	
examined	with	 reference	 to	his	baseline	photographs	and	
digital	 dermoscopic	 images.	His	 recorded	DMN	 remained	
similar	 in	 appearance	 from	 examination	 to	 examination.	
In	April	 2005,	 the	 dermoscopic	 view	 of	 a	 lesion	 on	 his	
abdomen	 had	 changed	 significantly	 when	 compared	
to	 an	 image	 recorded	 4	months	 earlier.	The	 lesion	 had	
grown	 in	 a	medial	 direction,	with	 the	new	component	 to	
the	 lesion	 being	 dark	 and	 displaying	 disrupted	 pigment	
patterning.	There	were	 also	 some	 peripheral	 dots	 and	
globules	 appearing	 in	 the	 lesion	 and	 the	 suggestion	 of	
radial	 streaming.	Figure 1	 shows	 a	 dermoscopic	 image	
of	Mr	BS’s	naevus	 in	 late	2004.	Figure 2	shows	the	same	
naevus	 in	April	 2005.	Figure 3	 shows	
Mr	BS’s	 abdomen	 in	April	 2005.	The	
changing	 lesion	 is	 just	 to	 the	 right	
of	the	umbilicus.	
	 Local	 excision	 confirmed	 that	 this	
lesion	was	a	second	primary	superficial	
spreading	 melanoma.	 It	 was	 an	
early	 Clark	 3,	 Breslow	 0.5	mm	 thick	
melanoma.	This	 was	 subsequently	
widely	excised	with	a	10	mm	minimum	
margin	(Figure 4).
	 Ongoing	management	will	 focus	
on	 the	 early	 detection	 of	 any	 further	
primary	melanoma.	 If	Mr	 BS	 is	 to	 die	 from	metastatic	
melanoma,	 it	 will	 most	 likely	 be	 a	melanoma	 not	 yet	
present	on	his	 skin	but	one	 that	was	delayed	 in	diagnosis	
and	management.	He	will	 need	 regular	 careful	 ongoing	
examinations,	both	of	his	existing	DMN	and	any	new	lesions	
that	 develop.	This	 surveillance	 should	be	undertaken	by	 a	
clinician	very	 familiar	with	dermoscopy	and	with	access	 to	
clinical	photography.	
Summary of important points 
•	A	patient	with	 five	or	more	DMN	has	a	>40	 fold	 risk	
of	 developing	melanoma.1	Management	 centres	 on	
surveillance	of	 the	skin	with	clinical	 photography	and	
dermoscopic	imaging.2	
•	DMN	 syndrome	 is	 sometimes	 inappropriately	
managed	 by	 removing	 all	 the	 DMN.	 Melanoma	
Case history
Mr BS, 55 years of age, presented with numerous naevi in 2001. His history 
included a 0.85 mm thickness Clarke 3 malignant melanoma excised from his 
scalp at 50 years of age.
Initial examination revealed dozens of likely dysplastic melanocytic naevi (DMN) 
on his skin, especially on the trunk. The diagnosis of dysplastic melanocytic 
naevus syndrome was confirmed when several of the most concerning naevi 
were biopsied for confirmatory histology. Mr BS also demonstrated numerous 
pigmented seborrhoeic keratoses, many of which were quite dark and irregular. 
There was no evidence of any residual or recurrent melanoma.
Dysplastic melanocytic 
naevus syndrome
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Figure 1. Dermoscopic image in late 2004
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frequently	 develop	 in	 areas	 of	 the	 skin	
previously	 not	 demonstrating	 dysplastic	
naevus.	Removing	 all	 a	 patient’s	DMN	still	
leaves	the	patient	at	high	risk	of	subsequent	
melanoma	development.	
•	While	 DMN	 can	 be	watched	 rather	 than	
excised,	 a	 changing	DMN	should	 lead	 the	
clinician	to	consider	excision.
•	Use	of	 dermoscopy	will	 improve	diagnosis	
of	melanoma	while	reducing	the	number	of	
benign	lesions	excised.3
•	General	 practitioners	wishing	 to	 improve	
their	 skills	 in	 skin	 cancer	 management	
should	 consider	 dermoscopic	 training.	As	
little	as	4	hours	of	dermoscopy	training	has	
been	 shown	 to	 significantly	 enhance	 the	
skills	of	GPs	in	detecting	melanoma.4	
•	Pigmented	 seborrhoeic	 keratoses	 are	
usually	characteristic,	but	at	times	diagnosis	
is	 unclear.	 A	 biopsy	 is	 needed	 when	
melanoma	 cannot	 be	 excluded.	 A	 large	
study	demonstrated	that	0.66%	of	removed	
seborrhoeic	 keratoses	were	melanoma.5	
Document	 photographs	 and	 dermoscopic	
images	of	 all	 seborrheic	 keratoses	 that	 are	
sufficiently	suspicious	to	require	histology.
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Dermoscopy of melanoma
While Mr BS’s superficial malignant melanoma did not demonstrate  
classic dermoscopic features, the clear change resulted in biopsy and 
diagnosis. In contrast, Figure 5 shows numerous dermoscopic features of 
malignant melanoma including scar-like depigmentation, thickened and 
disrupted pigment patterning, and radial streaming. Note that within the  
lesion there are regions coloured: white, red, grey, black, brown and blue.  
In this case histology confirmed an obvious clinical dermoscopic diagnosis. 
Recording a dermoscopic image does not need expensive equipment. Cheap 
readily available commercial digital cameras can be attached to inexpensive 
dermoscopes. The images can be downloaded into computer based medical 
records already in place in most Australian general practices. An outlay of 
$2000 will provide a practice with the dermoscope and camera to record 
dermoscopy on existing software (Figure 6).
Dysplastic melanocytic naevus syndrome
CORRESPONDENCE email: afp@racgp.org.au
Figure 3. Abdomen showing lesion to the right  
of umbilicus
Figure 4. Irregular proliferation of atypical spindled 
melanocytes in the dermis and epidermis. The 
cells show no downward maturation and at the 
base of the lesion is a lymphocytre infiltrate
Figure 5. Typical dermoscopic appearance of a 
malignant melanoma
Figure 6. Digital camera and dermoscopes
Figure 2. Dermoscopic image in April 2005
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Surgical excision and a transposition flap repair 
was undertaken in the rooms with local lignocaine 
and adrenal ine  as  the anaesthet ic  choice . 
Despite initial anxiety, Mrs OL coped well with 
the procedure. 
	
Histology	 confirmed	 a	 poorly	 differentiated	 squamous	
cell	 carcinoma	 (SCC).	Margins	were	 clear.	The	wound	
healed	promptly	and	the	offensive	odour	ceased.	Mrs	OL	
returned	 to	 her	 previous	 lifestyle	 and	was	 again	 able	 to	
have	her	hair	styled.	
	 Surgical	 follow	 up	 at	 the	 aged	 care	 facility	 provided	
the	complete	picture	of	the	impact	of	this	excision	on	her	
lifestyle.	The	result	at	3	months	was	encouraging	(Figure 
3).	Two	 years	 on	 there	was	 no	 evidence	 of	 recurrent	
tumour	and	Mrs	OL	was	progressing	well.	
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Case history
Mrs OL, 84 years of age, and living in an aged 
care facility, developed a nodule on her left 
cheek. She had a history of numerous past skin 
cancers, dementia, hypertension, epilepsy, and 
cerebrovascular accidents. Her memory was  
poor. Given her background health, the initial 
decision was made not to intervene with her  
left cheek lesion. 
However, the tumour rapidly progressed over  
1 year (Figure 1). It became chronically infected 
and resistant to antibiotic treatment and regular 
toileting. The soft friable surface of the tumour  
bled on contact and required constant dressings. 
The surface of the tumour had swirls of pink and 
red. There was no crusty keratotic surface. The 
border of the tumour was very sharply defined 
(Figure 2). The persistent offensive odour from 
the tumour resulted in other residents being 
unhappy to dine with Mrs OL. To keep the peace 
she ate alone in her room; eventually spending 
the majority of time in her room. She enjoyed her 
hair being styled but unfortunately the hairdresser 
would no longer attend her. Mrs OL’s husband 
continued to visit her regularly. Loneliness and 
depression became issues with her ongoing 
isolation resulting from her visually offensive and 
malodorous tumour. 
It was clear the tumour needed to be excised, 
primarily to allow Mrs OL to rejoin her friends 
and previous lifestyle. Her family requested 
that as much of the management as possible be 
undertaken on site in her own environment. 
Skin cancer in patients with 
multiple health problems
Figure 1. Chronically infected tumour
Figure 2. Tumour showing sharply defined border
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Summary of important points 
•	The	decision	to	treat	or	leave	can	be	difficult	
in	 patients	 with	multiple	 health	 issues.	
The	 patient’s	 general	 practitioner	 is	well	
placed	to	balance	the	cutaneous	oncology	
considerations	with	other	health	issues.	
•	3	mm	margins	 rather	 than	wider	margins	
were	effected	in	the	surgical	management	
of	 this	 tumour.	The	 emphasis	 was	 on	
returning	the	patient	to	her	lifestyle	rather	
than	maximising	long	term	survival.
•	Sk i n 	 c ance r s 	 on 	 t he 	 fa ce 	 have	
considerations	 in	 management	 well	
beyond	 the	 risks	 of	 local	 and	 systemic	
invasion.	 An	 unsightly	 tumour	 can	 have	
a	 major	 impact	 on	 daily	 activity.	 If	 it	
also	 has	 an	 offensive	 odour,	 treatment	
is	imperative.	
•	Poorly	differentiated	SCCs	look	and	behave	
very	differently	to	well	differentiated	SCCs	
–	they	lack	the	crusty	hard	surface	and	can	
spread.1	Metastatic	potential	 is	greater	 in	
these	soft	red	tumours	especially	if	>2	cm	
in	diameter.	
•	Nursing	resources	 involved	in	managing	a	
tumour	can	influence	the	decision	to	treat	
a	patient.	 In	this	case,	frequent	dressings	
and	toileting	were	required	by	a	stretched	
nursing	staff.	Following	a	relatively	simple	
surgical	procedure,	nursing	time	was	then	
available	 for	meeting	 other	 needs	 of	 the	
resident.
Conflict	of	interest:	none	declared.
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No treatment
There are times when the appropriate management of nonmelanoma skin 
cancer (NMSC) is to leave them. Consider an elderly patient with Bowen 
disease or superficial BCC below the knee. You may consider that other health 
issues are likely to influence the patient’s wellbeing long before the NMSC has 
any influence other than its appearance (which may not concern the patient). 
Simpler treatments such as cryotherapy and curettage can result in chronic 
infection and ulceration and may result in a greater disability for the patient 
than the NMSC was likely to produce if left alone.
Figure 3. Patient 3 months after surgery
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The nodule continued to grow and he became 
disillusioned. He asked for referral for a third opinion. 
I then saw him some 3 months after his first 
assessment. He demonstrated a large friable lesion 
27 mm across at its maximum diameter (Figure 1). 
There had been no biopsy taken up to this point. I 
aggressively debulked the lesion including all apparent 
pathologic tissue. Histology confirmed squamous cell 
carcinoma (SCC) (Figure 2).
	
He	 had	 ipsilateral	 inguinal	 nodes	 on	 presentation.	
Fortunately	 these	 were	 reactive	 and	 settled	 with	
antibiotics.	
	 Being	 a	 keen	 amateur	 photographer,	 Mr	 RR	 had	
captured	the	tumour	at	various	stages	in	its	growth.	Figure 
3 and	4	 show	 the	 tumour	 8	weeks	 and	 2	weeks	 before	
my	assessment.	
	 Following	histologic	confirmation,	 the	SCC	was	widely	
excised.	There	was	 no	 residual	 tumour	 on	 histology.	The	
defect	was	 closed	with	 a	 reducing	 opposed	multilobed	
(ROM)	 flap	 repair	 (Figure 5).	This	 closure	 technique	
produces	 better	 outcomes	 than	 traditional	 flaps	 and	
grafts	 for	medium	 sized	 defects	 below	 the	 knee.1	As	 is	
usual	 following	ROM	 flap	 repair,	Mr	RR	was	mobilising	
the	 same	day.	He	was	 advised	 to	 elevate	 his	 legs	when	
seated.	Two	months	postsurgery	the	flap	repair	has	healed	
wel l 	 and	 there	 is 	 no	 ev idence	 of 	 metastat ic	
disease	(Figure 6).
Summary of important points
•	Always	obtain	histology	to	confirm	a	clinical	diagnosis	
of	 keratoacanthoma	 (KA).	 Studies	 have	 shown	 that	
clinical	KAs	are	just	as	likely	to	be	SCCs.	The	converse	
is	also	true.	Early	histology	is	always	required	and	will	
guide	future	management.
•	Histo logy	 of 	 a 	 KA	 can	 a lso	 be	 d i ff icu l t .	
Dermatopathologists	 frequently	 debate	whether	 a	
lesion	 is	 KA	 or	 SCC.	The	 histologic	 differences	 can	
be	subtle.	You	may	choose	to	have	uncertain	reports	
reviewed	by	an	experienced	dermatopathologist.	
•	The	KA/SCC	dilemma	is	best	managed	by	treating	all	
KAs	 as	 if	 they	were	well	 differentiated	SCCs.	Most	
authorities	now	regard	a	KA	as	a	malignancy;	although	
with	slim	metastatic	potential.2	These	lesions	can	be	
removed	by	excision	or	curettage.	This	overcomes	any	
clinical	dilemma	and	eliminates	the	risk	
of	a	SCC	developing	a	metastasis	while	
it	is	‘watched’.	
•	SCCs	 at	 higher	 risk	 of	 developing	
metastases	 are	 recurrent	 tumours,	
those	 over	 2	 cm,	 and	 those	 on	 the	
ear,	 lip,	 eyelid	 or	 scalp.	Transplant	 and	
immunosuppressed	 patients	 are	 also	
at	 increased	 risk	 of	metastatic	 spread	
from	their	cutaneous	SCC.	
•	One	 should	 not	 be	 avoiding	 excision	
because	 the	defect	would	be	 too	 large	
to	close.	 If	 the	 tumour	needs	excision,	
it	 needs	 excision.	 Delaying	 excision	
because	defect	closure	is	problematic	is	
not	acceptable.	Consider	 referral	either	
before	or	after	biopsy	as	appropriate.
Case study
Mr RR, 74 years of age, developed a nodule on his lower right leg in mid 
2005. He was offered the option of excision, skin graft and 10 days bed stay 
with elevation at a private hospital, but declined due to the cost. He was then 
referred to a major urban cancer institute for opinion. He was advised that 
the nodule would most likely fall off and that a ‘watch and wait’ approach was 
indicated. Presumably there was a clinical diagnosis of keratoacanthoma.
Managing skin cancer 
below the knee
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Figure 1. Tumour before debulking procedure
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The challenge below the knee
Defects below the knee are a challenge for the clinician. All treatments 
have higher complication rates compared with other sites on the body. 
For example, we have demonstrated an infection rate below the knee 
of 7% compared with less than 1.5% above the knee.3 All sites below 
the knee are subject to greater infection risk including the calf, shin, 
foot, and the toes. Even less ‘invasive’ measures such as cryotherapy 
and topical imiquimod can result in chronic ulceration in these sites. 
We have demonstrated that the ROM flap reduces the risk of wound 
dehiscence, flap necrosis and overall complications when managing 
defects 11–45 mm below the knee.4 We no longer use skin grafts 
unless the defect is greater than 45 mm in diameter. 
Due to the increased infection risk below the knee, there is an 
argument for prophylactic antibiotics before surgery in these sites. 
We recommend 2 g oral dicloxacillin 1 hour before surgery. Above the 
knee, there are very few indications for antibiotic prophylaxis. Patients 
at high risk of endocarditis and patients with recent joint prosthetic 
surgery are special considerations. 
Figure 4. Tumour 2 weeks before debulking procedure
Figure 5. Layout for excision and ROM 
flap repair
Figure 6. Wound healing 2 months postsurgery
Figure 3. Tumour 8 weeks before debulking procedure
Figure 2. Papillary proliferation of mildly atypical 
squamous epithelium in this well differentiated invasive 
squamous cell carcinoma 
Photo courtesy Melbourne Skin Pathology
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Mr HG had the opportunity to enroll in a randomised 
controlled trial (RCT) trial of emerging treatments. After 
discussion of his condition, prognosis and options, he 
and his wife declined to do so, instead choosing to buy 
a caravan and travel Australia.
	
Mr	 HG	 remained	 well	 until	 he	 presented	 with	 a	
subcutaneous	 mass	 10	 cm	 from	 the	 primary	 site	
in	 2004.	 On	 dissection,	 a	 black	 mass	 was	 excised	
(Figure 2).	 Histology	 confirmed	 this	 was	 metastatic	
melanoma	 (Figure 3).	While	 scans	 in	 2002	were	 clear,	
computerised	 tomography	 (CT)	 scans	 now	 showed	
pulmonary	metastases.	Despite	 the	 poor	 prognosis,	 the	
family	 continued	 to	elect	 not	 to	enter	 any	emerging	drug	
trial.	The	concern	 regarding	 ‘numerous	 trips	 to	Melbourne’	
was	clear.	The	patient’s	wishes	were	respected.	
	 In	 time,	metastases	 developed	 elsewhere	 including	
numerous	 cutaneous	 and	 subcutaneous	 nodules	
(Figure 4).	Most	of	the	cutaneous	nodules	demonstrated	the	
dermoscopic	appearance	of	metastatic	melanoma	(Figure 5).	
Mr	HG	remained	well	through	2005.	In	this	year	he	and	his	
wife	toured	the	USA	and	Europe.	In	early	2006	he	became	
tired	and	nauseous.	Anaemia	was	treated	with	 transfusion.	
By	 this	 stage,	 subcutaneous	and	cutaneous	masses	were	
abundant.	Cerebellar	and	cerebral	secondaries	affected	gait	
and	motor	function.	The	inevitable	decline	continued.	Mr	HR	
succumbed	to	his	melanoma	in	May	2006.
Summary of important points
•	While	the	majority	of	patients	with	melanoma	present	
early	 and	 do	well,	 the	 case	 study	 reminds	 us	 that	
melanoma	 is	 a	 potentially	 fatal	
condition.	
•	Melanoma	 management 	 is	
not	 about	 fancy	 treatments	 in	
tertiary	 institutions.	 Effective	
management	 of 	 melanoma	
is	 simply	 about	 early	 detection	
and	wide	 excision.	Nothing	 else	
improves	long	term	outcome.1,2	
•	Subcutaneous	metastases	 from	
any	 tumour	 are	 ominous	with	 a	
7.5	month	average	survival.3	Lung	
cancer	 is	 the	 commonest	 cause	
of	 cutaneous	 secondaries	 (29%),	
melanoma	is	second	(18%).	
•	Tests	 such	 as	 SLNB	 are	 not	 reasons	 to	 delay	
the	 treatment	 that	matters	 –	wide	 local	 excision.	
Even	 if	 the	 patient	 decides	 to	 undertake	 SLNB,	
this	 can	 be	 performed	 after	 the	wide	 excision	with	
no	 demonstrated	 difference	 in	 the	 accuracy	 of	
the	test.4
•	Patients	 with	 advanced	 melanoma	 should	 be	
offered	the	opportunity	to	enroll	 in	trials	of	emerging	
treatments.	 We	 will	 not	 find	 that	 important	
breakthrough	 in	 future	 melanoma	 care	 without	
present	day	melanoma	patients’	participation	in	RCTs.	
•	Most	 commonly,	metastatic	 deposits	 of	melanoma	
have	 friable	 black	 contents,	 the	 histology	merely	
confirms	the	clinically	obvious.	
Conflict	of	interest:	none.
Melanoma with cutaneous 
melanoma secondaries
Case history
Mr HG presented in 2002 with a large black lesion on his left loin. It had been present for 
many years but had recently changed (Figure 1). Nearby, two similar lesions were apparently 
separated by normal skin. Histology confirmed these were malignant melanoma. The ‘normal’ 
skin between lesions also demonstrated melanoma beneath the surface. At its thickest, this 
melanoma was a (Breslow) 2.56 mm, Clark 4 lesion. The tumour was excised with a minimum 
20 mm margin of normal skin. Given the depth of the tumour, Mr HG was co-managed with the 
Victoria Melanoma Unit. There are no radiotherapy or chemotherapy programs that have been 
demonstrated to improve survival in patients with an advanced primary melanoma such as this. 
Following discussion, Mr HG chose not have a sentinel lymph node biopsy (SLNB). 
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Figure 1. Mr HG’s primary malignancy with ‘satellite’ 
lesions 
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Figure 2. Dissection of black subcutaneous mass  
10 cm from original melanoma 
Figure 3. Histology of subcutaneous mass. Within 
subcutaneous fat is a deposit of metastatic 
melanoma. There are atypical epitheloid cells 
with adjacent macrophages containing melanin 
pigment 
Photo courtesy Melbourne Skin Pathology
Figure 4. Mr HG’s chest wall shows numerous 
cutaneous and subcutaneous deposits of 
metastatic melanoma 
Figure 5. Dermoscopy of cutaneous metastaic 
melanoma. It has the appearance of malignant 
melanoma being ‘sprayed’ on to the site
Sentinel lymph node biopsy
Sentinel lymph node biopsy (SLNB) has been popular in recent years, 
especially with patients suffering a melanoma beyond 1 mm thickness. The 
idea is to detect early evidence of melanoma in the lymph node that drains 
the skin at the site of the primary tumour. When nodes were found to contain 
melanoma, the patient usually progressed to having the entire nodal basin 
excised.5 
However, there was always concern that such an intervention may not benefit 
the patient. We have known for some time through multiple RCTs that elective 
lymph node dissection on melanoma patients offers no survival benefit.6
10% of patients who undergo SLNB develop side effects and up to one-
third of patients who go on to block dissection experience complications.7 
Complications include infection, seroma and lymphoedaema. More serious 
complications include facial nerve8 and brachial plexus damage.9
Recently the first and only RCT of SLNB has demonstrated no survival benefit. 
Australia contributed many patients to this multi-national study known as 
MSLT-I. Concern has been expressed that the much presented trial has not yet 
been published.10 
Further, many investigators have demonstrated that a sentinel node with only 
small amounts of melanoma in it may not subject the patient to added risk and 
the patient may not benefit from then proceeding to block dissection.11–14 
As such, SLNB does not improve patient survival and does not guide further 
management. It does however, provide some added information to the patient 
regarding survival prospects as SLNB negative patients survive longer than 
positive patients.15–17 
In 2006, SLNB is not a standard of care in melanoma management. It is an 
option for patients who wish to have further information about their prospects 
and are aware of the risks and complications of such an invasive procedure. 
Counselling before SLNB should include advice that the test does not guide 
future management.
CORRESPONDENCE email: afp@racgp.org.au
Melanoma with cutaneous melanoma secondaries
872  Reprinted from Australian Family Physician Vol. 35, No. 11, November 2006
 CLINICAL 
PRACTICE 
Skin cancer 
series 
Anthony Dixon 
MBBS, FACRRM, is 
dermasurgeon and Director 
of Research, Skin Alert 
Skin Cancer Clinics and 
Skincanceronly, Belmont, 
Victoria. anthony@
skincanceronly.com
Following an unsuccessful attempt with topical 
imiquimod, Mr AB was referred for margin control (slow 
Mohs) surgery. Mr AB had a large area on his medial left 
cheek with small nodules resembling a field of smooth 
bumps (Figure 1). He needed excision with no attempt 
to close the defect until histologic confirmation of clear 
margins. After two stages of slow Mohs surgery, the 
defect on his left cheek was significant (Figure 2). This 
defect was closed with a large trilobed flap repair with 
a burrows graft (Figure 3).
	
Histology	 identified	 nodular	 and	micronodular	 BCC	 in	
the	 dermis	 associated	with	 a	 light	 chronic	 inflammatory	
infiltrate	 (Figure 4).	 Fortunately,	Mr	AB	did	 not	 suffer	 any	
tumour	invasion	of	the	infraorbital	nerve	or	its	branches.	
	 One	year	 later	there	 is	no	evidence	of	recurrence.	The	
wound	has	healed	reasonably	other	than	a	thickened	scar	
near	the	border	between	nose	and	cheek	(Figure 5).	Mr	AB	
elected	not	to	have	a	small	scar	revision	at	this	stage.	
Summary of important points
•	Micronodular	 basal	 cell	 carcinomas	 (BCCs)	 can	 look	
very	 innocuous.	They	are	often	 large	before	they	are	
diagnosed	 and	margins	 are	 invariably	 very	 difficult	
to	determine.	Like	morphoeic	BCCs,	 they	should	be	
regarded	as	‘tough’	and	treated	with	respect.1,2
•	Mohs	 surgery	 is	 the	 benchmark	 approach	 for	
micronodular	BCCs	on	the	face.1,3,4
•	 Imiquimod	 may	 be	 incorrectly	 considered	 for	
micronodular	BCCs	because	 they	 look	 thin	 and	 flat.	
Imiquimod	 is	 contraindicated	 for	micronodular	BCCs	
and	is	only	indicated	for	superficial	BCCs.5–9	
Micronodular basal cell 
carcinomas
Case study
Mr AB developed a firm rough surface on his medial left cheek. With increasing size his doctor 
organised a biopsy at the site. Histology showed micronodular basal cell carcinoma (BCC). 
Tumour was excised with a margin of apparently normal skin. Histology showed tumour at  
all margins. 
Some time later the borders of the skin wound revealed small nodules of obvious recurrence. 
Further surgery demonstrated tumour at all margins, once again. The wound was clinically clear 
and the area was managed expectantly. Later recurrence at margins was again apparent. 
Figure 1. Note small, smooth bubbles appearing on cheek and 
an old linear scar
Figure 2. A large defect remains following histologic 
confirmation that tumour is cleared
Reprinted from Australian Family Physician Vol. 35, No. 12, December 2006  965
CLINICAL PRACTICE
•	Proven	 residual	 BCC	 following	 surgery	
is	 not	 managed	 by	 observation.	 Some	
quarters	hold	to	a	misguided	belief	that	the	
inflammatory	process	following	surgery	will	
‘kill	off’	any	residual	tumour.	While	the	scar	
is	 ‘watched’,	BCCs	on	 the	 face	can	 invade	
into	many	structures	including	nerves.	
Conflict	of	interest:	none	declared.
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Figure 3. A trilobed flap did not close all the defect. 
A burrows graft completed the closure to the 
superomedial aspect of the defect
The face is different
From a skin cancer perspective, the face is different in many respects. 
Tumours look different: skin on the face is more pilo-sebaceous than 
elsewhere; the lower nose is especially pilo-sebaceous. This makes tumours 
often appear more subtle than they actually are. Dermoscopy of face 
lesions is altered by this pilo-sebaceous character. Pigment networking is 
often not seen and tumour features are less striking.
Structures are close: nerves, muscle, bone, cartilage, salivary glands and 
other structures can be very close to the skin surface and can be vulnerable 
at excision. Proximity also means tumours can invade vital structures if 
they extend beyond the dermis. 
Caution with less invasive treatments: imiquimod and photodynamic 
therapy (PDT) on the face have special concerns. The therapy can fail 
while the tumour continues to invade into deeper structures. Sometimes 
imiquimod or PDT is chosen to ‘avoid’ surgery only to result in delayed 
much larger surgery. 
Cosmetic features: the face has a myriad of cosmetic zones and features. 
These lines, borders and structures are always considerations in planning 
surgery and especially the repair of defects following surgery.10–13 
Figure 4. Micronodular and nodular BCC within 
the dermis
Photo courtesy Melbourne Skin Pathology
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Mrs MA was assessed by the multidisciplinary head 
and neck team. Computerised tomography (CT) scans 
revealed cervical nodes that were not considered 
significant. She was considered for radiotherapy 
given the increased risk of metastasis associated 
with such a large long standing SCC. She was not 
keen on any further intervention and this wish 
was respected. 
	
Twelve	months	 postsurgery	 there	was	 no	 sign	 of	 local	
or	 regional	 recurrence.	Mrs	MA	will	 have	 a	 permanent	
unsightly	 graft	 of	 skin	 covering	most	 of	 the	 top	 of	 her	
scalp	 (Figure 5).	 She	 routinely	wears	 a	 hat	 to	 cover	 the	
thin	bald	patch.	 (However,	as	she	was	wearing	a	hat	 for	
over	10	years	to	cover	her	psoriasis,	this	does	not	worry	
her	and	she	is	now	quite	accustomed	to	it.)	
Summary of important points
•	If	a	skin	condition	does	not	respond	to	management	
as	expected,	biopsy	the	region	rather	than	continue	
with	 the	 unsuccessful	 treatment.	An	 unexpected	
malignancy	may	be	identified.	
•	Partial	 thickness	 skin	 grafts	 are	 generally	 reserved	
for	the	largest	of	defects	where	other	closures	can	
be	problematic.	These	grafts	are	invariably	unsightly	
and	lack	the	character	of	normal	skin.
High risk squamous  
cell carcinoma
Case study
Mrs MA, 70 years of age, has a history of scalp psoriasis dating over 10 years. She explained 
that the rash was slowly progressing and had failed to respond to an array of topical treatments 
offered (Figure 1). 
Within the right lateral aspect of the 12 x 14 cm lesion a thick nodule had recently developed. 
It looked like squamous cell carcinoma (SCC). Biopsy of the raised lesion confirmed SCC as 
did four other biopsies at the poles of the region of ‘psoriasis’. Removing all surface debris 
confirmed this was one confluent scalp tumour (Figure 2).
The large scalp SCC was excised with a 5 mm margin. During surgery there was an area of 
apparent involvement of galea. This layer was widely excised along with periosteum at that 
point. Histology confirmed complete excision. There was no other point at which deep levels 
were involved. Periosteum was not involved. 
The large defect was closed with a partial thickness skin graft (Figure 3) harvested from the right 
anterior thigh (Figure 4).
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Figure 1. Scalp of presentation showing 
debris and matting of hair
Figure 2. Scalp with surface material 
removed showing large SCC
Figure 3. Scalp following wide excision of 
SCC and application of partial thickness  
skin graft
Figure 4. Partial thickness skin graft donor 
site on anterior right thigh
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•	Radiotherapy	 is	 problematic	 in	 this	
situation,	 as	 split	 grafts	 do	 not	 tolerate	
radiation	 as	 well	 as	 full	 thickness	 skin.	
Chronic	poor	healing	can	result.
•	Patients	with	 large	 tumours	 on	 the	 head	
can	benefit	from	the	collective	experience	
and	 opinions	 of	 skin	 surgeons,	 radiation	
oncologists,	 ENT	 surgeons	 and	medical	
oncologists.	
Conflict	of	interest:	none	declared.
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Figure 5. Thin bald graft 12 months postsurgery
High risk SCCs
Some cutaneous SCCs are recognised as at increased risk of developing 
metastatic disease. Most metastases occur within 2 years and 95% have 
occurred within 5 years. Surgery and adjuvant radiotherapy provide the best 
chance of achieving locoregional control.1 Risk factors for metastases from 
cutaneous SCC are: 
• recurrence2–4
• large tumours (>2 cm)2,3
• perineural involvement2,3 
• poorly differentiated tumours2,3
• tumours infiltrating well into or beyond the dermis3,5,6
• renal (and other) transplant patients7,8
• immunosuppressed patients3,8
• tumours located on ear3,9,10, lip,3,9–11, eyelid12 or sites that get no light.3,13
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Arc welding produces substantial ultraviolet (UV) 
radiation including the A (400–315 nm), B (315–280 
nm) and C (280–100 nm) spectrums. Little is known 
of the damage that can be caused by UVC because 
humans are rarely exposed to such short wavelength 
UV radiation.1–3 Virtually all solar UVC is absorbed 
in the atmosphere long before it reaches the 
earth’s surface.3,4 In contrast, UVC from arc welding 
is mostly absorbed by air immediately around 
the arc, but some could reach exposed skin on the 
welding operator. 
	
The	cause	and	effect	relationship	between	arc	welding	and	
skin	 cancer	has	not	been	demonstrated	 to	date,	 however	
there	has	been	little	research	into	this	occupational	hazard.	
One	study	 showed	no	 increased	 incidence	of	 skin	 cancer	
in	welders.5	However,	 this	study	 involved	a	plant	with	very	
high	 health	 and	 safety	 standards	 and	workers	were	well	
protected	with	mask	 and	 clothing	 whenever	 welding.	
Greater	 concern	 surrounds	workplaces	where	health	 and	
safety	 standards	may	 be	 suboptimal,	 such	 as	 farmers,	
sculptors,	 tradesmen	and	mechanics	who	may	undertake	
welding	without	formal	training.4	
	 Different	welding	 processes	 produce	 variation	 in	 the	
degree	of	UV	exposure	 for	 the	worker	 and	 any	 assistant.	
UV	 exposure	 is	 increased	with:	 decreasing	 proximity	 to	
Arc welding and the risk  
of cancer
Case study
Mrs LF, 71 years of age, presents with numerous squamous cell carcinomas (SCCs) on her hands 
(Figure 1). She comments that she had ‘perfect’ hands until recent years and had never been an 
‘outdoors person’. On questioning her about trauma or exposure to her hands she commented  
that she had frequently experienced ‘sunburn’ on her hands after assisting her son with his  
welding business. 
It turns out her son had started his own handyman business 10 years earlier. Most of the work 
involved arc welding repair jobs on fences and gates. He had bought a 240 volt welding unit and 
set up a mobile welding service out of his utility van. He had no money for staff, yet often needed 
an assistant to hold metal pieces to be welded together. Mum came to his rescue! She describes 
holding the metal with her bare hands and looking away to either the left or right while her son 
welded the sections. Her son wore a face mask, but sometimes did not wear gloves due to the hot 
conditions. This unfavourable health and safety story was supported by examination of Mrs LF’s 
skin. She had marked actinic damage on her hands and forearms, but none on her chest (Figure 2), 
abdomen, back or lower limbs. Her face demonstrated actinic damage and two SCCs. Her neck also 
demonstrated marked actinic damage with a basal cell carcinoma on the right side (Figure 3) and a 
SCC on the left (Figure 4). 
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Figure 1. Numerous SCCs have developed on 
both hands and forearms on a background 
of marked actinic damage
Figure 3. The right neck shows a  
morphoeic BCC
Figure 2. The chest, back and lower limbs are 
without actinic change
Figure 4. The left neck shows a well 
differentiated SCC. The face is markedly 
damaged with smaller SCCs needing attention
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the	 arc,	 increased	 arc	 energy,	 increased	 arc	
duration,	 higher	 current	 and	 certain	 angles	 of	
plate	 reflection.	 Different	welding	 processes	
produce	 different	UV	 exposure	 (Table 1).6	The	
most	 intense	UV	exposure	 is	 often	 associated	
with	welding	aluminium	or	stainless	steel	where	
gas	metal	 arc	 (GMA)	or	gas	 tungsten	arc	 (GTA)	
processes	are	often	used.	It	is	an	imperative	that	
arc	welders	 and	 their	 assistants	wear	 suitable	
gloves,	 forearm	clothing,	mask,	 and	 protection	
for	the	neck	(Figure 5, 6).
	 Skin	 is	 not	 the	 only	 organ	 at	 risk	 from	 arc	
welding.7	 Fumes	 from	 the	 welding	 process	
are	 linked	with	 pulmonary	 disease	 and	 other	
diseases.8,9	Eye	damage	from	arc	welding	is	also	
well	established.10–13
Summary of important points 
•	Arc	welding	may	be	a	contributory	cause	of	
skin	cancer	in	some	patients,	especially	when	
a	history	of	lack	of	protection	is	apparent.	
•	Welders	 and	 their	 assistants	 need	 advice	
regarding	 suitable	 protection	 when	 arc	
welding	(Figure 6).
•	Anyone	can	buy	an	inexpensive	arc	welding	
unit	 from	 the	 hardware	 store	without	 any	
training	in	its	use.	Part	time	welders	such	as	
farmers	and	tradesmen	may	be	unaware	of	
the	risks.
•	Welders	 should	 use	 sunblock	 for	 the	
protect ion	 of	 exposed	 skin. 	 Some	
sunscreens	 specifically	 include	 UVC	
protection	 and	welders	 can	be	encouraged	
to	select	these	products.		
•	Arc	 welding	 aluminium	 produces	 the	
most	 intense	UV	 radiation	due	 to	 high	 arc	
energies	involved	and	high	reflectivity	of	the	
metal	surface.	
•	Other	 occupational	 causes	 of	 skin	 cancer	
are	usually	 associated	with	solar	ultraviolet.	
These	include	outdoor	workers	such	as	road	
workers,	gardeners	and	farmers.	
Conflict	of	interest:	none	declared.
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Table 1. Welding process and the degree of UV radiation produced
UV level Welding process  Distance in metres for 1 minute duration before 
US daily threshold limit of UV is reached while 
welding mild steel 
High Gas metal arc welding  0.95 m at 90 amps
 Gas tungsten arc welding 0.90 m at 150 amps
Medium Most shielded metal arc welding including domestic units 3.2 m at 100 amps
Low Submerged arc welding Beyond any distance of concern
Minimal or nil Oxy-acetylene welding Minimal UV
 Resistance welding
 Friction welding
 Friction stir welding
Source: Lyon TL. Evaluation of the potential hazards for actinic ultraviolet radiation generated by electric welding and cutting arcs. US Army 
Environmental Hygiene Agency, 1976
Figure 5. An example of unsafe welding practice. 
Note the bare hands and forearms. The welder 
is working close to the arc and his neck is also 
unsafely exposed
Arc welding and the risk of cancer
Figure 6. A safer GTA welding practice. This welder 
should also have protection to the back of the neck 
as well some fume extraction system in place.
Reproduced with permission: Prototype 
Engineering Centre, 2006
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Many sebaceous carcinomas occur on the eyelids 
where the outcome is often poor;1 and some patients 
are prone to multiple other cutaneous SCCs. 
	
There	 is	also	a	rare	syndrome	called	Muir-torre	of	visceral	
neoplasms	 associated	 with	 sebaceous	 carcinoma	 on	
the	 skin.2	As	 this	 is	 an	 autosomal	 dominant	 condition,	
family	 history	 and	 counselling	 is	 an	 esssential	 part	 of	
management	 (enquire	 about	 family	 history	 of	 internal	
malignancies).	 A	 family	 member's	 diagnosis	 can	 be	
important	 for	 other	 family	members	 and	offers	 screening	
for	internal	and	cutaneous	malignancies.	
	 Mr	LA’s	 tumour	 reminds	us	 that	 among	 the	basal	 cell	
carcinomas	 (BCCs),	 SCCs	 and	melanomas	 removed	 in	
large	 numbers	 in	Australia	 every	 day,	 there	 are	 unusual	
malignancies	that	we	may	come	across	from	time-to-time.	
While	we	 have	 large	 studies	 comparing	management	
options	in	the	more	common	cutaneous	malignancies,	it	is	
rarely	possible	to	have	large	management	trials	of	tumours	
that	none	of	us	see	frequently.	Treatment	is	less	clear	and	
needs	several	good	minds	working	together.	
	 The	 relative	 severity	 of	 some	 of	 the	 rare	 tumours	 is	
tiered	 and	 summarised	 in	 Table 1.	 Sarcomas	 generally	
have	among	the	poorest	outcomes.3
Summary of important points
•	Rare	 tumours	 don’t	 get	 diagnosed	 clinically.	They	
are	 invariably	 diagnosed	 as	 a	 ‘surprise’	 on	 the	
histology	report.3
•	Consider	biopsy	of	 the	atypical	or	 recalcitrant	actinic	
keratoses	before	proceeding	to	another	‘freeze’.	
•	Send	every	specimen	to	 the	histologist,	not	 the	bin.	
A	clinical	sebaceous	cyst,	wart,	seborrhoeic	keratosis	
Rare skin cancers in  
general practice
Case study
Mr LA has long been troubled with actinic damage to his skin, especially his face. He has had 
many squamous cell carcinomas (SCCs) removed and many solar keratoses managed.
On this occasion Mr LA had two actinic lesions on his left cheek that failed to respond to 
cryotherapy (Figure 1). A biopsy of each site produced a surprise. Histology of the superior 
lesion revealed sebaceous carcinoma (Figure 2). This is an uncommon yet aggressive cutaneous 
malignancy derived from sebaceous glands. The 5 year survival rate is 60–70%.
The tumour was widely excised with a minimum 10 mm margin. A multidisciplinary approach 
resulted in a decision not to proceed to adjunctive radiotherapy. The wound was well healed by 
8 weeks (Figure 3). Four years on there is no sign of local or regional recurrence (Figure 4).
Anthony Dixon 
MBBS, FACRRM, is 
dermasurgeon and Director 
of Research, Skin Alert 
Skin Cancer Clinics and 
Skincanceronly, Belmont, 
Victoria. anthony@
skincanceronly.com
Figure 1. Two actinic lesions on the left face 
have failed to respond to cryotherapy
Figure 2. Within the dermis are lobules 
of epithelial cells showing cytoplasmic 
vacuolation, mitoses, and nuclear atypia 
characteristic of sebaceous carcinoma
Photo courtesy Melbourne Skin Pathology
Figure 3. Satisfactory healing 8 weeks 
following wide excision of sebaceous 
carcinoma
Figure 4. Four years postsurgery there is no 
regional recurrence
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or	 lipoma	 can	 sometimes	 lead	 to	 such	
a	‘surprise’.4
•	Consult	 with	 colleagues	 and	 consider	
involving	 multidisciplinary	 experts	 in	
management	 of	 that	 surprise	 unusual	
tumour.	 Management	 predominantly	
involves	surgery	but	can	 involve	adjunctive	
radiotherapy	or	chemotherapy	(Table 1).
•	Unusual	 tumours	 are	 often	 diagnosed	 late	
and	many	have	poor	prognoses.	
•	Sometimes	a	small	biopsy	may	not	provide	
the	 answer	 and	 complete	 local	 excision	 is	
required	for	histologic	diagnosis.3
•	Check	 whether	 there	 are	 management	
trials	for	possible	enrolment	of	your	patient	
with	an	unusual	tumour.
Conflict	of	interest:	none.
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Cutaneous angiosarcoma 
(AS)5,6
15% Mostly on face, scalp, or breast. Local 
recurrence and metastatic spread frequent, 
especially to lung. Can occur in postradiation 
scar 
Very wide 
local excision 
Often Often
Merkel cell carcinoma 
(MCC)7–9
40–68% Local recurrence common even after very 
wide surgery. Mostly on head and neck. 
Spontaneous regression can occur  
Mohs or very 
wide surgery 
Occasionally Often
Sebaceous carcinoma 
(SC)1,2,10
60–70% Often subcutaneous, often on eyelids or scalp. 
Can be associated with visceral tumours  
Very wide local 
excision 
No Often
Dermatofibrosarcoma 
protuberans (DFSP)9,11–13
93+% Local recurrence/destruction in 50–75% of 
cases; can be fatal. <5% metastasise. Can look 
like a morphoeic BCC. Often extends well 
beyond apparent borders. Typically in young/
middle aged with predilection for pectoral and 
pelvic regions  
Mohs 
surgery ideal 
Limited Some
Digital papillary 
adenocarcinoma14
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and hence less aggressive than the reality. 
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digit 
Some Often
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Kaposi sarcoma (KS)20,21 Death from 
other cause 
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• elderly of Jewish/Mediterranean descent
•  immunosuppressed (eg. postrenal 
transplant)
• HIV/AIDS related  
No Often Usual
 
Tumour
5 year 
survival
Clinical  
characteristics 
Surgery 
involved
Chemotherapy
involved 
Radiation  
involved
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Bleeding complications in skin surgery
The following points about bleeding complications are 
relevant to Mr AB’s case:
• Postoperative bleeds from abdominal, brain and chest 
surgery can be catastrophic, but no life threatening 
bleed has ever been reported following cutaneous 
surgery1,2
• Surgeons often claim to be able to tell during surgery 
whether or not the patient is on anticoagulants. The 
evidence suggests surgeons cannot make such a 
differentiation3
• In skin surgery, most complications are managed by 
conservative measures such as toileting the wound, 
applying pressure and applying dressings. Antibiotics 
are sometimes required for overt wound infection 
• Operative intervention for skin surgery complications 
is rare. If a bleed is active and ongoing then surgical 
control of the bleeding may be required. If the bleed 
is old and stable, nature and time will invariably sort 
the matter out 
• Diathermy, preferably bipolar, should be available for 
skin surgery cases so as to control and minimise any 
intra-operative bleeding when this does happen.
At our Geelong (Victoria) based skin cancer centre we 
completed a prospective study from July 2002 until 
October 2006 of 6000 patients looking at the effects 
of thrombosis preventive medication on skin surgery.4 
Patients did not have their aspirin or warfarin ceased unless 
the International Normalised Ratio (INR) was greater than 
three. In 6000 cases, the postoperative bleeding incidence 
was 0.67%.4 There were four independent risk factors for 
postoperative bleeding:
• warfarin management
• surgery in or near the ear
• age over 67 years, and
• closure with flap or graft. 
Table 1 demonstrates how the risk of bleeding increases 
as these four risk factors accumulate. The study found that 
aspirin is not an independent risk factor for postoperative 
Case study
Mr AB, aged 78 years, developed a lentigo maligna (LM) on his left cheek just below the orbital 
margin (Figure 1). Dermoscopy was typical for LM, with thickened variable peri-follicular 
pigmentation, some granular pigmentation, and an area of regressive depigmentation (Figure 2). 
Mr AB has a past history of aortic valve replacement and has been taking warfarin prophylaxis 
for many years.
The tumour was excised with a 6 mm margin and effected a laterally based transposition flap. 
Warfarin was not ceased either before or after surgery. A small bleed occurred from the wound 2 
days postsurgery. Redressing was effected but no other intervention was required. Sutures were 
removed on day 8. Two days after removal of sutures, Mr AB bumped his left cheek in a stumble 
and the wound started bleeding again. He developed a haemorrhage under the flap resulting in 
significant haematoma (Figure 3), flap necrosis, and subsequent ulceration (Figure 4) at the site. 
This required wound toileting and repeated dressings in a prolonged postoperative course. Over 
time, the wound healed with conservative management (Figure 5).
Managing bleeding 
complications in skin surgery
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Table 1. The risk of bleeding complications for 
patients grouped by the number of bleeding risk 
factors in 6000 consecutive cases4
Number of risk  Overall bleeding
factors  rate
0  1 in 1000
1  4 in 1000
2  12 in 1000
3  43 in 1000
4  56 in 1000
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bleeding. There is no case for ceasing aspirin for 
skin surgery. 
 Warfarin may be ceased if the risks of 
continuation outweigh the benefits. This is only 
likely when three or more of the identified risk 
factors are present. However, warfarin should 
never be ceased within 1 month of a life 
threatening thromboembolic event.5 Warfarin 
should invariably be continued in patients 
undergoing leg surgery given that reduced 
mobility following such surgery compounds the 
thromboembolic risk to the patient. If continuing 
warfarin, ensure the INR level before and after 
surgery is in the therapeutic range.6
 Newer agents such as clopidogril and 
ticlopidine were not included in this prospective 
study as they were not in common usage 
during the design phase of the study. No advice 
can be drawn on the ceasing or otherwise 
of these newer agents. The study found that 
smoking and diabetes were not risk factors for 
postoperative bleeding. 
 Discussion of the role of short term 
subcutaneous heparins is now somewhat moot 
and supports previous studies2 demonstrating 
that there is little if any case for a switch to 
short term heparins to effect skin surgery. The 
main consideration in the past has been for leg 
excisions requiring prolonged immobilisation. 
Immobilisation is not commonly required with 
more current approaches below the knee.7 It 
would now only be considered with skin graft 
surgery for large defects >5 cm diameter.6 
Defects of this size account for around 1% of 
skin defects arising from elective excision of 
skin lesions below the knee.
 When managing melanoma, given a 1 cm 
margin of normal skin is usually appropriate,8–10 
a melanoma would need to be around 3 cm in 
diameter to result in a 5+ cm defect.
Conflict of interest: none declared. 
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Figure 1. LM on left cheek. Surgery in this region 
must ensure there is no pull that might result  
in ectropion
Figure 2. Dermoscopy of the LM 
Figure 3. A large haematoma develops
Figure 4. As the bleed matures an area of 
ulceration develops
Figure 5. Despite the graphic appearance following 
the bleed, the wound settles CORRESPONDENCE email: afp@racgp.org.au
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Mr KC now presents with numerous hyperkeratotic 
lesions on his face (Figure 1). Biopsies were taken 
of the clinically most suspicious actinic lesions. This 
is done to identify which, if any, lesions are SCCs. 
(These are surgically excised.) Numerous actinic 
keratoses still covered most of his face including 
most of his left forehead.
	
He	was	 keen	 to	 try	 imiquimod	 for	 his	 residual	 actinic	
keratoses.	We	 divided	 his	 face	 up	 into	 regions	 about	
the	 size	 of	 a	 playing	 card.	 In	 turn	 he	 treated	 each	
region	with	 an	 application	 of	 imiquimod	 three	 times	per	
week	 for	 6	weeks.	This	 is	 the	 recommended	 protocol	
for	usage	of	imiquimod	for	actinic	keratoses.
	 The	 final	 section	 of	 face	 skin	 to	 be	 treated	was	 the	
right	 forehead.	Mid	 treatment	 the	area	was	 red	and	angry	
looking,	as	part	of	the	expected	immune	response	induced	
by	 the	 imiquimod1	 (Figure 2).	This	 erythema	and	 irritation	
was	never	 disturbing	 to	 the	patient.	 If	 imiquimod	 causes	
excess	irritation,	the	clinician	can	advise	the	patient	to	leave	
out	a	dose	or	two.	Upon	completion	Mr	KC	had	no	apparent	
actinic	lesions	on	his	face	or	forehead	(Figure 3).
Summary of important points 
•	Treat	malignant	 lesions	 before	 benign	 lesions.	 It	 is	
the	 SCCs	 that	 can	metastasise	 and	 potentially	 kill	
patients.	Once	the	SCCs	are	excised,	 the	focus	can	
turn	to	the	premalignant	lesions.
•	There	 are	 many	 options	 for	 managing	 actinic	
keratoses.	Percentage	complete	clearance	of	lesions	
with	 cryotherapy	 is	 in	 the	 order	 of	 80%,	 topical	
imiquimod	70%	and	5	fluorouracil	50%.2–5
•	Some	 patients	 will	 find	 some	 of	 the	 options	
more	 tolerable	 than	 others.	 Consider	 trying	
a l te rna t i ve 	 approaches 	 fo r 	 pa t ients 	 wi th	
Case study
Mr KC, 61 years of age, has extensive 
actinic damage including squamous cell 
carcinomas (SCCs) and actinic keratoses 
(AKs) on his face and forehead. He has 
had cryotherapy for many years with 
limited success. Lesions have generally 
resolved with cryotherapy but he finds 
the treatment very uncomfortable and can 
only tolerate a small number of lesions 
being treated on each visit. He develops 
lesions faster than lesions are treated.
Treating actinic keratoses 
with imiquimod
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Figure 2. The skin is typically red and angry looking for the 
duration of imiquimod management of actinic keratoses. 
Imiquimod was only commenced following all surgical excisions
Figure 1. The patient’s face is covered with actinic lesions, 
especially the forehead. The lesions marked with pen are all 
SCCs and were surgically excised. There was further 
SCC on the right eyebrow, also surgically excised
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numerous	 AKs.	 Allow	 the	 patient	 to	
discover	 with	 you	 which	 management	
option	works	best	for	them.	
•	Imiquimod	 is	 approved	 in	 Australia	 for	
field	 actinic	 keratoses	 only	 on	 the	 face	
and	 forehead.	The	 patient	 applies	 a	 full	
sachet	 three	 times	 per	week	 to	 an	 area	
of	 skin	 equivalent	 to	 the	 forehead	 on	
one	 side.	 One	 sachet	 will	 cover	 a	 field	
about	 this	 size.	 Once	 one	 region	 has	
completed	 management,	 a	 new	 region	
may	be	commenced.	
Conflict	of	interest:	none	declared.
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Numerous actinic keratoses
There are five characters of an actinic keratosis that should be considered upon 
examination:
•  Hyperkeratosis: to what extent does the keratosis extend above the skin 
surface?
•  Full thickness: when the lesion is manipulated with your fingers upon 
examination, does it appear to be deeply into the skin or very much a surface 
structure?
•  Surrounding induration: is there enhanced thickness in the tissue adjacent to 
the keratosis?
•  Surrounding erythema: is the immediate adjacent skin clearly redder than the 
background skin colour?
•  Tenderness: is the lesion causing the patient any degree of discomfort?  
Does the patient withdraw when you touch one or more lesions in the field of 
lesions you examine?
The more of these characteristics an individual lesion has, the more likely the 
lesion is to be a malignant SCC rather than a premalignant lesion. In patients 
with large numbers of keratoses, consider biopsy of the lesions that have the 
greatest number of these features. 
Regardless of the number of keratoses a patient suffers, lesions with three or 
more of these five features should be biopsied.
If any lesion demonstrating several of these features does not respond to 
cryotherapy, biopsy rather than treating repeatedly with cryotherapy or 
imiquimod or 5 fluorouracil.
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Figure 3. Following treatment there is no apparent 
residual actinic lesions
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